{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/contentassets/3ffd57f65fd6424db70dd209748a13c3/legemiddelforbruket-i-norge-20162020.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "og Reseptregisteret Drug Consumption in Norway 2016-2020 Data from Norwegian Drug Whol esales Statistics and the Norwegian Prescription DatabaseLEGEMIDDELSTATISTIKK Legemiddelforbruket i Norge 2016-2020 Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret Drug Con sumption in Norway 2016-2020 Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database Hilchen Thode Sommersch ild Christian fra Grossistbasert legemiddelstatistikk og Reseptregisteret Drug Consumption in Norway 2016 -2020 - Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database Forfattere/Authors: Hilchen Thode nettsider: www.fhi.no The report is only - Data fra Grossistbasert legemiddelstatistikk og Reseptregisteret / Drug Consumption in Norway 2016 -2020 - Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database , 2016 1981: Legemiddelforbruket i Legemiddelforbruk et -1983 1985: 1986: Legemiddelforbruket Legemiddelforbruket Legemid Legemiddelforbruket i 1990: Legemiddelforbruket i 1991: Legemiddelforbruket -1990 1992: Legemiddelforbruket -2018 2020: 2009: Legemiddelstatisti kk 2009:2: Reseptregisteret 2004- drugs 2011: the elderly 2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008- 2012 2014: Legemiddelstatistikk 2014:2: Reseptregisteret 2009- 2016: Legemiddelstatistikk 2016:2: Reseptregisteret the elderl y 2019: Legemiddelstatistikk Reseptregisteret 2014- 2018 2014- 2018. 2 Innhold INNHOLD 2 SAMMENDRAG 3 SUMMARY 5 1 INNLEDNING 7 2 MATERIALE OG METODE 9 2.1 Datakilder 9 2.2 Vareregisteret 9 2.3 ATC og DDD 10 2.4 M\u00e5leenheter og indikatorer 11 2.5 Vurderinger og forbehold 12 3 13 3.1 Totalt legemiddelsalg 13 3.2 Sammenstilling av datakildene 16 3.3 Utleveringsgrupper (A, B, C og F) og reseptkategorier (norma l-/refusjonsresepter) 17 3.4 Reseptpliktige legemidler 19 3.5 Reseptfrie legemidler 26 3.6 Veterin\u00e6re legemidler (ATC gruppe Q) 30 4 STATISTIKK FOR ATC HOVEDGRUPPER 31 4.1 Forklaringer til hovedtabellene 31 4.2 A Ford\u00f8yelsesorganer stoffs kifte 32 4.3 B Blod og bloddannende organer 44 4.4 C Hjerte og kretsl\u00f8p 49 4.5 D Dermatologiske midler 58 4.6 G Urogenitalsystem og kj\u00f8nnsho 4.9 Antineoplastiske M Muskler N 105 4.12 P Antiparasit\u00e6re midler, insekticider o g insektmidler 116 4.13 R Respi rasjonsorganer 119 4.14 S Sanseorganer 127 4.15 V Varia 132 5 HISTORIKK OG BAKGRUNNSINFORMASJON 134 FOLKEMENGDE I NORGE 2016 -2020 JA OVER salget 2000 20 20, angitt i kroner (AIP) og DDD. Kostnadsveksten har over h\u00f8yere i kroner , og utgjorde 25 % N\u00e6r 98 % av legemidlene i Reseptregisteret (m\u00e5lt i DDD) ble utlevert til enkeltpersoner i 20 20. De reste rende 2 % ble i hovedsak utlevert til institusjon Av den utlevert minst ett legemiddel p\u00e5 resept i 20 20, 77 % av mennene N) og legemidler som brukes for sykdommer i luftveiene (ATC gruppe R). I 2019 var midler til systemisk bruk mot infeksjoner (ATC gruppe J) nummer tre fremg\u00e5 med antall og andel brukere . 5 Summary This year's report Drug consumption in Norway include s data and information from two sources, Norwegian Drug Wholesale s Statistics and the Norwegian Prescription Database (NorPD) , for the period 2016 -2020. Together, these sources provide a complementary picture of drug sales and consumption in Norway. Closer analyses o f drug consumption in relation to the corona pandemic has not been performed, but in those cases we believe data should be seen in this context it is pointed out in the report. Norwegian Drug Wholesale s Statistics In 20 20, drugs for human use were sold for a total of NOK 21 .1 thousand million (pharmacy purchase price (AIP )), an increase of 7.3% from the previous year (Table 3.1). Over time, there has been a steady increase in sales measured in defined daily doses (DDD). In 20 20, the number of D DDs was 2. 7% higher than the previous year. Over time, the increase in cost has been higher than the increase in volume, measured in DDD. The sale includes medicines with and without Marketing Authorization in Norway. Non -prescription drugs accounted for a round 9% of total sales measured in DDD. T he sales of veterinary medicines were NOK 1.5 thousand million. Figure 3.1 shows the development in total sales of drugs for human use in the period 2000 to 2020 in NOK (AIP) and DDD . Increased prices as well as introduction of new and more expensive drugs have affected cost increases. Costs will also be affected by exchange rates. Population growth and an increased proportion of older people contribute to increased drug consumption. Antineoplastic and immunomodul atory agents (ATC group L), had the highest turnover in NOK and accounted for 25% of costs for human medicines in 20 20 (Table 3.1). The group includes expensive drugs for the treatment of cancer as well as biological drugs fo r the treatment of, for example, arthritis and multiple sclerosis. Norwegian Prescription Database (NorPD) Since the Norwegian Prescription Register was established in 2004, almost 6 million have been included. The number of drugs dispensed according to prescription during this period is just below 734 million. Almost 98% of the medicines in the NorPD (measured in DDD) were dispensed to individuals in 2020. Of the Norwegian population, 7 0% we re dispensed at least one drug in 20 20, 77% of the women and 6 3% of the men (Table 3.4.1). The proportion (prevalence) was lowest in the age group 5 -9 years for both genders and increases with age. In people over the age of 70, around 90% of the individuals w ere given a prescription drug (f igure 3.4.1). The t wo drug groups most commonly used by both genders are agents acting on the nervous system (ATC group N) and agents acting on the respiratory system (ATC group R). In 2019 antiinfectives for systemic use (ATC group J) was number three on the list, but is number four in 2020 . This is probably a con sequence of fewer infection s due to control measures during the corona pandemic. Table 3.4.2 shows prevalence for each of the 14 ATC main groups; total and among women and men. 6 The main tables in Part 4 contain data from both data sources. Data from Nor PD include medicines on prescription to individuals indicated as number and proportion of users. The Norwegian Drug Wholesale s Statistics also include s sales to hospitals , other health institutions and non- pharmacy outlets , mainly listed as DDD/1000 inhabi tants/day. Not all medicines have an assigned DDD, here only data from NorPD is included with number and proportion of users. 7 1 Innledning \u00c5rets rapport , Legemiddelforbruket i Reseptregisteret (Norwegian Prescription Database; NorPD). Fra og med 2020 er disse data samlet i en rapport, mens D vil n\u00e6rmere i Del 2 Materiale og metoder. WHO Collaborating Centre for Drug Statistics Methodology er lokalisert ved Avdeling for legemiddelstatistikk, Folkehelseinstituttet, informasjon, www.whocc.no 1) Sommerschild et al. Data resource Drug Utilization and Pharmacoepidemiology . D . disse f ra 2010 v\u00e6rt under 1 % (0,1 % i 2020). For de tre store legemiddelgrossistene (Alliance Healthcare Norge AS, Apotek 1 etter mmenteres aktuelle ATC grupper i Del 4. Se nettsiden til WHO Collaborating Centre for Drug Statistics Methodology for mer informasjon om ATC/DDD systemet i de tilfeller der legemiddelet kun aktuelt for del telles i l\u00f8pet av et \u00e5r, enten legemidler 2000 il 2020, angitt i kroner (AIP) og DDD. Kostnadsveksten har over h\u00f8yere hadde omsetning i kroner, og utgjorde 25 % av legemidler koronapandemien . 14 Figure 3.1 Total sales of medicines for human use in 2000 to 20 20, NOK in 1000 million (AIP, left axis) and number of DDD s in 1000 million (right axis). Source: Norwegian Drug Wholesales Statistics. 01234567 0510152025 2001 2003 2005 2007 2009 2011 2013 2015 2017 2019 1000 million DDD1000 million NOK (AIP)Sales in 1000 million NOK (AIP) Year 15 Table 3.1: Sales of drugs per ATC main group in 20 20 and changes (%) from 201 9. Both drugs with and without marketing authorisa tion are included. Sales in NOK in pharmacy purchase price (AIP). Source: Norwegian Drug Wholesales Statistics. ATC main group Sales in mill DDD % change in DDDs Sales in mill NOK (AIP) % change in NOK (AIP) % share of total cost human medicines A - Alimentary tract and metabolism 530 3.5 2 433 11.0 11.5 B - Blood and blood forming organs 300 1.9 2 078 4.1 9.8 C - Cardiovascular system 903 4.1 1 195 2.4 5.7 D - Dermatologicals 6 7.7 514 10.1 2.4 G - Genito urinary system and sex hormones 239 0.5 889 5.9 4.2 H - Systemic hormonal preparations, excl. sex hormones and insulins 95 -2.2 459 -1.4 2.2 J - Antiinfectives for systemic use 35 -5.6 1 669 4.0 7.9 L - Antineoplastic and immunomodulating agents 50 6.3 5 210 24.7 M - Musculo -skeletal system 128 3.8 768 4.2 3.6 N - Nervous system 504 3.0 3 176 17.1 15.0 P - Antipar asitic products, insecticides and repellents 2 -1.6 62 66.2 0.3 R - Respiratory system 457 1.7 1 696 4.0 8.0 S - Sensory organs 38 2.2 570 9.6 2.7 V - Various 19.2 416 20.2 2.0 Total human medicines 3 287 2.7 21 135 7.3 100 16 Reseptregisteret Reseptregisteret ble opprettet 1. januar 2004, og period er over 734 millioner. I 2020 ble i underkant av 98 % av legemidlene i Reseptregisteret (m\u00e5lt utgjorde det 86 %. 17 Table 3.2 Comparison of drug sale based on data from the Norwegian Drug Wholesales Statistics a nd the Norwegian Prescription Database in 20 20. Source: Norwegian Drug Wholesales Statistics and the No rwegian Prescription Database ATC group Norwegian Drug Whol esales Statistics NorPD Total sale (millon DDD) OTC sale in percent (%) of total sal es in DDD Sale to individuals in percent (%) of total sales in DDD A - Alimentary tract and metabolism 530 21 77 B - Blood and blood forming organs 300 4 91 C - Cardiovascular system1) 903 NA 97 D - Dermatologicals2) 6 NA 98 G - Genito u rinary system and sex hormones 239 3 95 H - Systemic hormonal preparations, excl. sex hormones and insulins 95 NA 86 J - Antiinfectives for systemic use 35 0 84 L - Antineoplastic and immunomodulating agents2,3) 50 NA 81 M - Musculo -skeleta l system 128 16 80 N - Nervous system 504 10 82 P - Antiparasitic products, insecticides and repellents 2 18 73 R - Respiratory system 457 23 74 S - Sensory organs2) 38 NA 93 V - Various 1 3 73 Total 3287 9 86 1) In the ATC -grou p C the OTC preparations have not been assigned DDDs 2) In the ATC -groups D, L and S a major proprotion of the substances have not been assigned DDDs 3) In the ATC -groups H and L there are no OTC preparations 3.3 Utleveringsgrupper (A, B, C og F) og res eptkategorier (normalresept, (AIP). Reseptfrie legemidler l egemidler ned med rundt 18 prosent fra til Sales according to prescription groups 201 6-2020, (narcotics (A), addictive medicines (B), other prescription medicines (C), Over the Counter (OTC) (F) in million DDD and million NOK (AIP). Both drugs with and without marketing authorisation are included. Source: Norwegian Drug Wholesales Statistics Year Narcotics (A) Addictive medicines (B) Other prescription medicines (C) OTC medicines (F) Total sales (AIP) Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK Mill DDD Mill NOK 2016 38 527 126 249 2 473 14 878 386 1 380 3 022 17 034 2017 40 575 120 247 2 549 16 094 383 1 475 3 091 18 392 2018 41 574 120 284 2 614 16 682 343 1 523 3 119 19 063 2019 44 585 123 313 2 717 17 152 314 1 632 3 199 19 683 2020 46 677 120 313 2 813 18 385 308 1 759 3 287 21 135 Table 3.3.2 Sales according to prescription groups 201 6-2020, (narcotics (A), addictive medicines (B), other prescription medicines (C), Over the Counter (OTC) (F) in million DDD. Both drugs wi th and without marketing authorisation in Norway are included. Source: Norwegian Prescription Database Year Narcotics (A) Addictive medicines (B) Other prescription medicines (C) OTC medicines (F) Mill DDD Number of prescriptions Mill DDD Numb er of prescriptions Mill DDD Number of prescriptions Mill DDD Number of prescriptions 2016 33 1 131 263 116 5 021 879 2317 41 817 942 19 1 430 709 2017 35 1 225 098 111 4 927 120 2404 43 410 010 20 1 613 943 2018 37 1 273 171 112 4 952 017 2474 44 557 9 46 18 1 596 912 2019 39 1 341 519 114 5 033 589 2562 45 853 182 16 1 663 318 2020 41 1 407 525 112 4 851 286 2665 47 183 239 17 1 766 890 19 Table 3.3.3 Number of individuals and proportion of the population by prescription category 2016 -2020. Source: N orwegian Prescription Database Year Non -reimbursable prescriptions Reimbursement prescriptions Health trust financed prescriptions Number of individuals Proportion (%) of the population Sales in mill NOK Number of individuals Proportion (%) of the population Sales in mill NOK Number of individuals Proportion (%) of the population Sales in mill NOK 2016 3 107 622 59.6 3253 2 444 7 22 46.9 11 811 35 807 0.7 3297 2017 3 144 537 59.8 3294 2 526 893 48.1 12 174 46 020 0.9 4169 2018 3 152 124 59.5 3265 2 592020 48.9 12 073 57 871 2019 3 199 306 60.0 3412 2 689152 50.5 11 740 65 695 1.2 5548 2020 3 093 350 57.6 3517 2 750 610 51.1 12 761 81 305 Reseptpliktige minst ett legemiddel p\u00e5 resept, lille 3.4.1 Number of individuals and one -year prevalence (%) of the population who had at least one drug dispensed in Norway 2016 -2020. Source: Norwegian Prescription Database Year 2016 2017 2018 2019 2020 Women n (%) 1 981 012 (76.5) 2 007 231 (76.9) 2 022 967 (77.0) 2 054 099 (77.7) Men (%) 1 649 (62.9) 680 (63.4) 741 580 (64.9) 1 709 971 (63.2) Both genders (%) 3 630 914 (69.6) 3 688 097 (70.1) 3 724 411 (70.3) 3 795 679 (71.2) 3 746 214 (69.8) 20 Figure 3.4.1 One -year prevalence (%) of the population who had at least one drug dispensed in 2020 in Norway according to age and gender. The orange line shows the one -year prevalence (%) for women excluding contraceptives for topical use (ATC code G02B) and hormonal contraceptives for systemic use (ATC code G03A). Source: Norwegian 15 otalt, N) og legemidler som brukes for sykdommer i luftveiene (ATC gruppe R). I 2019 var midler til systemisk bruk mot infeksjoner (ATC gruppe J) nummer tre er 2020 3.4.2 One -year prevalence (%) of the population who had at least one drug dispensed in Norway in 2020 according to the main AT C groups. Source: Norwegian Prescription Database ATC Number of individuals per age group Total number of individuals Women % Men % Both gend ers % <15 15-44 45-69 70 A Alimentary tract and metabolism 48 773 285 546 492 887 358 489 1 185 695 25.2 % 19.1 % 22.1 % B Blood and blood forming organs 6 108 88 792 280 728 363 688 739 316 13.9 % 13.7 % 13.8 % C Cardiovascular system 10 399 102 951 561 305 500 217 1 174 872 21.8 % 22.0 % 21.9 % D Dermatologicals 130 747 307 160 256 587 143 294 837 788 17.4 % 13.8 % 15.6 % G Genito urinary system and sex hormones 4 303 431 198 292 482 169 612 897 595 25.5 % 8.1 % 16.7 % H Systemic hormonal preparations. excl. sex hormones and insulins 16 147 108 014 193 280 143 541 460 982 11.6 % 5.6 % 8.6 % J Antiinfectives for systemic use 83 341 417 324 405 694 277 487 1 183 846 26.6 % 17.6 % 22.1 % L Antineoplastic and immunomodulating agents 1 908 28 746 57 936 39 134 127 724 2.7 % 2.0 % 2.4 % M Musculo -skeletal system 12 907 314 889 450 746 188 676 967 218 20.8 % 15.3 % 18.0 % N Nervous system 35 153 483 866 646 108 371 491 1 536 618 33.9 % 23.4 % 28.6 % P Antiparasitic products, insecticides and repellents 3 392 39 446 30 811 12 338 85 987 1.9 % 1.3 % 1.6 % R Respiratory system 146 783 496 897 485 879 225 289 1 354 848 28.4 % 22.1 % 25.2 % S Sensory organs 79 716 198 407 224 615 171 993 674 731 14.5 % 10.6 % 12.6 % V Various 6 146 17 497 12 578 8 282 44 503 0.8 % 0.8 % 0.8 % 22 Tabell 3.4.3 viser en oversikt med flest brukere i i 2020. av ATC -kodene som ikk e lenger p\u00e5 listen R05DA01 etylmorfin 13. ca. 130 000 individer . 23 Table 3.4.3 Drugs with the highest number of users in Norway 2020. Sourc e: Norwegian Prescription Database ATC code Active ingredient Use Number of individuals Proportion (%) of the population 1 N02BE01 paracetamol1) Analgesic 641037 11.9 metformin 2.5 1) The ATC -level comprises OTC -medicinal products. The number of individuals is registered for prescription sale only 24 I tabell 3.4.4 er data hen tet fra nettsiden www.reseptregisteret.no/ www.norpd.no. har forh\u00e5ndsdefinerte legemiddelgruppe r. H to datakildene. 25 Table 3.4.4 : Number of users per 1000 inhabitants (prevalence) by selected drug categories in 2016- 2020 and proportion of women (%) within each drug category in 2020. The table contains data for all the predefined drug categories available at www.reseptregisteret.no/ www.norpd.no Selected drug categories Users per 1000 inhabitants Proportion of women (%) within the drug category 2016 2017 2018 2019 2020 2020 Drugs for Analgesics excluding opioids (ATC -codes: M01A and N02B) 1) 200. 9 205. 7 205. 8 209. 4 211. 7 59 % Analgetics (ATC -codes: M01A, N02A and N02B) 1) 236. 4 239. 6 238. 8 241. 1 241. 5 58 % Analgetics (Opioids) (ATC -code: N02A) 106. 7 106. 7 105. 3 104. 7 102. 3 56 % Antibacterials (ATC -code: J01) 211. 6 201. 2 192. 8 194. 8 165. 1 61 % Antibacterials excl. methenamine (ATC -code: J01 excl. J01XX05) 209. 7 199. 1 190. 6 192. 9 162. 9 61 % Anti -dementia drugs (ATC -code: N06D) 2.9 2.9 2.9 2.8 R01B, S01G)2) 167. 1 175. 7 179. 4 190. 9 190. 0 57 % Antihypertensives and drug used for other cardiovascular disorders (ATC -codes: C02, C03, C07, C08 and C09) 166. 5 168. 4 169. 8 171. 4 173. 4 49 % Antimigraine drugs (ATC -code: N02C) 20.6 21.9 22.4 23.5 23.9 80 % Contraceptives IUD (ATC -code: G03A) 67.6 66.5 65.1 -code: A10) 35.0 36.4 37.5 38.8 41.1 43 % erectile dysfunction (ATC -code: G04BE) 18.0 19.3 20.3 21.1 18.5 0 % in menopause (ATC -codes: G03C and G03F) 34.8 35.4 36.4 37.8 (ATC N05C) 82.3 82.6 82.3 sedatives (ATC -codes: N05B and N05C) 110. 8 110. 6 109. 6 110. 2 110. 2 63 % Hypnotics, excl. m elatonin and % Lipid modifying drugs (ATC -code: C10) 104. 3 107. 5 109. 6 111. 4 114. 0 44 % Drugs for obstructive airway diseases (ATC - code R03, excl. R03CA) 84.9 86.2 86.6 88.8 86.8 55 % 1) The ATC levels M01A and N02B contain several OTC drugs. The actual, total number of users will thus be higher than the number of users in the database 2) This group contains many OTC drugs. The actual, total number of users will thus be higher than the number of users in th e database 26 3.5 Reseptfrie legemidler I OTC medicines available in non -pharmacy outlets and in pharmacies 2016- 2020, total OTC sale given in DDD/1000 inhabitants/day. Source: Norwegian Drug Wholesales Statistics. Active ingredient Total OTC sale given in DDD/1000 inhabitants/day (ATC code) Indication 2016 2017 2018 2019 2020 ibuprofen1) Pain 9.3 9.3 8.7 8.8 8.8 (M01AE01 ) Pain 15.1 14.8 14.9 15.2 8.0 5.5 5.8 5.8 6.4 7.2 (R06AE07 ) 1) Includes sales of OTC packages only . 2) Includes oxymetazolin og xylometazolin (inclusive combinations with ipratropium), for sales per 3.5.1 Total sales of paracetamol (OTC and prescription only packages) in DDD/1000 inhabitants/day in pharmacy and non -pharmacy outlets 200 i 2020 m\u00e5lt i DDD. av reseptfri ibuprofen var salg av NSAIDs ble redusert med i overkant av 1 % fra 2019. I tillegg ble det i 2020 solgt i underkant av 600 000 pakninger og ParacetDuo\u00ae). 0102030405060 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020DDD/1000 inhabitants/dayPrescription only OTC - non-pharmacy outlets OTC - in pharmacies Year 28 % fra 2019 m\u00e5lt I 2020 ble million en nedgang i forhold til solgt cirka 200 000 pakninger disse legemidlene i 2020, i 2020, en reduksjon p\u00e5 21 % sammenlignet med 2019. Dette av disse produktene, og salget med 10 % forhold Disse midlene (sildenafil) 2020 2020. Dette tilsvarer i underkant av 3 % av salget sildenafil (reseptfritt og 114 jon. krem var i underkant av 230 i 2020 og omtrent uendret mot allergi i 2020, og \u00f8kte med over 13 % m\u00e5lt i DDD sammenlignet Reseptfritt salg redusert 5 % i 2020 i forhold til 2019 i med 2019. Reseptfritt salg av nesespray med kortikosteroid \u00f8kte 2020 sammenlignet med 2019. Dette er som forventet i i ATC gruppe Q - Veterin\u00e6re legemidler var % siden 201 St\u00f8rste del i legemidler midler enkeltpersoner. angi tt antall an del per 1. 4.2 A (GERD). Protonpumpehemmer til bruk noen av de andre gruppene. viser at ATC gruppe ,5 % av de totale legemiddelkostnadene (m\u00e5lt i AIP) og 16 % av betesbehandling (A10) If\u00f8lge Folkehelserapporten 1) har diabetes. Av disse beregnet at 23 har type 1 -diabetes. Salget til viser salget av legemidler -diabetes en gang har if\u00f8lge tall fra Reseptregisteret \u00f8kt med 25 % fra 2016 til 2020 som tilsvarer en \u00f8kning p\u00e5 mer enn 36 000 brukere. \u00d8kningen fra 2019 til 2020 var med 13 000 brukere. 1) https://www.fhi.no/nettpub/hin/ikke -smittsomme/diabetes 34 Figur legemidler til behandling 2 -diabetes tidligere ukjente tilfeller diagnostiseres, og at de som og har et bedre behandlingstilbud. Metformin karsykdommer og pasi enter for type 2 -diabetes behandles ogs\u00e5 med i insulin. Figure 4. 1 Proportio n of the population (prevalence %) who had dispensed at least one drug for treatment of diabetes type-2 (A10B Blood glucose lowering drugs, excl. insulins) 2016 -2020. Source: T he Norwegian Prescription Database 0,00,51,01,52,02,53,03,54,0 A10BA - BiguanidesA10BB - SulfonylureasA10BD - Combinations of oral glucose lowering (%) of the population2016 2017 2018 2019 2020 35 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 A ALIMENTARY TRACT AND METABOLISM A02 DRUGS FOR ACID RELATED DISORDERS 64.12 66.63 68.52 71.42 73.30 493 536 94.6 109.8 A02A ANTACIDS 1.29 1.26 1.18 1.17 1.26 6 361 6 351 6 488 6 869 7 556 1.2 1.4 A02AA Magnesium compounds 0.00 0.00 0.00 0.01 0.01 69 84 99 125 140 0.0 A02AA04 magnesium hydroxide (3 g) 0.00 0.00 0.00 0.01 0.01 69 84 99 125 140 0.0 A02AC Calcium compounds A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 0.46 0.45 0.44 0.43 0.48 1 771 1 489 1 488 1 614 1 938 0.3 0.4 A02AD01 ordinary salt combinations 0.46 0.45 0.44 0.43 0.48 1 771 1 489 1 488 1 614 1 938 0.3 0.4 A02AH Antacids with sodium bicarbonate 0.23 0.25 0.26 - 0.29 3 996 4 249 4 444 4 659 5 000 0.8 0.9 A02B DRUGS FOR PEPTIC ULCER 3.75 3.67 3.56 2.56 0.66 877 45 543 47 144 42 314 5 683 8.8 1.1 A02BA01 cimetidine (0.8 g) 0.00 0.00 0.00 0.00 0.01 19 18 18 64 129 0.0 0.0 A02BA02 ranitidine (0.3 g) 3.28 3.19 3.13 2.13 45 523 45 163 46 861 41 396 <5 8.7 - A02BA03 famotidine (40 mg) 0.47 0.47 0.43 0.43 0.65 434 441 303 1 649 5 578 0.1 1.0 A02BB Prostaglandins 0.03 0.03 0.03 0.03 0.03 371 476 512 471 445 0.1 0.1 A02BB01 misoprostol (0.8 mg) 0.03 0.03 0.03 0.03 0.03 371 476 512 471 445 0.1 405 41 463 39 402 39 132 39 976 8.1 7.5 A02BC02 (40 mg) 23.93 25.74 27.87 30.38 32.89 338 897 45.9 63.1 A02BC03 lansoprazole (30 mg) 5.11 4.92 4.61 4.48 4.35 36 516 34 983 33 068 31 735 30 964 7.0 5.8 mg) 23.28 24.43 24.94 26.37 27.74 168 378 176 064 181 117 191 338 202 381 32.3 37.7 A02BX Other drugs for peptic ulcer 0.66 0.66 0.73 4 273 5 367 5 382 6 110 7 020 0.8 1.3 A02BX02 sucralfate (4 g) 0.06 0.06 0.06 0.1 A02BX12 bismuth subnitrate - - - - - 37 58 11 12 0 0.0 0.0 A02BX13 alginic acid 0.55 0.59 0.59 0.60 0.65 3 788 4 824 4 894 5 612 6 394 0.7 1.2 A03 DRUGS FOR FUNCTIONAL GASTROINTESTIN AL DISORDERS 2.82 2.82 2.75 2.79 2.78 68 127 70 684 72 780 75 450 77 732 13.1 14.5 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 1.53 1.53 1.47 1.49 1.49 5 059 5 738 5 628 6 099 8 005 1.0 1.5 A03AA Synthetic anticholinergics, esters with tertiary amino group 0.00 0.00 0.00 0.00 0.00 36 56 77 69 75 0.0 0.0 36 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 A03AA04 mebeverine (0.3 g) 0.00 0.00 0.00 0.00 (0.6 g) quaternary ammonium compounds 0.04 0.05 0.05 0.05 0.06 1 155 1 382 1 411 1 731 2 371 0.2 0.4 A03AB02 glycopyrronium bromide (0.3 mg P) 0.04 0.05 0.05 0.05 0.06 1 148 1 373 1 401 1 722 2 362 0.2 0.4 propantheline (60 0.00 0.00 0.00 (0.1 g) 0.00 0.00 0.00 0.00 0.00 42 45 28 40 42 0.0 0.0 A03AX Other drugs for functional gastrointestinal disorders 1.49 1.47 1.42 1.43 1.43 3 848 4 284 4 134 4 294 5 564 0.7 1.0 A03AX13 silicones (0.5 g) 1.49 1.47 1.42 1.43 1.43 3 848 4 284 4 134 4 294 4 206 0.7 0.8 A03AX15 menthae piperitae aetheroleum 0.00 0 0 0 0 1 396 0.0 0.3 A03B BELLADONNA AND DERIVATIVES, PLAIN 0.15 0.15 0.15 0.15 0.15 2 680 3 108 3 398 3 788 3 913 0.5 0.7 A03BA Belladonna alkaloids, tertiary amines 0.12 0.12 0.12 0.12 0.11 1 850 1 919 2 096 2 206 2 027 0.4 0.4 A03BA01 atropine (1.5 mg) 0.05 0.05 0.04 0.04 0.04 21 8 13 13 10 0.0 0.0 A03BA03 hyoscyamine (1.2 mg) 0.07 0.07 0.07 0.08 0.07 1 830 1 911 2 083 2 193 2 017 0.4 0.4 A03BB Belladonna alkaloids, semisynthetic, quaternary am monium compounds 0.03 0.03 0.03 0.04 0.04 842 1 202 1 318 1 602 1 912 0.2 0.4 A03BB01 butylscopolamine (60 mg) 0.03 0.03 0.03 0.04 0.04 842 1 202 1 318 1 602 1 912 0.2 0.4 A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 0.00 0.00 0.00 22 19 19 16 0.0 0.0 A03CA Synthetic anticholinergic agents in combination with psycholeptics 0.00 0.00 0.00 0.00 19 psycholeptics 0.00 0.00 0.00 19 16 0.0 0.0 A03F PROPULSIVES 1.14 1.14 1.12 1.15 1.13 61 727 63 378 65 341 67 370 68 181 11.8 12.7 A03FA Propulsives 1.15 1.15 1.13 1.15 1.14 61 727 63 378 65 341 67 370 68 181 11.8 12.7 A03FA01 metoclopramide (30 mg) 1.14 1.14 1.12 1.15 1.13 61 627 63 262 65 211 67 268 68 051 11.8 12.7 A03F A03 domperidone (30 mg O,P/0.12 g R) 0.01 0.01 0.01 0.01 0.01 110 133 141 110 141 0.0 0.0 A03FA05 alizapride (0.15 0.36 0.35 0.38 0.37 19 680 20 854 22 099 23 852 23 9 76 3.8 4.5 A04A ANTIEMETICS AND ANTINAUSEANTS 0.38 0.36 0.35 0.38 0.37 19 680 20 854 22 099 23 852 23 976 3.8 4.5 A04AA Serotonin (5HT3) antagonists 0.34 0.33 0.33 0.35 0.35 16 470 18 169 19 412 21 022 22 115 3.2 4.1 A04AA01 ondansetron (16 mg) 0.33 0.32 0.31 0.34 0.33 15 859 15 811 16 482 17 610 18 518 3.0 3.5 37 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 A04AA02 granisetron (2 mg O/3 mg 0.00 0.00 0.00 0.00 80 85 134 134 0.0 0.0 A04AA05 palonosetron (0.5 mg O/0.25 P mg) 0.01 0.00 0.00 0.00 0.00 83 52 16 12 15 0.0 0.0 A04AA55 palonosetron, combinations 0.00 0.01 0.01 0.01 0.02 983 3 760 4 678 5 146 5 621 0.2 1.1 A04AD Other antiemetics 0.04 0.03 0.03 0.03 0.02 5 953 3 785 3 257 3 269 2 202 1.1 0.4 A04AD01 scopolamine (1 plaster) 0.02 0.03 0.02 0.02 0.02 2 355 2 572 2 710 2 904 1 954 0.5 0.4 A04AD10 dronabinol 0 0 <5 0 <5 0.0 - A04AD12 mg P/165 mg O) 0.02 0.01 0.00 0.00 0.00 3 605 1 223 551 369 254 0.7 0.1 A05 BILE AND LIVER THERAPY 0.45 0.47 0.50 0.54 0.59 3 210 3 373 3 599 3 766 3 835 0.6 0.7 A05A BILE THERAPY 0.45 0.47 0.50 0.54 0.59 3 210 3 373 3 599 3 766 3 835 0.6 0.7 A05AA Bile acids and derivatives 0.45 0.47 0.50 0.54 0.59 3 210 3 373 3 599 3 766 3 835 0.6 0.7 A05AA01 acid 0.45 0.47 0.50 0.53 0.58 3 209 3 373 3 595 3 758 3 826 0.6 0.7 A05AA04 obeticholic acid (10 mg) 0.00 0.00 0.00 0.01 0 7 30 43 68 0.0 A06 DRUGS FOR CONSTIPATION 22.63 22.85 22.76 22.46 25.31 83 960 94 189 102 443 109 059 122 820 16.1 22.9 A06A DRUGS FOR CONSTIPATION 22.63 22.85 22.76 22.46 25.31 83 960 94 189 102 443 109 059 122 820 16.1 22.9 A06AA Softeners, emollients 0.09 0.10 0.12 0.00 0.20 1 295 1 344 1 521 1 421 1 743 0.3 0.3 A06AA01 liquid paraffin 0.09 0.10 0.12 0.20 1 295 1 344 1 521 1 421 1 743 0.3 0.3 A06AB Contact laxatives 9.03 8.76 8.48 8.25 8.55 30 656 30 836 30 018 29 853 30 487 5.9 5.7 A06AB02 bisacodyl (10 mg) 3.12 2.97 2.84 2.66 2.75 5 667 5 533 5 642 5 430 5 743 1.1 1.1 A06AB06 senna glycosides 1.49 1.41 1.30 1.19 1.16 1 462 1 329 1 270 1 162 1 148 0.3 0.2 A06AB08 sodium picosulfate (5 mg) 4.37 4.33 4.29 4.35 4.59 16 038 16 766 17 244 17 864 19 463 3.1 3.6 A06AB20 contact laxatives in combination - - - - - 21 16 0 0 0 0.0 0.0 A06AB56 senna glycosides, combinations - - - - - <5 0 0 0 0 - 0.0 A06AB58 sodium picosulfate, combinations 0.05 0.05 0.05 0.05 0.04 9 198 8 889 7 628 7 046 5 965 1.8 1.1 A06AC Bulk -forming laxatives 1.35 1.56 1.61 1.60 2.12 3 643 4 717 6 120 7 542 9 420 0.7 1.8 A06AC01 ispaghula (psylla seeds) (7 g) 1.35 1.56 1.61 1.60 2.12 3 643 4 717 6 120 7 542 9 420 0.7 A06AD Osmotically acting laxatives 10.75 10.98 11.09 11.17 12.76 54 417 64 136 78 188 91 395 10.4 17.0 A06AD11 lactulose (6.7 g) 9.00 8.87 8.59 8.52 9.12 17 324 18 482 18 532 19 491 21 621 3.3 (10 g) 0.00 0.00 0.00 0.00 0.00 33 28 17 17 22 sodium phosphate (50 g) 0.00 0.00 0.00 0.00 801 combinations 1.74 2.10 2.49 2.64 3.64 38 581 47 418 56 190 61 537 73 447 7.4 13.7 A06AG Enemas 1.21 1.18 1.16 1.15 1.19 6 254 6 790 6 748 6 920 7 361 1.2 1.4 A06AG02 bisacodyl 0.14 0.13 0.12 0.12 0.12 1 556 1 452 1 263 1 159 1 149 0.3 0.2 38 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 A06AG04 glycerol - - - - - 819 1 024 1 069 1 027 1 079 0.2 0.2 A06AG06 oil - - - - - 129 114 106 183 212 0.0 0.0 A06AG10 docusate sodium, incl. combinations 0.11 0.10 0.10 0.10 0.09 1 709 1 900 2 023 2 131 2 318 0.3 0.4 A06AG11 2 779 2 773 2 892 3 187 0.5 0.6 A06AH Peripheral opioid receptor antagonists 0.05 0.07 0.08 0.10 0.12 637 801 903 1 078 1 224 0.1 0.2 A06AH01 methylnaltr exone bromide (6 mg) 0.01 0.01 0.01 0.01 0.01 153 132 82 103 116 0.0 0.0 A06AH03 naloxegol (25 mg) 0.04 0.06 0.08 0.09 0.11 836 1 005 1 137 0.1 0.2 A06AX Other drugs for constipation 0.17 0.20 0.22 0.20 0.36 2 478 2 676 2 984 3 226 3 995 0.5 0.7 A06AX01 glycerol - - - - - 137 134 128 204 206 0.0 0.0 A06AX04 linaclotide (0.29 mg) 0.14 0.16 0.18 0.15 0.31 1 927 2 160 2 478 2 592 3 261 0.4 0.6 A06AX05 prucalopride (2 mg) 0.03 0.04 0.04 0.04 0.05 504 480 464 549 722 0.1 0.1 A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/A NTIINFECTIVE AGENTS 7.83 7.85 8.22 8.57 8.83 85 501 88 869 92 404 94 456 946 16.4 17.7 A07A INTESTINAL ANTIINFECTIVES 0.30 0.30 0.31 0.32 0.33 36 202 36 965 37 504 37 756 37 107 6.9 6.9 A07AA Antibiotics 0.30 0.30 0.31 0.32 0.33 36 202 36 965 37 504 37 756 37 107 6.9 6.9 A07AA01 neomycin (5 g) 0.00 0.00 <5 0.0 - A07AA02 nystatin (1.5 MU) 0.25 0.24 0.23 0.23 0.23 35 641 36 290 36 738 36 929 36 228 6.8 A07AA06 paromomycin (3 g) 0.00 0.00 0.00 0.00 0.00 77 42 76 31 (2 g) 0.00 0.00 0.00 0.00 370 rifaximin (0.6 g) 0.04 0.06 0.08 0.09 0.10 276 303 403 447 0.0 A07B INTESTINAL ADSORBENTS 0.06 0.04 0.04 0.04 0.03 173 196 261 290 274 0.0 0.1 A07BA Charcoal preparations 0.06 0.04 0.04 0.04 0.03 94 65 95 74 67 0.0 0.0 A07BA01 medicinal charcoal (5 g) 0.06 0.04 0.04 0.04 0.03 94 65 95 74 67 0.0 0.0 A07BB Bismuth preparations - - - - - 79 131 166 216 207 0.0 0.0 A07C ELECTROLYTES WITH CARBOHYDRATES 0.04 0.04 0.04 0.04 0.04 444 445 444 447 256 0.1 0.1 A07CA Oral rehydration salt formulations 0.04 0.04 0.04 0.04 0.04 427 426 420 424 250 0.1 0.1 A07D ANTIPROPULSIVES 1.51 1.60 1.68 1.74 1.64 21 467 23 288 25 560 26 595 26 885 4.1 5.0 A07DA Antipropulsives 1.51 1.60 1.68 1.74 1.64 21 467 23 288 25 560 26 595 26 885 4.1 5.0 A07DA01 diphenoxylate (15 mg) - - - - - <5 0 0 0 0 - 0.0 A07DA02 opium (0.1 g) 0.02 0.02 0.03 0.04 0.05 268 306 400 486 575 0.1 0.1 A07DA03 loperamide (10 mg) 1.44 1.50 1.55 1.62 1.54 21 098 22 778 24 846 26 083 26 443 4.1 4.9 A07DA06 eluxadoline (0.2 g) 0.00 0.02 0.00 0 119 432 57 0 0.0 0.0 A07DA53 loperamide, combinations 0.05 0.07 0.09 0.08 0.05 400 437 423 438 368 0.1 0.1 39 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 A07E INTESTINAL ANTIINFLAMMATORY AGENTS 5.91 5.86 6.14 6.42 6.77 29 560 30 654 31 533 32 418 33 586 5.7 6.3 A07EA Corticosteroids acting locally 0.41 0.44 0.44 0.45 0.47 6 834 7 507 7 712 7 977 8 545 1.3 1.6 A07EA01 prednisolone (1 enema) 0.00 0.00 0.00 9 0.0 0.0 A07EA02 hydrocortisone 0.03 0.02 0.01 0.00 390 322 198 67 <5 0.1 - A07EA06 budesonide enema R/9 mg O) 0.38 0.42 0.43 0.45 0.47 6 500 7 230 7 543 7 902 8 536 1.3 1.6 0.01 47 53 0.0 0.0 A07EB01 cromoglicic acid (0.8 g) 0.00 0.00 0.01 0.00 0.00 42 47 53 47 40 0.0 0.0 A07EC Aminosalicylic acid and similar agents 5.50 5.41 5.69 5.97 6.30 25 111 25 797 26 488 27 071 27 753 4.8 5.2 A07EC01 sulfasalazine (2 g) 0.71 0.68 0.66 0.59 0.56 5 683 5 457 5 410 5 240 4 872 1.1 0.9 A07EC02 mesalazine (1.5 g) 4.34 4.66 4.96 5.32 5.68 19 121 20 045 20 861 21 617 22 927 3.7 4.3 A07EC03 olsalazine (1 g) 42.0 04.0 04.0 04.0 g) 0.1 A07F ANTIDIARRHEAL MICROORGANISMS 01 .0 01 .0 00 .0 00 .0 01 .0 725 559 422 418 500 0.1 0.1 A07FA Antidiarrheal microorganisms 0.01 0.01 0.00 0.00 0.01 725 559 422 418 500 0.1 0.1 A07FA01 lactic acid producing organisms - - - - - 370 294 215 153 132 0.1 0.0 A07FA02 saccharomyces boulardii (1 g) 0.01 0.01 0.00 0.00 0.01 377 287 217 268 371 0.1 0.1 A07FA51 lactic acid producing organisms, co mbinations - - - - 53 <5 <5 <5 <5 0,0 - A07X OTHER ANTIDIARRHEALS - - 7 <5 0 0 0 0,0 0,0 A07XA Other antidiarrheals - - - - <5 0 0 0 0,0 0,0 A07XA04 racecadotril - - - - - <5 0 0 0 0 - 0.0 A08 ANTIOBESITY PREPARATIONS, DIET PRODUCTS 0.32 6 293 6 256 8 052 415 14 222 1.2 2.7 A08A ANTIOBESITY PREPARATIONS, DIET PRODUCTS 0.32 6 293 6 256 8 052 10 415 14 222 1.2 2.7 A08AA Centrally acting antiobesity products 0.01 0.13 0.28 0.49 0 265 3 072 6 090 10 328 0.0 1.9 A08AA62 bupropion and naltrexone 0.01 0.13 0.28 0.49 0 265 3 072 6 090 10 328 0.0 1.9 A08AB Peripherally acting antiobesity products 0.32 0.31 0.27 0.24 0.23 6 293 6 019 5 187 4 625 4 232 1.2 0.8 A08AB01 orlistat (0.36 g) 0.32 0.31 0.27 0.24 0.23 6 293 6 019 5 187 4 625 4 232 1.2 0.8 A09 DIGESTIVES, INCL. ENZYMES 0.75 0.79 0.81 0.91 0.94 6 091 6 597 6 919 7 356 7 774 1.2 1.5 A09A DIGESTIVES, INCL. ENZYMES 0.75 0.79 0.81 0.91 0.94 6 091 6 597 6 919 7 356 7 774 1.2 1.5 A09AA Enzyme preparations 0.75 0.79 0.81 0.91 0.93 6 022 6 364 6 657 013 7 320 1.2 1.4 A09AA02 multienzymes (lipase, protease etc.) 0.75 012 6 359 6 648 6 999 7 280 1.2 1.4 A09AB Acid preparations 0.08 0.08 0.09 0.09 0.13 64 65 63 73 146 0.0 0.0 A09AB01 glutamic acid hydrochloride (1.5 g) 0.08 0.07 0.08 0.09 0.11 53 51 53 52 53 0.0 0.0 40 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 A09AB02 betaine hydrochloride (1 g) 0.00 0.00 0.00 0.00 0.02 9 9 10 18 90 0.0 0.0 A09AB03 hydrochloric acid - - - - - <5 5 0 <5 <5 - - A09AC Enzyme an d acid preparations, combinations - - - - - 31 195 217 289 343 0.0 0.1 A09AC01 pepsin and acid preparations - - - - - 28 194 217 289 336 0.0 0.1 A09AC02 multienzymes and acid preparations - - - - - <5 <5 0 0 0 - 0.0 A10 DRUGS USED IN DIABETES 53.03 55.42 56.23 58.50 60.26 183 452 192 542 199 563 208 034 221 619 35.2 41.3 A10A 20.49 20.71 20.49 529 65 733 68 137 70 320 72 759 12.2 13.6 A10AB Insulins and analogues for injection, fast -acting 8.03 8.36 8.71 8.87 8.92 42 145 43 534 45 172 46 167 47 414 8.1 8.8 A10AB01 insulin (human) (40 U) 0.12 0.11 0.09 0.07 0.07 825 742 640 541 484 0.2 0.1 A10AB04 insulin lispro (40 U) 2.29 2.35 2.06 1.95 1.89 10 717 11 202 10 699 10 017 9 755 2.1 1.8 A10AB05 insulin aspart (40 U ) 5.53 5.82 6.50 6.79 6.91 31 059 32 700 35 590 36 819 38 243 6.0 7.1 A10AB06 insulin glulisine (40 for injection, intermediate -acting 6.64 6.35 5.86 5.45 4.86 34 174 33 804 32 247 30 443 28 508 6.6 5.3 A10AC01 insulin (human) (40 U) 6.64 6.35 5.86 5.45 4.86 34 174 33 804 32 247 30 443 28 508 6.6 5.3 A10AD Insulins and analogues for injection, intermediate - or long - acting combined with fast-acting 1.27 1.13 0.94 0.79 0.64 5 323 4 678 4 081 3 474 2 918 1.0 0.5 A10AD04 insulin lispro (40 U) 0.10 0.09 0.07 0.06 0.05 481 405 342 296 237 0.1 0.0 A10AD05 insulin aspart (40 U) 1.18 1.05 0.87 0.73 0.59 4 853 4 278 3 741 3 182 2 685 0.9 0.5 A10AE Insulins and analogues for in jection, long -acting 3.85 4.41 4.99 5.60 6.06 21 381 25 315 29 213 33 165 36 318 4.1 6.8 A10AE02 insulin (beef) (40 U) 0.00 0.00 0.00 0.00 0.00 0 0 0 0 - 0.0 A10AE04 insulin glargine (40 U) 2.60 2.77 2.80 2.86 2.88 15 044 16 352 16 677 16 950 17 159 2.9 3.2 A10AE05 insulin detemir (40 U) 1.11 0.99 0.82 0.72 0.59 6 126 5 721 4 957 4 536 3 920 1.2 0.7 A10AE06 insulin degludec (40 U) 0.14 0.51 0.97 1.34 1.78 1 087 3 386 5 938 8 349 10 874 0.2 2.0 A10AE54 insulin glargine and lixisenatide (40 U) 0.00 0.02 0.02 0 0 32 129 134 0.0 0.0 A10AE56 insulin degludec and liraglutide (40 U) 0.00 0.16 0.40 0.66 0.79 46 1 642 3 459 5 152 6 134 0.0 1.1 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 33.24 35.17 35.74 37.79 39.77 145 510 154 27.9 33.9 A10BA Biguanides 14.71 15.12 15.08 463 126 588 132 455 21.9 24.7 A10BA02 metformin (2 g) 14.71 15.12 15.08 15.69 15.75 113 917 120 061 122 463 126 588 132 455 21.9 24.7 A10BB Sulfonylureas 7.33 6.77 5.82 5.20 4.52 32 265 29 721 26 538 23 787 21 131 6.2 3.9 A10BB01 glibenclamide (7 mg) 0.09 0.09 0.07 0.06 530 471 A10BB07 glipizide (10 mg) 0.37 0.31 0.27 0.23 0.18 2 466 2 109 1 785 1 552 1 297 0.5 0.2 A10BB12 glimepiride (2 mg) 6.87 6.37 5.48 4.91 4.29 29 212 27 064 24 274 21 820 19 464 5.6 3.6 41 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 A10BD Combinations of oral blood glucose lowering drugs 3.67 4.21 4.54 4.94 4.93 23 050 26 294 28 781 31 085 31 811 4.4 5.9 (2 UD) 0.00 0.00 0.00 0.0 0.0 A10BD07 metformin and sitagliptin (2 UD) 1.72 2.05 2.36 2.63 2.59 10 815 13 391 15 199 16 627 16 932 2.1 3.2 A10BD08 and 1.69 1.76 1.62 786 10 655 162 9 710 9 048 2.1 1.7 A10BD10 metformin and saxagliptin (2 UD) 0.02 0.02 0.02 0.01 0.01 117 110 112 101 67 0.0 0.0 A10BD11 metformin and metformin and dapagliflozin (2 UD) 0.09 0.13 0.16 0.22 0.28 588 852 1 166 1 519 1 927 0.1 0.4 A10BD19 linagliptin and empagliflozin (2 UD) 0.01 0.03 0.04 0 0 122 227 268 0.0 0.1 A10BD20 metformin and empagliflozin (2 UD) 0.04 0.12 0.22 0.33 0.45 331 881 1 527 2 278 2 954 0.1 0.6 A10BD21 saxagliptin and dapagliflozi n (1 UD) 0.01 0.03 0.04 0.04 0 91 201 243 255 0.0 0.1 A10BD23 metformin and ertugliflozin (2 UD) 0.00 0.00 A10BD24 sitagliptin and ertugliflozin (1 UD) 0.00 0.01 0.01 0 0 17 67 91 0.0 0.0 A10BF Alpha glucosidase inhib itors 0.04 0.04 0.03 0.02 442 416 369 275 0.1 0.1 A10BF01 acarbose (0.3 g) 0.04 0.04 0.03 0.02 0.03 463 442 416 369 275 0.1 0.1 A10BG Thiazolidinediones 0.23 0.20 0.23 0.20 0.17 1 492 1 415 1 373 1 327 1 153 0.3 0.2 A10BG03 pioglitazone (30 mg) 0.23 0.20 0.23 0.20 0.17 1 492 1 415 1 373 1 327 1 153 0.3 0.2 A10BH Dipeptidyl peptidase 4 (DPP -4) inhibitors 3.39 3.86 4.10 4.28 4.17 21 861 25 212 27 093 28 211 28 314 4.2 5.3 A10BH01 sitagliptin (0.1 g) 1.78 2.14 2.40 2.60 2.55 12 060 14 903 16 770 18 144 18 199 2.3 3.4 A10BH02 vildagliptin (0.1 g) 0.34 0.33 0.30 0.28 0.25 2 500 2 374 2 163 2 035 2 079 0.5 0.4 A10BH03 saxagliptin (5 mg) 0.23 0.21 0.19 0.17 0.14 1 351 1 233 1 087 968 844 0.3 0.2 A10BH05 linagliptin (5 mg) 1.03 1.18 1.22 1.23 1.22 6 268 7 066 7 333 7 379 7 461 11 074 12 861 14 626 20 448 31 650 2.1 5.9 A10BJ01 exenatide (15 mcg/0.286 mg) 0.20 0.18 0.16 0.14 0.12 1 324 1 251 1 112 1 004 844 0.3 0.2 A10BJ02 liraglutide (1.5 mg) 1.28 1.39 1.52 1.63 1.90 7 980 9 083 10 119 11 206 13 080 1.5 2.4 A10BJ03 lixisenatide (20 mcg) 0.10 0.07 0.06 0.05 0.36 725 525 398 347 248 0.1 0.1 A10BJ05 dulaglutide (0.16 mg) 0.22 0.40 0.56 0.70 0.81 1 432 2 314 3 277 4 135 4 764 0.3 0.9 A10BJ06 semaglutide (0.11 mg) 0.00 0.41 1.55 0 0 18 5 267 14 483 0.0 2.7 A10BK Sodium -glucose co - transporter 2 (SGLT2) inhibitors 2.05 2.90 3.62 4.52 5.45 14 041 20 330 25 613 31 293 37 723 2.7 7.0 A10BK01 dapagliflozin (10 mg) 1.51 1.68 1.79 1.96 2.20 9 437 10 588 11 297 12 225 14 176 1.8 2.6 A10BK02 canagliflozin (0.2 g) 0.03 0.13 0 0 0 440 1 033 0.0 0.2 A10BK03 empagliflozin (17.5 mg) 0.55 1.21 1.83 10 105 907 22 755 0.9 4.2 A10BK04 ertugliflozin ( 10 mg) 0.00 0.02 0.03 0 0 49 189 213 0.0 0.0 42 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 A10BX Other blood glucose lowering drugs, excl. insulins 0.03 0.03 0.02 0.02 0.02 172 163 156 149 126 0.0 0.0 A10BX02 repaglinide (4 mg) 0.03 0.03 0.02 0.02 0.02 172 163 156 149 126 0.0 0.0 A12 0.00 0.00 0.00 0.00 8 5 6 9 5 0.0 0.0 A12AA04 calcium carbonate (3 g) 0.00 0.00 0 0 0 154 193 0.0 0.0 A12AA06 calcium lactate gluconate (3 g) 0.30 0.31 0.14 1012 843 999 0.2 0.2 A12AX Calcium, combi nations with vitamin D and/or 1.15 18209 18118 17922 17753 3.5 3.3 A12BA02 potassium 0.23 0.24 0.25 2705 2647 2898 3104 3315 0.5 0.6 A12BA30 potassium (different in combinati on) - - - - - <5 5 6 5 7 - 0.0 A12C OTHER MINERAL SUPPLEMENTS 1.20 1.22 1.16 1.31 1.45 8088 8996 9500 9419 0.03 0.03 0.03 0.03 607 566 456 405 394 0.1 0.1 A12CB01 zinc sulfate (0.6 g) 0.04 0.03 0.03 0.03 0.03 607 566 456 405 394 0.1 0.1 A12CC 0.00 80 146 150 0.0 0.0 A12CC10 magnesium oxide - - - - - 222 289 399 412 405 0.0 0.1 A12CC30 magnesium (different salts in combination) 5750 5803 5465 6353 1.0 1.2 A12CX Other mineral products - - - - - 16 17 15 21 22 0.0 0.0 A14 ANABOLIC AGENTS FOR SYSTEMIC USE derivati ves - - - - - 1030 974 951 928 1107 0.2 0.2 A14AA07 prasterone - - - - - 1028 973 951 928 1105 0.2 0.2 A14AB Estren 0.00 0.00 (2 mg) 0.01 0.00 0.00 0.00 0.00 21 20 11 <5 13 0.0 0.0 43 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/day 2016 2017 2018 2019 2020 A16 OTHER METABOLISM 462 466 and derivatives 30.60 37.10 39.50 36.56 42.98 208 229 205 (2 g) 63.63 73.06 84.12 91.41 169 174 183 0.0 0.0 A16AA03 glutamine - - - - - 7 5 <5 <5 <5 0.0 - A16AA04 mercaptamine (2 g) 5.90 6.50 6.90 6.36 7.22 10 10 10 10 9 0.0 0.0 A16AA05 carglumic acid (0.2 g) 3.40 9.60 11.30 <5 g) 21.30 21.00 21.30 22.30 26.23 23 24 24 26 27 A16AB Enzym es 63.94 66.23 64.43 66.38 (300 U) 6.24 6.43 6.13 6.34 9 7 6 agalsidase alfa (1 mg) 16.70 15.50 14.30 14.30 20.63 17 16 16 16 27 beta (5 mg) 35.50 38.70 38.40 38.70 41 43 43 41 0.0 0.0 A16AB05 laronidase (1 TU) 1.30 1.30 1.20 1.33 1.24 - - - - - - - A16AB07 alglucosidase alfa (0.1 g) (20 mg) 2.90 4.40 5.20 5.3 3.84 6 10 12 12 11 0.0 0.0 A16AX Various alimentary tract and metabolism products 69.01 81.18 103.21 155 179 209 A16AX01 thioctic acid (0.6 g) 6.91 7.48 6.08 5.93 14.24 41 42 35 32 86 0.0 0.0 A16AX03 sodium phenylbutyrate (20 46.64 15 16 17 18 21 0.0 0.0 A16AX05 zinc acetate (0.15 g) 9.20 8.00 9.40 9.25 11.27 14 14 15 17 15 0.0 0.0 A16AX06 miglustat (0.3 g) 5.70 7.40 8.40 9.21 7.73 6 8 10 8 7 0.0 0.0 A16AX07 sapropterin - - - - - 22 33 36 39 44 0.0 0.0 A16AX08 teduglutide (5 mg) 4.20 15.80 28.80 29.59 48 44 0.0 A16AX09 glycerol phenylbutyra te (15 g) 1.14 1.83 0 0 0 <5 5 0.0 0.0 A16AX10 eliglustat <5 - - A16AX12 trientine - - - - 14.75 12 14 14 16 17 0.0 0.0 A16AX14 migalastat (61.5 mg) 0.80 3.60 6.75 7.80 0 <5 5 9 10 0.0 0.0 A16AX15 telotristat (0.75 g) 1.73 6.99 12.13 0 0 <5 21 17 0.0 0.0 44 4.3 Blod DDD foreskrevet 83 % av all DDD i gruppe B01AC, etterfulgt av klopidogrel 10 % . menn over 65 \u00e5r fikk forskrevet et peroralt antikoagulanti kum 80 \u00e5r var andelen enda h\u00f8yere (henholdsvis 19 % og 28 %). Fra 2016 til 2020 ble andel brukere av warfarin har andel brukere av apiksaban \u00f8kt fra 28 % i 2016 til 57 % i 2020. 45 Fig. 4.3.1. Sales of oral anticoagulants at andel brukere 12 har \u00f8kt siste 5 \u00e5r. I vitamin f\u00e5r n\u00e5 tablettbehandling (49 % i 2020 vs 39 % i 2019). Dette er i tr\u00e5d med 2020 an del brukere av % mens andel b inhabitants/day Yearwarfarin dabigatran rivaroxaban apixaban Database DDD/1000 inhabitants/day Number of indiv iduals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 B BLOOD AND BLOOD FORMING ORGANS 678 638 699 782 5.01 4.20 3.59 60 605 51 304 42 737 35 585 30 110 11.6 5.6 B01AA01 dicoumarol (0.1 g) 0.00 0.00 0.00 0.00 33 29 (7.5 mg) 7.16 6.02 5.01 4.20 3.59 60 561 51 268 42 704 35 558 30 078 11.6 5.6 B01AA07 acenocoumarol (5 mg) 0.00 0 0 0 0 5 0.0 0.0 B01AB Heparin group 6.20 6.25 6.08 6.09 5.54 56 268 56 928 56 295 54 8 53 49 935 10.8 9.3 B01AB01 heparin (10 TU) 0.15 0.17 0.16 0.17 0.27 1 184 1 327 1 230 1 227 1 395 0.2 0.3 B01AB02 antithrombin III (2.1 TU) 0.00 0.00 - - - - - - TU) 3.42 3.58 3.59 3.32 2.96 34 748 36 168 36 792 33 337 29 271 6.7 5.5 B01AB05 enoxaparin (2 TU) 2.62 2.50 2.34 2.60 2.31 21 078 20 307 19 037 21 309 20 382 239 75.8 71.2 B01AC04 clopid ogrel (75 mg) 4.07 4.55 5.18 6.05 6.90 27 618 30 764 34 742 40 351 45 069 5.3 8.4 B01AC05 ticlopidine (0.5 g) 0.02 0.02 0.01 0.01 0.01 108 104 81 72 69 0.0 0.0 B01AC06 acetylsalicylic 967 70.7 63.9 B01AC07 dipyridamole (0.4 g O/0.2 g P) 2.84 2.83 2.49 2.11 1.25 18 752 17 789 16 485 14 447 8 713 B01AC21 treprostinil (4.3 mg) 0.00 0.00 0.00 0.00 0.01 20 24 18 20 23 0.0 0.0 B01AC22 prasugrel (10 mg) 0.20 0.20 0.20 0.20 0.20 1 627 1 625 1 645 1 599 1 693 0.3 0.3 B01AC23 cilostazol (0.2 g) 0.00 0.0 - B01AC24 ticagrelor (0.18 g) 1.13 1.12 1.11 1.14 1.05 9 476 9 588 9 654 9 857 9 456 1.8 1.8 B01AC25 cangrelor (50 mg) 0.00 0.00 0.00 - - (1.8 mg) 0.00 0.00 0.00 0.00 21 21 0.0 0.0 B01AC30 acetylsalicylic acid and dipyridamole (2 caps) 2.75 2.70 2.61 2.72 2.69 16 805 16 809 16 207 17 199 16 667 3.2 3.1 number of DDDs/year 2016 2017 tants/day 2016 2017 2018 inhibitors 1.89 1.88 1.87 1.84 1.73 13 331 13 118 12 918 12 373 11 684 2.6 2.2 B01AE07 dabigatran etexilate (0.3 g) 1.89 1.88 1.87 1.84 1.73 13 331 13 118 12 918 12 373 11 684 2.6 2.2 B01AF Direct 036 83 117 170 131 248 12.5 24.5 B01AF01 rivaroxaban (20 mg) 4.43 4.80 5.02 5.08 5.04 28 935 30 795 31 823 32 160 32 457 5.6 6.1 B01AF02 apixaban (10 mg) 4.62 7.03 9.27 11.53 13.29 37 297 54 002 69 381 84 053 96 830 7.2 18.0 B01AF03 edoxaban (60 mg) 0.00 0.05 0.18 0.35 0.50 15 448 1 479 2 589 3 630 0.0 0.7 B01AX Other antithrombotic agents 0.00 0.00 0.00 0.00 0.00 18 21 34 26 25 0.0 0.0 47 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of indiv iduals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 B01AX05 fondapari nux (2.5 mg) 0.00 0.00 0.00 0.00 21 34 26 25 0.0 0.0 B02 ANTIHEMORRHAGICS 0.22 0.22 0.21 0.22 0.22 13 711 14 447 14 724 13 968 14 741 2.6 2.8 B02A ANTIFIBRINOLYTICS 0.20 0.20 0.20 0.20 0.21 13 112 13 819 14 075 13 247 14 025 2.5 2.6 B02AA Amino acids 0.20 0.20 0.20 0.20 0.21 13 110 13 817 14 074 13 246 14 024 2.5 2.6 B02AA02 tranexamic acid (2 g) 0.20 0.20 0.20 0.20 0.21 13 110 13 817 14 074 13 246 14 024 2.5 2.6 B02B VITAMIN K AND OTHER HEMOSTATICS 0.02 0.02 0.01 0.01 0.01 697 740 771 827 843 0.1 0.2 B02BA Vitamin K 0.02 0.02 0.01 0.01 0.01 280 269 283 272 242 0.1 0.1 B02BA01 phytomenadione (20 mg) 0.02 0.02 0.01 0.01 0.01 280 269 283 272 242 0.1 0.1 B02BD Blood coagulation factors - - - - - 280 287 295 313 308 0.1 0.1 B02BD02 coagulation factor VIII - - - - - 191 198 200 212 214 0.0 0.0 B02BD03 factor VIII inhibitor bypassing activity - - - - - 11 8 6 5 <5 0.0 - B02BD04 coagulation factor IX - - - - - 49 51 58 53 56 0.0 0.0 B02BD06 von Willebrand factor and coagulation factor VIII in co mbination - - - - - 12 14 12 23 16 0.0 0.0 B02BD08 coagulation factor VIIa - - - - - 17 15 19 21 14 0.0 0.0 B02BX Other systemic hemostatics 0.02 0.03 0.03 0.04 0.04 137 182 192 248 298 0.0 0.1 B02BX04 romiplostim (30 mcg) 0.01 0.01 0.01 0.01 0.01 30 41 45 45 53 0.0 0.0 B02BX05 eltrombopag (50 mg) 0.01 0.02 0.02 0.02 0.03 113 150 154 206 250 0.0 0.1 B02BX06 emicizumab (15 mg) 0.00 0.00 0 0 0 540 34.5 43.9 B03A IRON PREPARATIONS 6.80 6.65 6.40 6.51 6.63 38 027 41 525 44 375 48 560 50 350 7.3 9.4 B03AA Iron bivalent, oral preparations 6.72 6.55 6.29 6.39 6.51 36 331 39 712 42 46 688 48 391 7.0 9.0 B03AA01 ferrous glycine sulfate (0.2 g) 1.53 1.22 1.33 1.51 1.58 11 113 10 275 12 755 15 799 16 126 2.1 3.0 B03AA02 ferrous fumarate (0.2 g) 0.17 0.16 0.08 1 822 1 959 1 380 7 0 0.4 0.0 B03AA07 ferrous sulfate (0.2 g) 5.19 5.34 4.96 4.88 4.93 23 850 28 907 29 019 31 408 32 791 4.6 6.1 B03AB Iron trivalent, oral preparations - - - - - 0 0 10 45 50 0.0 0.0 B03AB10 ferric maltol - - - - - 0 0 10 45 50 0.0 0.0 B03AC Iron, parenteral preparations 0.08 0.09 0.10 0.12 0.12 1 853 1 968 2 065 2 028 2 170 0.4 0.4 B03B VITAMIN B 12 AND FOLIC ACID 35.69 37.81 39.55 42.28 44.76 146 564 160 171 522 182 574 193 598 28.1 36.1 B03BA Vitamin B 12 (cyanocobalamin and analogues) 19.89 18.75 19.04 20.15 20.07 102 261 104 146 111 353 118 472 119 106 19.6 22.2 B03BA01 cyanocobalamin (1 mg O/20 mcg P) 2.67 3.09 5.79 7.97 9.90 14 032 20 180 39 218 53 135 63 874 2.7 11.9 B03BA03 hydroxocobalamin (20 mcg) 17.19 15.64 13.25 12.17 10.16 91 031 87 855 76 290 69 701 59 107 17.5 11.0 B03BA05 mecobalamin (1.5 mg O/0.2 mg P) 0.03 0.02 0.01 0.01 0.01 173 179 64 45 47 0.0 0.0 B03BB Folic acid and derivatives 15.80 19.06 20.51 22.13 24.69 49 263 62 657 67 279 72 327 84 256 9.5 15.7 B03BB01 folic acid (0.4 mg) 15.80 19.06 20.51 22.13 24.69 49 204 62 614 67 205 72 212 84 123 9.4 15.7 48 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of indiv iduals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 B03X OTHER ANTIANEMIC PREPARATI 0.63 0.64 0.66 0.73 0.75 3 591 3 653 3 758 4 010 4 117 0.7 0.8 B03XA Other antianemic 0.07 0.08 0.09 259 237 254 332 (4 mcg) 0.03 0.01 0.04 0.08 0.15 205 109 372 731 1180 0.0 0.2 number of DDDs/year ATC 2016 4221 5024 5579 5943 6413 HEMATOLOGICAL AGENTS 4221 5024 5579 5943 6413 117 135 141 143 156 0.0 0.0 B06AA Enzymes - - - - - 5 8 10 11 12 0.0 0.0 B06AA03 hyaluronidase - - - - - 5 8 10 11 12 0.0 0.0 B06AC Drugs used in hereditary angioedema 4221 5024 5579 5943 111 126 130 132 plasma derived (1.4 TU) 2779 3448 4042 4310 72 88 90 (30 mg) 1442 1576 1537 1601 90 99 108 0.0 0.0 B06AC04 conestat alfa (3.5 TU) 32 1 0 0 0 <5 <5 0.0 - B06AC05 lanadelumab (21.4 mg) 98 0 0 0 <5 <5 0.0 - 49 m\u00e5lt i DDD (903 Reseptregisteret av befolkningen utlevert minst ett . Source: Drug Statistics mid ler Figur 4.4.2 viser at midler over lengre tid. 050100150200250300 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020DDD/1000 inhabitants/dayantihypertensives (C02) (C07) ACE inhibitors plain and comb. (C09A and C09B) ARBs plain and comb. (C10AA) mest brukte middelet som i antall DDD for statiner. 2020. Andre lipidsenkende midler brukes lite, men har fra 2016 til 2020 \u00f8kt med 46 %. Denne gruppen in 2001-2020. Source: Norwegian Drug Wholesales Statistics 020406080100120140160 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 lipidsenkende midler Year 52 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 C CARDIOVASCULAR SYSTEM C01 CARDIAC THERAPY 10.29 10.03 9.62 9.46 8.89 110 226 109 552 109 094 107 577 105 015 21.1 19.6 C01A CARDIAC GLYCOSIDES 1.26 1.14 1.02 0.96 0.85 11 878 11 153 10 482 10 012 9 626 2.3 1.8 C01AA Digitalis g lycosides 1.26 1.14 1.02 0.96 0.85 11 878 11 153 10 482 10 012 9 626 2.3 1.8 C01AA04 digitoxin (0.1 mg) 0.04 0.03 0.02 0.02 0.01 525 398 322 244 194 0.1 0.0 C01AA05 digoxin (0.25 mg) 1.22 1.11 1.00 0.94 0.84 11 377 10 769 10 167 9 778 9 441 2.2 1.8 C01B ANTIARRHYTHMICS, CLASS I AND III 2.24 2.33 2.38 2.51 2.48 16 006 16 810 17 401 18 265 18 795 3.1 3.5 C01BA Antiarrhythmics, class Ia 0.02 0.02 0.02 0.02 0.01 100 100 99 102 84 0.0 0.0 C01BA03 disopyramide (0.4 g) 0.02 0.02 0.02 0.02 0.01 96 96 94 98 81 0.0 0.0 C01BC Antiarrhythmics, class Ic 1.16 1.18 1.17 1.19 1.13 7 890 8 152 8 194 8 353 8 420 1.5 1.6 C01BC04 flecainide (0.2 g) 1.16 1.18 1.17 1.19 1.13 7 885 8 145 8 190 8 349 8 410 1.5 1.6 C01BD Antiarrhythmics, class III 1.06 1.13 1.19 1.31 1.33 8 315 8 871 9 391 10 124 10 588 1.6 0.77 0.79 0.81 0.87 0.89 6 232 6 551 6 813 7 270 7 508 1.2 1.4 C01BD07 dronedarone (0.8 g) 0.29 0.34 0.38 0.43 0.45 2 253 2 520 2 792 3 128 3 343 0.4 0.6 C01C CARDIAC 0.40 874 27 586 484 29 342 28 817 5.0 5.4 C01CA Adrenergic and dopaminergic agents 0.22 0.23 0.24 0.24 0.31 25 874 27 586 29 484 29 342 28 817 5.0 5.4 C01CA17 midodrine (30 mg) 0.00 0.00 0.00 0.01 0.01 54 69 72 115 163 0.0 0.0 C01CA24 epinephrine (0.5 mg) 0.22 0.22 0.23 0.23 0.30 25 752 27 455 29 352 29 177 28 603 4.9 5.3 C01D VASODILATORS USED IN CARDIAC DISEASES 6.37 6.14 5.79 5.55 5.11 60 017 57 317 54 878 52 919 50 546 11.5 9.4 C01DA Organic nitrates 6.37 6.14 5.79 5.55 5.11 60 017 57 316 54 877 52 919 50 545 11.5 9.4 C01DA02 glyceryl trinitrate (2.5 mg SL/5mg O/TD) 1.19 1.17 1.11 1.05 0.91 46 507 44 297 42 415 40 747 38 397 8.9 7.2 C01DA08 isosorbide dinitrate (60 mg) 0.07 722 231 0 0 0 0.1 0.0 C01DA14 isosorbide mononitrate (40 mg) 5.11 4.97 4.68 4.50 4.20 24 237 23 752 22 774 22 006 21 306 4.7 4.0 C01E OTHER CARDIAC PREPARATIONS 0.03 0.04 0.04 0.05 0.05 172 286 289 373 430 0.0 0.1 C01EB Other cardiac preparations 0.03 0.04 0.04 0.05 0.05 172 286 289 373 430 0.0 0.1 C01EB09 ubidecarenone - - - - - 0 0 10 22 24 0.0 0.0 C01EB10 adenosine (15 mg) 0.02 0.02 0.02 0.01 0.01 - - - - - - - C01EB15 trimetazidine (40 mg) 0.00 0.00 0.00 0.00 7 11 9 0.0 0.0 C01EB17 ivabradine (10 mg) 0.01 0.02 0.02 0.03 0.03 141 249 241 305 357 0.0 0.1 C01EB18 ranolazine (1.5 g) 0.00 0.00 0.00 0.00 0.0 C02 ANTIHYPERTENSIVES 4.01 4.05 3.70 3.75 3.52 17 147 17 723 17 686 16 774 18 006 3.3 3.4 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTIN G 1.25 1.29 1.25 1.40 1.37 6 644 7 025 7 169 7 787 9 148 1.3 1.7 C02AB Methyldopa 0.00 0.00 0.00 0.00 (1 g) 0.00 0.00 0.00 0.00 0.00 57 46 40 41 30 0.0 0.0 53 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 C02AC Imidazoline receptor agonists 1.25 1.29 1.24 1.39 1.37 6 592 6 982 7 132 7 749 9 121 1.3 1.7 C02AC01 clonidine (0.45 mg) 0.02 0.02 0.03 0.04 0.09 125 200 282 514 1 866 0.0 0.4 C02AC02 guanfacine (3 mg) 0.01 0.04 0.05 0.07 0.09 96 417 477 638 734 0.0 0.1 C02AC05 moxonidine (0.3 mg) 1.22 1.23 1.16 1.29 1.19 6 373 6 367 6 377 6 600 6 528 1.2 1.2 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 2.67 2.67 2.37 2.26 2.06 10 610 10 818 10 630 9 064 8 930 2.0 1.7 C02CA Alpha -adrenoreceptor antagonists 2.67 2.67 2.37 2.26 2.06 10 610 10 818 10 630 9 064 8 930 2.0 1.7 C02CA01 prazosin (5 mg) 0.01 0.01 0.02 0.02 0.02 95 140 145 122 145 0.0 0.0 C02CA04 doxazosin (4 mg) 2.66 2.66 2.35 2.24 2.04 10 517 10 681 10 488 8 943 8 790 2.0 1.6 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 0.03 0.03 0.04 0.04 0.03 383 383 411 427 439 0.1 0.1 C02DB Hydrazinophthalazine derivatives 0.03 0.03 0.04 0.04 0.03 330 322 363 370 366 0.1 0.1 C02DB02 hydralazine (0.1 g) 0.03 0.03 0.04 0.04 0.03 330 322 363 370 366 0.1 0.1 C02DC Pyrimidine derivatives 0.00 0.00 0.00 0.00 0.01 56 62 C02DC01 minoxidil (20 mg) 0.00 0.00 0.00 0.00 0.01 56 62 50 63 76 0.0 0.0 C02K OTHER ANTIHYPERTENSIVES 0.05 0.05 0.05 0.06 0.06 304 326 337 361 357 0.1 0.1 C02KX Antihypertensives for pulmonary arterial hypertensi on 0.05 0.05 0.05 0.06 0.06 294 317 328 354 350 0.1 0.1 C02KX01 bosentan (0.25 g) 0.02 0.02 0.01 0.01 0.01 111 106 103 112 109 0.0 0.0 C02KX02 ambrisentan (7.5 mg) 0.01 0.01 0.01 0.01 0.01 55 58 47 53 51 0.0 0.0 C02KX04 macitentan (10 mg) 0.02 0.02 0.02 0.03 0.03 114 144 155 168 170 0.0 0.0 C02KX05 riociguat (4 .5 mg) 0.00 0.00 0.01 0.01 0.01 19 21 28 28 0.0 C03 DIURETICS 33.62 32.01 31.69 30.80 29.77 175 921 170 169 412 163 999 162 119 33.7 977 28 447 27 595 6.8 5.1 C03AA Thiazides, plain 1.87 1.84 1.79 1.65 1.64 12 857 12 495 13 253 11 874 12 499 2.5 2.3 C03AA03 hydrochlorothiazide (25 mg) 1.87 1.84 1.79 1.65 1.64 12 857 12 492 13 250 11 870 12 498 2.5 2.3 C03AB Thiazides and potassium in combination 3.64 3.30 2.98 2.66 2.41 22 519 20 465 18 795 16 630 15 152 4.3 2.8 C03AB01 bendroflumethiazide and potassium (2.5 mg) 3.64 3.30 2.98 2.66 2.41 22 519 20 465 18 795 16 630 15 152 4.3 2.8 C03C HIGH -CEILING DIURETICS 23.33 10.85 11.24 11.63 79 694 75 970 74 597 78 887 79 256 15.3 14.8 C03CA02 bumetanide (1 mg) 11.41 11.37 11.85 11.20 10.14 42 921 44 130 46 220 44 135 43 382 8.2 8.1 C03D POTASSIUM -SPARING AGENTS 1.68 1.72 1.84 2.00 2.18 21 421 22 492 24 209 26 290 28 147 4.1 5.2 C03DA Aldost erone antagonists 1.68 1.72 1.84 2.00 2.18 21 406 22 476 24 196 26 275 28 128 4.1 5.2 C03DA01 spironolactone (75 mg) 1.51 1.54 1.60 1.67 1.79 20 091 20 980 22 160 23 591 24 835 3.9 4.6 C03DA04 eplerenone (50 mg) 0.17 0.18 0.24 0.33 0.39 1 489 1 671 2 236 2 918 3 551 0.3 0.7 54 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 C03E DIURETICS AND POTASSIUM -SPARING AGENTS IN COMBINATION 3.08 2.61 2.36 1.99 1.71 16 977 15 279 13 339 11 099 9 768 3.3 1.8 C03EA Low -ceiling diuretics and potassium -sparing agents 3.08 2.61 2.36 1.99 1.71 16 977 15 279 13 339 11 0 99 9 768 3.3 1.8 C03EA01 hydrochlorothiazide and potassium -sparing agents (1 UD) 3.08 2.61 2.36 1.99 1.71 16 977 15 279 13 339 11 099 9 768 3.3 1.8 C03X OTHER DIURETICS 0.01 0.02 0.04 0.05 0.07 78 160 187 224 275 0.0 0.1 C03XA Vasopressin antagonists 0.01 0.02 0.04 0.05 0.07 78 160 187 224 275 0.0 0.1 C03XA01 tolvaptan (30 mg) 0.01 0.02 0.04 0.05 0.07 78 160 187 224 275 0.0 0.1 C04 PERIPHERAL VASODILATORS 0.08 0.07 0.06 0.06 0.06 0.08 0.07 0.06 0.08 0.07 0.06 g) 0.08 0.07 0.06 0.06 0.06 631 565 507 501 BLOCKING AGENTS 35.33 34.76 34.06 33.84 32.97 375 425 378 400 379 605 382 270 381 904 72.0 71.2 C07A BETA BLOCKING AGENTS 34.68 34.14 33.48 33.31 32.48 372 172 375 321 376 704 379 602 379 443 71.4 70.7 C07AA Beta blocking agents, non-selective 1.54 1.51 1.40 1.36 1.31 20 165 20 491 21 170 22 064 21 680 3.9 4.0 C07AA05 propranolol (0.16 g) 0.83 0.86 0.82 0.84 0.81 274 15 992 17 116 18 383 18 289 2.9 3.4 C07AA07 sotalol (0.16 g) 0.70 0.64 0.57 0.51 0.48 4 768 4 346 3 872 3 484 3 165 0.9 0.6 C07AA12 nadolol (0.16 g) 0.01 0.01 0.02 0.02 0.02 139 163 189 206 245 0.0 0.1 C07AB Beta blocking agents, selective 30.51 30.01 29.52 29.39 28.64 333 820 336 283 411 054 288 235 53.8 53.7 C07AB 03 atenolol (75 mg) 3.50 3.14 2.74 2.74 2.29 24 654 23 277 21 435 18 868 17 517 4.7 3.3 C07AB07 bisoprolol (10 mg) 2.91 3.01 3.10 3.21 3.24 31 582 33 069 34 311 35 632 36 314 6.1 6.8 C07AB12 nebivolol (5 mg) 0.00 0.01 0.01 0.02 0.02 41 79 98 127 143 0.0 0.0 C07AG Alpha and beta blocking agents 2.64 2.62 2.56 2.56 2.53 21 956 22 064 22 019 22 439 22 391 4.2 4.2 C07AG01 labetalol (0.6 g) 0.18 0.18 0.18 0.18 0.18 2 789 2 819 2 963 3 134 3 164 0.5 0.6 C07AG02 carvedilol (37.5 mg) 2.45 2.44 2.38 2.38 2.35 19 189 19 267 19 077 19 335 19 258 3.7 3.6 C07B BETA BLOCKING AGENTS AND THIAZIDES 0.65 0.62 0.58 0.53 0.49 3 563 3 342 3 113 2 883 2 738 0.7 0.5 C07BB Beta blocking agents, selective, and thiazides 0.65 0.62 0.58 0.53 0.49 3 563 3 342 3 113 2 883 2 738 0.7 0.5 C07BB07 bisoprolol and thiazides (1 UD) 0.65 0.62 0.58 0.53 0.49 3 556 3 336 3 105 2 875 2 735 0.7 0.5 C07BB12 CHANNEL BLOCKERS 58.48 57.95 58.78 61.57 62.21 249 264 002 269 500 47.9 50.2 C08C 250 245 256 090 45.0 (5 mg) 32.57 31.37 33.78 37.12 37.85 134 703 137 090 155 136 163 575 167 038 25.8 31.1 55 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 C08CA02 felodipine (5 mg) 3.48 3.36 3.40 3.58 3.45 13 522 12 982 14 561 14 804 14 194 2.6 2.6 C08CA03 isradipine (5 mg) 0.07 0.07 0.02 422 351 275 <5 0 0.1 0.0 C08CA05 nifedipine (30 mg) 9.45 9.98 7.72 5.77 5.64 46 124 50 280 47 653 25 203 24 057 8.9 4.5 C08CA06 nimodipine O/50 mg P) 0.00 0.00 0.00 31 45 lercanidipine (10 mg) 10.57 10.79 11.63 12.95 13.12 43 626 44 738 51 137 54 170 54 688 8.4 10.2 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 2.33 2.38 2.22 2.14 2.15 15 746 15 374 15 121 14 918 14 478 3.0 2.7 C08DA Pheny lalkylamine derivatives 1.69 1.75 1.60 1.56 1.52 11 965 11 662 11 357 11 261 10 914 2.3 2.0 C08DA01 verapamil (0.24 g) 1.69 1.75 1.60 1.56 1.52 11 965 11 662 11 357 11 261 10 914 2.3 2.0 C08DB Benzothiazepine derivatives 0.64 0.63 0.62 0.58 0.62 3 3 641 0.7 (0.24 0.62 0.62 3 763 3 820 3 742 3 641 0.7 0.7 C09 44.17 43.75 135 955 137 321 138 649 138 734 137 469 26.1 25.6 C09AA ACE inhibitors, plain 44.17 44.05 44.07 44.50 43.75 135 955 137 321 138 649 138 734 137 469 26.1 25.6 C09AA01 captopril (50 mg) 0.30 0.27 0.24 0.20 0.19 1 381 1 339 1 205 1 094 976 0.3 0.2 C09AA02 enalapril (10 mg) 10.12 9.97 9.77 9.87 9.73 46 041 46 333 46 453 46 507 46 173 8.8 8.6 C09AA03 lisinopril (10 mg) 4.69 4.46 4.29 4.19 4.04 21 466 20 709 20 334 19 418 18 721 4.1 3.5 C09AA04 perindopril (4 mg) 0.00 0.01 0.01 0.01 0.02 39 52 60 80 202 0.0 0.0 C09AA05 ramipril (2.5 mg) 29.06 29.34 29.76 30.22 29.77 67 69 406 71 099 72 069 71 858 13.0 13.4 C09B ACE INHIBITORS, COMBINATIONS 5.27 5.12 4.78 4.58 4.37 30 217 29 243 28 185 27 004 25 849 5.8 4.8 C09BA ACE inhibitors and diuretics 4.97 4.77 4.44 4.18 3.94 28 485 27 337 26 093 24 630 23 206 5.5 4.3 C09BA02 enalapril and diuretics (1 UD) 3.07 2.97 2.80 2.69 2.56 17 658 17 149 16 553 15 866 15 180 3.4 2.8 C09BA03 lisinopril and diure tics (1 UD) 1.90 1.80 1.64 1.50 1.38 10 836 10 189 9 561 8 777 8 036 2.1 1.5 C09BB ACE inhibitors and calcium channel blockers 0.30 0.35 0.34 0.40 0.43 1 755 1 930 2 125 2 418 2 684 0.3 0.5 C09BB02 enalapril and lercanidipine (1 UD) 0.30 0.35 0.34 0.40 0.43 1 755 1 930 2 125 2 418 2 684 0.3 0.5 C09C ANGIOTENSIN 66 606 67 344 69 440 71 294 71 549 12.8 13.3 C09CA02 eprosartan (0.6 g) 0.20 0.17 0.15 0.12 0.11 1 105 988 902 830 686 0.2 0.1 C09CA03 valsartan (80 mg) 8.79 9.51 9.73 10.34 10.85 35 101 38 060 40 080 40 005 42 958 6.7 8.0 C09CA04 irbesartan (0.15 g) 4.37 4.28 4.12 4.09 3.91 18 209 17 853 17 579 17 232 16 540 3.5 3.1 C09CA06 candesartan (8 mg) 28.64 30.63 33.14 37.10 39.43 110 321 118 609 129 744 141 509 151 381 21.2 28.2 C09CA07 telmisartan (40 mg) 1.36 1.34 1.40 1.40 1.41 5 705 5 680 5 794 5 840 5 920 1.1 1.1 C09CA08 olmesartan medoxomil (20 mg) 0.28 0.30 0.30 0.30 0.30 542 1 538 1 644 1 700 1 695 0.3 0.3 56 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 C09D ANGIOTENSIN 784 43.5 795 164 843 34.2 30.7 C09DA01 and diuretics (1 UD) 11.27 11.04 10.63 10.14 9.77 64 474 63 337 61 870 58 886 57 080 12.4 10.6 C09DA02 eprosartan and diuretics (1 UD) 0.21 0.20 0.18 0.16 0.15 1 201 1 113 1 024 945 867 0.2 0.2 C09DA03 valsartan and 633 26 833 530 24 991 3.71 23 578 22 301 21 177 19 678 18 438 4.5 3.4 10.23 10.21 10.25 10.18 10.12 58 597 59 488 60 366 59 966 60 139 11.2 11.2 C09DA07 telmisartan and diuretics (1 UD) 0.58 0.55 0.53 0.50 0.48 3 414 3 266 3 131 2 970 2 885 0.7 0.5 C09DA08 olmesartan medoxomil and diuretics (1 UD) 0.18 0.17 0.17 0.16 0.15 992 972 973 928 907 0.2 0.2 C09DB Angiotensin II receptor blockers (ARBs) and calcium channel blockers 4.90 5.18 5.40 6.45 7.14 29 272 31 687 34 464 38 960 42 854 5.6 8.0 C09DB01 390 5.6 321 0.1 0.1 5.87 24 276 26 922 29 32 713 36 183 4.7 5.14 23 861 26 003 28 023 29 852 31 796 4.6 5.9 C09DX04 valsartan and sacubitril (1 UD) 0.05 0.14 0.27 0.47 0.73 417 921 1 682 2 871 4 414 0.1 0.8 C09X OTHER AGENTS ACTING ON THE RENIN - ANGIOTENSIN SYSTEM 0.01 0.01 0.00 0.00 0.00 35 32 10 8 9 Renin -inhibitors 0.01 0.01 0.00 0.00 0.00 35 32 10 8 9 0.0 0.0 C09XA02 aliskiren (0.15 g) 0.01 0.01 0.00 0.00 0.00 35 32 10 8 9 0.0 LIPID MODIFYING AGENTS 131.89 135.61 112.54 147.66 161.29 546 563 741 614 195 104.8 232 429 212 312 192 106 174 850 160 085 44.6 29.8 pravastatin (30 mg) 3.12 2.99 2.88 2.76 2.57 18 317 17 903 17 497 16 597 15 917 3.5 3.0 C10AA04 fluvastatin (60 mg) 1.28 1.18 1.15 1.14 1.12 7 731 7 469 5 152 5 202 5 199 1.5 1.0 C10AA05 atorvastatin (20 mg) 75.30 82.29 59.46 94.98 107. 73 264 578 295 715 329 577 349 027 382 459 50.7 71.3 C10AA07 rosuvastatin (10 mg) 5.36 6.24 7.35 8.90 10.71 20 448 25 959 30 921 36 645 43 736 3.9 C10AA08 pitavastatin (2 mg) 0.00 0.00 0.00 30 26 25 0.0 0.0 C10AB Fibrates 0.05 0.05 0.05 0.05 0.05 301 316 329 329 336 0.1 0.1 C10AB02 bezafibrate (0.6 g) 0.00 0.00 0.00 0.01 0.01 36 36 39 49 49 0.0 0.0 C10AB04 gemfibrozil (1.2 g) 0.01 0.01 0.01 0.01 0.01 68 67 61 57 53 0.0 0.0 57 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 C10AB05 fenofibrate (0.2 g) 0.03 0.04 0.04 0.03 0.04 197 215 230 223 235 0.0 0.0 C10AC Bile acid seq uestrants 0.15 0.16 0.16 0.17 0.17 3 011 3 277 3 412 3 488 3 290 0.6 0.6 C10AC01 colestyramine (14 g) 0.08 0.09 0.09 0.10 0.10 2 328 2 610 2 763 2 858 2 712 0.5 0.5 C10AC02 colestipol (20 g) 0.01 0.01 0.01 0.01 0.00 242 216 196 189 205 0.1 Other lipid modifying agents 5.05 5.58 7.65 8.06 11.85 33 353 38 964 53 421 56 626 75 845 6.4 14.1 C10AX06 omega -3-triglycerides incl. other esters and acids (4 tab) 0.53 0.56 0.56 0.56 0.58 4 480 4 725 4 813 4 716 4 766 0.9 0.9 C10AX09 ezetimibe (10 mg) 4.45 4.91 6.91 7.23 10.89 29 420 34 729 49 075 52 118 71 190 5.6 13.3 C10AX13 evolocumab (10 mg) 0.03 0.04 0.07 0.10 0.14 217 317 484 664 931 0.0 0.2 C10AX14 alirocumab (5.4 mg) 0.04 0.06 0.11 0.17 0.24 185 280 474 665 921 0.0 0.2 C10B LIPID MODIFYING AGENTS, COMBINATIONS 2.14 2.66 2.79 3.41 1.04 14 974 20 260 21 745 24 468 10 694 2.9 2.0 C10BA Combinations of various lipid modifying agents 2.14 2.66 2.79 3.41 1.04 14 974 20 260 21 745 24 468 10 694 2.9 2.0 0.67 251 4 555 629 4 652 4 206 0.8 1.47 10 871 15 847 17 293 20 021 4 766 2.1 0.9 C10BA 06 rosuvastatin and ezetimibe (1 UD) 0.21 0 0 0 <5 2 007 0.0 0.4 58 4.5 D Dermatologiske systemiske antibiotikapreparater i ATC gruppe J01. 60 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 D DERMATOLOGICALS - - - - - D01 ANTIFUNGALS FOR DERMATOLOGICAL USE - - - - - 145 187 150 144 153 603 161 220 162 666 27.9 30.3 D01A ANTIFUNGALS FOR TOPICAL USE - - - - - 127 061 132 033 134 334 142 726 144 114 24.4 26.9 D01AA Antibiotics - - - - - 13 27 41 33 30 0.0 0.0 D01AA01 nystatin - - - - - 13 27 41 33 30 0.0 0.0 D01AC Imidazole and triazole derivatives - - - - - 102 356 107 077 109 066 117 744 119 006 19.6 22.2 D01AC01 clotrimazole - - - - - 10 096 10 505 10 533 11 342 11 003 1.9 2.1 D01AC02 miconazole - - - - - 2 321 2 309 2 382 2 330 2 411 0.5 0.5 D01AC03 econazole - - - - - 975 1 016 1 035 1 177 1 231 0.2 0.2 D01AC08 ketoconazole - - - - - 19 256 20 378 21 874 24 981 24 796 3.7 4.6 D01AC20 imidazoles/triazoles in combination with corticosteroids - - - - - 74 981 78 325 78 597 84 038 85 641 14.4 16.0 D01AE Other antifungals for topical use - - - - - 28 410 28 823 29 126 29 029 29 355 5.5 5.5 D01AE02 methylros aniline - - - - - 812 873 586 221 667 0.2 0.1 D01AE14 ciclopirox - - - - - 4 645 4 773 4 976 4 978 4 991 0.9 0.9 D01AE15 terbinafine - - - - - 19 117 19 520 19 823 20 306 20 216 3.7 3.8 D01AE16 amorolfine - - - - - 4 335 4 152 4 212 4 023 3 984 0.8 0.7 D01B ANTIFUNGALS FOR SYSTEMIC USE 1.22 1.24 1.28 1.22 1.24 22 551 22 760 24 057 23 256 23 476 4.3 4.4 D01BA Antifungals for systemic use 1.22 1.24 1.28 1.22 1.24 22 551 22 760 24 057 23 256 23 476 4.3 4.4 D01BA01 griseofulvin (0.5 g) 0.00 0.00 0.00 0.00 23 20 17 0.0 0.0 D01BA02 terbinafine (0.25 g) 1.22 1.24 1.28 1.22 1.24 22 533 22 733 24 038 23 243 23 463 4.3 4.4 D02 EMOLLIENTS AND PROTECTIVES - - - - - 22 533 22 733 24 038 23 243 23 463 4.3 4.4 D02A EMOLLIENTS AND PROTECTIVES - - - - - 28 189 75 655 111 677 141 006 162 641 5.4 30.3 D02AE Carbamide products - - - - - 26 158 73 598 109 620 139 113 161 191 5.0 30.0 D02AE01 carbamide - - - - - 26 158 73 598 109 620 139 113 161 191 5.0 30.0 D05 ANTIPSORIATICS - - - - - 30 801 31 250 30 297 30 874 31 453 5.9 5.9 D05A ANTIPSORIATICS FOR TOPICAL USE - - - - - 28 920 29 303 28 441 29 061 29 680 5.6 5.5 D05AA Tars - - - - - 1 550 1 917 1 940 2 194 2 446 0.3 0.5 D05AC Antracen derivatives - - - - - <5 7 7 5 <5 - - D05AC01 dithranol - - - - - <5 7 7 5 <5 - - D05AX Other antipsoriatics for topical use - - - - - 27 610 27 683 26 768 27 199 27 613 5.3 5.1 D05AX02 calcipotriol - - - - - 116 369 471 333 355 0.0 0.1 D05AX03 calcitriol - - - - - 1 284 1 162 1 022 956 828 0.3 0.2 D05AX52 calcipotrio l, combinations - - - - - 26 701 26 676 25 818 26 336 26 819 5.1 5.0 D05B ANTIPSORIATICS FOR SYSTEMIC USE 0.18 0.18 0.18 0.18 0.18 2 446 2 519 2 463 2 464 2 446 0.5 0.5 D05BA Psoralens for systemic use 0.00 0.00 0.00 0.00 0.00 11 16 15 15 7 0.0 0.0 61 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 0.00 0.00 0.00 15 15 for treatment of 2 361 2 442 412 2 443 2 436 0.5 0.5 D05BB02 acitretin (35 mg) 0.18 0.18 0.18 0.18 0.17 2 361 2 442 2 412 2 443 2 436 0.5 0.5 D05BX Other antipsoriatics for systemic use - - - - - 78 66 38 7 <5 0.0 - D05BX51 fumaric acid derivatives, combinations - - - - - 78 66 38 7 <5 0.0 - D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE - - - - - 111 663 108 688 106 034 106 769 100 859 21.4 18.8 D06A ANTIBIOTICS FOR TOPICAL USE - - - - - 56 016 54 255 53 258 54 360 51 502 10.7 9.6 D06AA Tetracycline and derivatives - - - - - 3 230 3 226 3 276 3 636 3 502 0.6 0.7 D06AA02 chlortetracycline - - - - - 16 29 28 17 20 0.0 0.0 D06AA03 oxytetracycline - - - - - 3 214 3 198 3 248 3 619 3 482 0.6 0.7 D06AX Other antibiotics for topical use - - - - - 52 966 51 217 50 165 50 923 48 170 10.2 9.0 D06AX01 fusidic acid - - - - - 48 979 47 857 47 492 49 608 46 224 9.4 8.6 D06AX 05 bacitracin - - - - - 2 357 2 893 2 805 1 341 2 029 0.5 0.4 5 - 0.0 D06AX09 mupirocin - - - - - 47 43 39 49 64 0.0 0.0 D06AX13 retapamulin - - - - - 1 813 640 0 0 0 0.4 0.0 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE - - - - - 57 534 56 248 54 555 54 144 50 987 11.0 9.5 D06BA Sulfonamides - - - - - 3 124 2 866 2 893 2 603 2 609 0.6 0.5 D06BA01 silver sulfadiazine - - - - - 3 124 2 866 2 893 2 603 2 609 0.6 0.5 D06BB Antivirals - - - - - 35 673 35 270 34 585 32 831 33 432 6.8 6.2 D06BB03 aciclovir - - - - - 14 818 15 101 15 302 14 465 14 489 2.8 2.7 D06BB04 podophyllotoxin - - - - - 12 096 10 834 10 353 9 624 8 818 2.3 1.6 D06BB06 penciclovir - - - - - 958 871 691 560 457 0.2 0.1 D06BB10 imiquimod - - - - - 8 494 9 299 8 973 8 698 10 107 1.6 1.9 D06BB12 sinecatechins - - - - - 75 0 0 0 0 0.0 0.0 D06BB53 aciclovir, combinations - - - - - 0 0 32 133 178 0.0 0.0 D06BX Other chemotherapeutics - - - - - 19 386 18 720 17 665 19 305 15 270 3.7 2.8 D06BX01 metronidazole - - - - - 14 082 13 311 12 426 13 908 14 961 2.7 2.8 D06BX02 ingenol mebutate - - - - - 5 363 5 459 5 276 5 440 313 1.0 0.1 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS - - - - - 406 760 420 091 424 140 434 154 452 908 78.0 84.4 D07A CORTICOSTEROIDS , PLAIN - - - - - 349 112 360 719 361 931 369 300 384 962 67.0 71.7 D07AA Corticosteroids, weak (group I) - - - - - 34 121 36 466 36 147 39 765 40 077 6.5 7.5 D07AA02 hydrocortisone - - - - - 34 121 36 466 36 147 39 765 40 077 6.5 7.5 D07AB Corticostero ids, moderately potent (group II) - - - - - 117 426 124 714 125 572 128 189 134 780 22.5 25.1 62 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 D07AB02 hydrocortisone butyrate - - - - - 92 705 98 183 99 177 110 928 121 213 17.8 22.6 D07AB08 desonide - - - - - 26 249 28 161 27 855 19 569 15 290 5.0 2.9 D07AC Corticosteroids, potent (group III) - - - - - 176 406 176 748 173 575 182 629 184 840 33.8 34.4 D07AC01 betamethasone - - - - - 58 525 55 767 54 130 53 421 48 901 11.2 9.1 D07AC03 desoximetasone - - - - - 12 571 11 848 10 660 12 208 4 854 2.4 0.9 D07AC04 fluocinolone acetonide - - - - - 5 773 5 634 5 132 5 936 8 835 1.1 1.7 D07AC08 fluocinonide - - - - - 446 376 362 365 444 0.1 0.1 D07AC13 mometasone - - - - - 98 164 102 116 102 281 115 156 127 335 18.8 23.7 D07AC17 fluticasone - - - - - 8 791 8 661 7 759 3 622 2 718 1.7 0.5 D07AD Corticosteroids, very potent (group IV) - - - - - 71 624 74 810 76 790 69 790 79 874 13.7 14.9 D07AD01 clobetasol - - - - - 71 624 74 810 76 790 69 790 79 874 13.7 14.9 D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEP TICS - - - - - 32 087 32 979 37 187 37 083 42 064 6.2 7.8 D07BB Corticosteroids, moderately potent, combinations with antiseptics - - - - - 9 621 4 673 6 995 9 <5 1.9 - D07BB02 desonide and antiseptics - - - - - 9 621 4 673 6 995 9 <5 1.9 - D07BC Cortic osteroids, potent, combinations with antiseptics - - - - - 23 369 28 949 30 910 37 077 42 064 4.5 7.8 D07BC01 betamethasone and antiseptics - - - - - 19 354 26 980 28 898 34 338 39 213 3.7 7.3 D07BC02 fluocinolone acetonide and antiseptics - - - - - 4 78 6 2 260 2 135 2 960 3 067 0.9 0.6 D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS - - - - - 26 192 26 831 25 976 27 865 26 938 5.0 5.0 D07CA Corticosteroids, weak, combinations with antibiotics - - - - - 25 707 26 181 25 439 27 828 26 897 4.9 5.0 D07CA01 hydrocortisone and antibiotics - - - - - 25 707 26 181 25 439 27 828 26 897 4.9 5.0 D07CC Corticosteroids, potent, combinations with antibiotics - - - - - 514 687 563 39 42 0.1 0.0 D07CC01 betamethasone and antibiotics - - - - - 513 684 562 37 41 0.1 0.0 D07X CORTICOSTEROIDS, OTHER COMBINATIONS - - - - - 30 276 31 931 32 027 33 261 35 306 5.8 6.6 D07XA Corticosteroids, weak, other combinations - - - - - 5 11 <5 0 0 0.0 0.0 D07XA01 hydrocortisone - - - - - 5 11 <5 0 0 0.0 0.0 D07XC Corticosteroid s, potent, other combinations - - - - - 30 271 31 920 32 023 33 261 35 306 5.8 6.6 D07XC01 betamethasone - - - - - 30 271 31 920 32 023 33 261 35 306 5.8 6.6 D10 ANTI -ACNE PREPARATIONS - - - - - 78 061 82 095 83 203 85 751 92 600 15.0 17.3 D10A ANTI -ACN E PREPARATIONS FOR TOPICAL USE - - - - - 68 595 71 573 70 961 72 251 77 874 13.2 14.5 D10AD Retinoids for topical use in acne - - - - - 43 437 46 115 47 702 50 432 54 251 8.3 10.1 63 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 D10AD01 tretinoin - - - - - 3 253 3 483 3 608 4 134 4 376 0.6 0.8 D10AD03 adapalene - - - - - 7 161 6 883 6 789 7 364 7 789 1.4 1.5 D10AD51 tretinoin, combinations - - - - - 9 127 10 042 10 111 10 663 11 441 1.8 2.1 D10AD53 adapalene, combinations - - - - - 26 519 28 445 29 909 31 280 34 052 5.1 6.3 D10AE Peroxides - - - - - 2 630 3 390 3 939 4 193 4 502 0.5 0.8 D10AE01 benzoyl peroxide - - - - - 2 630 3 390 3 939 4 193 4 502 0.5 0.8 D10AF Antiinfectives for treatment of acne - - - - - 15 651 14 791 11 271 8 527 9 342 3.0 1.7 D10AF01 clindamycin - - - - - 15 619 14 758 11 246 8 478 9 298 3.0 1.7 D10AF02 erythromycin - - - - - 33 35 26 51 45 0.0 0.0 D10AX Other anti -acne preparations for topical use - - - - - 14 338 14 562 15 006 15 613 17 002 2.8 3.2 D10AX03 azelaic acid - - - - - 14334 <5 - - D10B ANTI -ACNE PREPARATIONS FOR SYSTEMIC USE 1.15 1.24 1.40 1.53 1.68 14 285 15 925 17 959 19 924 22 030 2.7 4.1 D10BA Retinoids for treatment of acne 1.15 1.24 1.40 1.53 1.68 14 285 15 925 17 959 19 924 22 030 2.7 4.1 D10BA01 isotretinoin (30 mg) 1.15 1.24 1.40 1.53 1.68 14 285 15 925 17 959 19 924 22 030 2.7 4.1 D11 OTHER DERMATOLOGICAL PREPARATIONS - - - - - 32 631 38 672 41 048 43 883 48 733 6.3 9.1 D11A OTHER DERMATOLOGICAL PREPARATIONS - - - - - 32 631 38 672 41 048 43 883 48 733 6.3 9.1 D11AC Medicated shampoos - - - - 2253 2585 0.4 0.5 2585 0.4 0.5 D11AF Wart and anti -corn preparations - - - - - 2 884 3 214 3 010 333 312 0.6 0.1 D11AH Agents for dermatitis, excluding corticosteroids 0.07 0.09 0.08 0.09 0.14 17 758 19 667 20 505 23 057 26 380 3.4 4.9 D11AH01 tacrolimus - - - - - 10 859 11 229 11 511 12 090 12 955 2.1 2.4 D11AH02 pimecrolimus - - - - - 6 543 8 054 8 630 10 640 12 989 1.3 2.4 D11AH04 alitretinoin (20 mg) 0.07 0.09 0.08 0.09 0.10 853 967 973 1 041 1 104 0.2 0.2 D11AH05 dupilumab (21.4 mg) 0.00 0.00 0.04 0 0 6 19 389 0.0 0.1 D11AX Other dermatologicals minoxidil - - - - 397 469 597 644 738 0.1 0.1 D11AX10 finasteride (1 mg) 0.07 0.07 0.06 0.07 0.06 515 519 511 560 530 0.1 0.1 D11AX16 eflornithine - - - - - 790 934 1 019 1 086 1 202 0.2 0.2 D11AX18 diclofenac - - - - - 368 406 304 261 345 0.1 0.1 D11AX21 brimonidine - - - - - 1 954 1 805 1 405 1 518 1 435 0.4 0.3 D11AX22 ivermectin - - - - - 4 655 8 311 10 395 13 068 14 099 0.9 2.6 64 4.6 G Urogenitalsystem genitalia er den st\u00f8rste av undergruppene i gruppe G (72 % av all DDD i 2020). Reseptregisteret v iser at i 2020 fikk 22 % av ut siden 2015, og 2019 til 2020 ser vi en reduksjon p\u00e5 rundt 2 % m\u00e5lt i (G03AC08). p -piller og hormonal contracept ives 2011 -2020. Source: Norwegian Drug Wholesales Statistics 020000400006000080000100000120000140000160000180000200000220000240000260000280000 2011 2012 2013 2014 2015 2016 2017 Sales IUDs (G02BA03) and contraceptive implants (G03AC08) 2011 -2020 Source: Norwegian Drug Wholesales Statistics Figure 4.6.3 Number of Norwegian women in age groups 10 -49 years who had dispensed at least one hormonal contraceptive in 2020 according to the following categories: Intrauterine contraceptives (G02BA), vaginal rings (G02BB), progestogens and estrogens, fi xed pro gestogens and estrogens, sequential preparations (G03AB) and mini pills, injections and implants 00070 000 2019 2020Intrauterine devices (IUDs) (G02BA03) Contraceptiveimplants (G03AC08)Number of IUDs/ s.c. implants Year 020000400006000080000100000120000 10 - 19 20 - 29 30 - 39 40 - 49Number of users Intrauterine contraceptives (IUDs) Intravaginal contraceptives (vaginal ring) Progestogens and estrogens, fixed combinations Progestogens and estrogens, sequential preparations Progestogens (mini pills, injections and implants) 67 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Num ber of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 G GENITO URINARY SYSTEM 070 42 519 41 124 40 941 40 735 7.7 7.6 G01A ANTIINFECTIVES 0.82 40 070 42 519 41 124 40 941 40 735 7.7 7.6 G01AA Antibiotics 0.06 0.06 0.05 0.05 0.03 24 308 23 450 22 820 21 954 16 277 4.7 3.0 G01AA10 clindamycin (0.1g) 0.06 0.06 0.05 0.05 0.03 24 308 23 450 22 820 21 954 16 277 4.7 3.0 G01AC Quinoline derivatives 0.00 0.01 0.02 0.02 0.02 1 928 6 558 7 965 8 153 11 039 0.4 2.1 G01AC05 dequal inium (20 mg) 0.00 0.01 0.02 0.02 0.02 1 928 6 558 7 965 8 153 11 039 0.4 2.1 G01AD Organic acids - - - - - 12 10 11 6 7 0.0 0.0 G01AD02 acetic acid - - - - - 12 10 11 6 7 0.0 0.0 G01AF Imidazole derivatives 0.83 0.76 0.77 0.77 0.77 15 785 15 115 13 005 13 657 17 047 3.0 3.2 G01AF01 metronidazole (0.5 g) 0.03 0.02 0.02 0.02 0.03 6 968 6 303 6 261 6 257 9 038 1.3 1.7 G01AF02 clotrimazole (0.1 g) 0.77 0.69 0.69 0.68 0.70 7 976 7 989 5 936 6 574 7 480 1.5 1.4 G01AF05 econazole (0.1 g) 0.04 0.05 0.06 0.07 0.04 1 127 1 127 1 034 1 122 924 0.2 (90 mg) 0.00 0.00 0.00 0.00 0.00 9 8 0.0 0.0 G02 OTHER GYNECOLOGICALS 50 823 52 144 55 341 54 026 53 259 9.8 9.9 G02A UTEROTONICS 0.01 0.01 0.01 0.01 0.01 7 11 - G02AD Prostaglandi ns 0.01 0.01 0.01 0.01 0.01 - - - - - - - 2016 2017 2018 2019 2020 G02B CONTRACEPTIVES FOR TOPICAL USE 48 551 49 912 53 117 51 838 51 048 9.3 9.5 G02BA Intrauterine contraceptives 31 358 34 139 38 444 38 191 38 253 6.0 7.1 G02BA03 plastic IUD with progestogen, numbers of IUD 49 304 54 975 60 423 59 914 59 191 31 358 34 139 38 444 38 191 38 253 6.0 7.1 G02BB Intravaginal contraceptives 17 547 16 170 15 083 13 982 13 127 3.4 2.5 G02BB01 vaginal ring with progestogen and estrogen, given in DDD/day 12 002 11 303 10 535 10 283 9 333 17 547 16 170 15 083 13 982 13 127 3.4 2.5 DDD/1000 inhabitants/day 2016 2017 2018 2019 0.11 0.11 0.11 0.09 2 331 2 296 2 295 2 256 2 257 0.5 0.4 G02CB Prolactine inhibitors 0.12 0.11 0.11 0.11 0.09 2 315 2 293 2 295 2 256 2 257 0.4 0.4 G02CB01 bromocriptine (5 mg) 0.05 0.05 0.04 0.04 0.03 728 654 595 473 367 0.1 0.1 G02CB03 caberg oline (0.5 mg) 0.04 0.04 0.04 0.05 0.05 1 424 1 503 1 579 1 684 1 788 0.3 0.3 68 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Num ber of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 G02CB04 quinagolide (65 mcg) 0.03 0.03 0.02 0.02 0.02 206 175 162 151 145 0.0 0.0 G02CX Other gynecologicals - - - - - 16 <5 0 0 0 0.0 0.0 G02CX04 Cimicifugae rhizoma - - - - - 16 <5 0 0 0 0.0 0.0 DDD/day 2016 2017 2018 2019 2020 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 593 953 594 870 594 131 602 681 600 553 113.9 111.9 G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE 353 941 351 197 345 927 347 090 346 708 67.9 64.6 G03AA Progestogens and estrogens, fixed combinations 199 067 196 432 188 200 189 457 83 429 236 034 230 419 222 612 219 31 982 788 26 039 24 840 7.1 G03AA12 5041 7 926 630 7 351 7 564 1.6 1.4 G03AA14 nomegestrol and estradiol 835 794 837 429 1 095 1 068 1 080 1 025 5 0.2 0.0 G03AA1 6 dienogest and ethinylestradiol 54 226 436 0 0 306 591 0.0 0.1 G03AB Progestogens and estrogens, sequential preparations 8 462 7 737 6 829 6 373 4 107 10 426 9 293 8 116 7 635 6 842 2.0 1.3 G03AB04 norethisterone and ethinylestradiol 7 249 6 576 5 742 5 231 2 640 8 750 7 727 6 684 6 057 5 005 1.7 0.9 G03AB08 dienogest and estradiol 1 213 1 160 1 087 1 142 1 467 1 694 1 577 1 441 1 590 2 232 0.3 0.4 G03AC Progestogens 128 200 132 116 134 849 138 200 141 125 24.6 26.3 G03AC01 norethist erone (oral) 2 990 2 740 2 470 2 340 2 286 4 625 4 256 3 823 3 673 3 657 0.9 0.7 G03AC06 medroxyprogesterone (parenteral) 12 830 12 190 11 540 11 200 9 603 17 296 16 340 15 329 14 679 12 807 3.3 2.4 G03AC08 etonogestrel (number of s.c. implants) 23 030 25 510 29 820 30 191 30 200 19 677 23 778 27 216 27 999 28 363 3.8 5.3 G03AC09 desogestrel (oral) 59 250 60 880 62 010 64 730 68 174 90 935 92 421 92 913 95 886 101 888 17.4 19.0 G03AD Emergency contraceptives 350 340 330 310 311 151 141 115 102 101 0.0 0.0 G03AD01 levonorgestrel (1.5 mg) 80 90 110 100 130 64 56 56 45 52 0.0 0.0 G03AD02 ulipristal (30 mg) 270 250 220 210 181 88 85 60 58 50 0.0 0.0 G03B ANDROGENS 8 190 9 170 8 740 9 010 9 470 14 554 15 427 15 997 16 387 17 830 2.8 3.3 G03BA 3-oxoandrost en (4) derivatives 8 190 9 160 8 740 9 000 9 460 14550 15422 15997 16386 17828 mg P/ 60 mg SL/ 50 mg TD gel/ 3 mg TD) 8 190 9 160 8 740 9 000 9 460 14 550 15 422 15 997 16 386 17 828 2.8 3.3 G03BB 5-androsta non (3) derivatives 0 10 0 10 10 8 9 6 7 9 0.0 0.0 G03BB01 mesterolone (50 mg) 0 10 0 10 10 8 9 6 7 9 0.0 0.0 69 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/day 2016 2017 2018 2019 2020 G03C ESTROGENS 45 940 47 960 48 780 51 760 56 730 144 129 150 015 156 07 3 163 866 168 971 27.6 31.5 G03CA Natural and semisynthetic estrogens, plain 40 750 42 990 44 100 47 190 52 410 137 669 143 976 150 343 158 505 163 695 26.4 30.5 G03CA01 Ethinylestradiol (0.025 mg) 20 40 30 30 20 13 17 12 9 8 0.0 0.0 G03CA03 estradiol (50 mcg TD/ 1 mg TD mg O/ 25 mcg V/ 7.5 mcg vaginal ring) 23 260 26 060 27 950 31 490 37 180 129 932 136 672 142 826 149 693 154 332 24.9 28.8 G03CA04 estriol (2 mg O/0.2 mg V) 17 470 16 890 16 120 15 670 15 210 9 242 8 853 9 411 11 176 12 043 1.8 2.2 G03CA57 conjugated estrogens (0.625 mg) 0 0 0 <5 <5 <5 - - G03CX Other estrogens 5 190 4 970 4 680 4 570 4 320 7 301 6 897 6 528 6 137 6 067 1.4 1.1 G03CX01 tibolone (2.5 mg) 5 190 4 970 4 680 4 570 4 320 7 301 6 897 6 52 8 6 137 6 067 1.4 1.1 G03D PROGESTOGENS 7 810 8 220 8 860 10 170 9 740 38 079 39 183 39 586 39 083 29 926 7.3 5.6 G03DA Pregnen (4) derivatives 5 070 5 380 6 070 7 430 8 250 15 875 16 568 17 737 18 184 20 215 3.0 3.8 G03DA02 medroxyprogesterone (5 mg O /7 mg P) 2 220 2 310 2 700 3 820 3 990 6 469 6 869 7 303 7 041 8 255 1.2 1.5 G03DA04 progesterone (30 mg O/ 5 mg P/ 90 mg V) 2 850 3 070 3 370 3 610 4 260 9 584 9 934 10 675 11 399 12 268 1.8 2.3 G03DB Pregnadien derivatives 90 130 180 220 330 191 241 388 561 843 0.0 0.2 G03DB01 dydrogesterone (10 mg) 30 90 130 210 0 64 221 379 626 0.0 0.1 G03DB08 dienogest (2 mg) 90 100 90 90 120 190 177 167 182 217 0.0 0.0 G03DC Estren derivatives 2 650 2 710 2 610 2 520 1 160 22767 23274 22376 21400 9803 4.4 1.8 G03DC02 norethisterone (5 mg) 2 650 2 710 2 610 2 520 1 160 22767 9803 4.4 1.8 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 31 100 29 650 30 770 31 610 33 280 42 769 41 514 42 210 43 995 46 098 8.2 8.6 G03FA Progestogens and estrogen s, fixed combinations 23 830 22 740 23 560 24 180 25 520 33 661 32 749 33 086 34 509 36 093 6.5 6.7 G03FA01 norethisterone and estrogen 23 050 21 970 22 760 23 490 24 530 32 742 31 823 32 146 33 772 35 122 6.3 6.5 G03FA12 medroxyprogesterone and estrogen 780 770 800 670 590 1 014 1 027 1 053 1 035 733 0.2 0.1 G03FA14 dydrogesterone and estrogen 20 400 0 0 0 64 710 0.0 0.1 G03FB Progestogens and estrogens, sequential preparations 7 270 6 910 7 210 7 430 7 760 10 196 9 801 10 129 10 571 11 155 2.0 2.1 G03FB05 norethisterone and estrogen 7 270 6 910 7 210 7 420 7 560 10 196 9 801 10 129 10 547 10 837 2.0 2.0 G03FB08 dydrogesterone and estrogen 10 200 31 380 0.0 0.1 70 Norwegian Drug Wholesales Statistics Norwegian Prescription Datab ase DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/day 2016 2017 2018 2019 2020 G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS 2 712 2 029 1 537 1 367 1 272 10 733 9 047 8 573 8 165 7 994 2.1 1.5 G03GA Gonadotropins 1 182 1 249 1 007 987 922 7 143 7 587 7 743 7 636 7 517 1.4 1.4 G03GA01 chorionic gonadotrophin (250 U) 360 390 110 60 70 639 736 91 46 42 0.1 0.0 G03GA02 human menopausal gonadotrophin (75 U) 330 330 320 350 2832 2849 2782 2796 2503 0.5 0.5 G03GA04 urofollitropin (75 U) 0 0 20 30 30 5 <5 225 357 353 0.0 0.1 G03GA05 follitropin alfa (75 U) 280 380 420 460 450 2 812 3 532 4 000 4 197 4 018 0.5 0.8 G03GA06 follitropin beta (75 U) 180 110 80 20 2 2 086 1 324 851 226 41 0.4 0.0 G03GA08 choriogonadotropin alfa (0.25 mg) 29 29 36 38 37 6 240 6 467 7 067 7 022 6 884 1.2 1.3 G03GA09 corifollitropin alfa (0.15 mg) 1 2 2 1 0 352 486 469 192 103 0.1 0.0 G03GA10 follitropin delta (12 mcg) 3 7 9 10 0 98 220 274 290 0.0 0.1 G03GA30 combinations 2 5 12 19 23 34 96 215 294 326 0.0 0.1 G03GB Ovulation stimulants, synthetic 1 530 780 530 380 350 4 489 1 935 1 031 707 651 0.9 0.1 G03GB02 clomifene (9 mg) 1 530 780 530 380 350 4 489 1 935 1 031 707 651 0.9 0.1 G03H ANTIANDROGENS 11 310 11 050 10 560 10 630 10 140 14 968 14 553 13 982 13 806 13 336 2.9 2.5 G03HA Antiandrogens, plain 80 80 90 110 130 221 255 312 364 482 0.0 0.1 G03HA01 cyproterone (0.1 g) 80 80 90 110 130 221 255 312 364 482 0.0 0.1 G03HB Antiandrogens and estrogens 11 230 10 970 10 470 10 520 10 010 14749 14301 13672 13446 12855 2.8 2.4 G03HB01 cyproterone and estrogen 11 230 10 970 10 470 10 520 10 010 14749 14301 13672 13446 12855 2.8 2.4 G03X OTHER MODULATORS OF THE GENITAL SYSTEM 797 816 468 578 505 1 903 2 062 1 155 1 608 1 921 0.4 0.4 G03XA Antigonadotropins and similar agents 10 10 10 10 10 46 46 44 39 37 0.0 0.0 G03XA01 danazol (0.6 g) 10 10 10 10 10 46 46 44 39 37 0.0 0.0 G03XB Progesterone receptor modulators 527 596 268 298 55 1 559 1 766 894 844 318 0.3 0.1 G03XB01 mifepristone (0.2 g) 37 36 38 38 <5 <5 <5 - - G03XB02 ulipristal (5 mg) 490 560 230 260 15 1 557 1 765 893 843 317 0.3 0.1 G03XC Selective estrogen receptor modulators 260 210 190 180 150 298 250 217 194 176 0.1 0.0 G03XC01 raloxifene (60 mg) 260 210 190 180 150 298 250 217 194 176 0.1 0.0 G03XX Other sex hormones and modulators of the genital system 90 290 0 0 0 533 1 391 0.0 0.3 G03XX01 prasterone (6.5 mg) 90 290 0 0 0 533 1 391 0.0 0.3 71 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 G04 30.65 31.06 224 538 239 43.1 48.2 G04B UROLOGICALS 12.79 13.44 14.15 15.31 15.38 154 301 171 791 29.6 32.0 G04BA Acidifiers <5 <5 6 urinary frequency and incontinence 10.09 10.48 10.81 11.58 11.25 62 109 65 824 69 472 73 627 74 491 11.9 13.9 G04BD04 oxybutynin (3.9 mg TD/15 mg O) 0.17 0.19 0.22 0.24 0.23 2 364 2 839 3 499 3 929 3 816 0.5 0.7 G04BD07 tolterodine (4 mg) 1.08 0.98 0.86 0.74 0.52 7 939 7 389 6 550 5 714 5 143 1.5 1.0 G04BD08 solifenacin (5 mg) 3.32 3.18 3.11 3.28 2.99 17 047 16 400 16 145 15 881 15 479 3.3 2.9 G04B D10 darifenacin (7.5 mg) 0.45 0.44 0.38 0.35 0.35 2 187 2 011 1 803 1 605 1 556 0.4 0.3 G04BD11 fesoterodine (4 mg) 1.90 1.81 1.72 1.65 1.54 9 437 8 942 8 483 8 162 7 619 1.8 1.4 G04BD12 mirabegron (50 mg) 3.18 3.88 4.51 5.31 5.63 28 867 34 219 39 629 45 113 47 919 5.5 8.9 DDD/day 2016 2017 2018 2019 2020 G04BE Drugs used in erectile dysfunction 14 093 15 577 17 682 19 917 22 034 94 327 101 982 107 706 113 372 99 828 18.1 18.6 G04BE01 alprostadil (0.02 mg) 186 196 184 182 141 3 169 3 091 3 280 3 296 2 615 0.6 0.5 G04BE03 sildenafil (50 mg) 6 283 7 264 8 071 8 906 10 518 44 279 49 803 54 310 56 199 47 390 8.5 8.8 G04BE08 tadalafil (10 mg) 6 659 7 136 8 518 9 879 10 519 48 390 50 838 53 661 57 012 51 936 9.3 9.7 G04BE09 vardenafil (10 mg) 950 943 818 821 708 8 256 8 188 6 931 6 635 5 266 1.6 1.0 G04BE10 avanafil (0.1 g) 14 64 98 107 0 286 1 224 1 606 1 574 0.0 0.3 G04BE30 fentolamin, combinations 15 24 27 31 41 403 636 727 796 1 084 0.1 0.2 G04BX Other urologica ls 65 66 74 73 82 229 378 491 451 447 0.0 0.1 G04BX01 magnesium hydroxide (0.5 g) 19 18 17 15 14 23 17 20 19 20 0.0 0.0 G04BX14 dapoxetine (30 mg) 2 6 9 8 7 139 294 394 347 323 0.0 0.1 G04BX15 pentosan polysulfate sodium (0.3 g) 41 38 44 46 57 60 61 72 75 83 0.0 0.0 G04BX16 tiopronin (0.8 g) 3 4 4 4 4 <5 5 5 <5 5 - 0.0 DDD/1000 inhabitants/day 2016 2017 2018 2019 2020 G04C DRUGS BENIGN PROSTATIC HYPERTROPHY 13.25 13.81 14.47 15.33 15.67 83 917 89 368 94 666 100 212 104 134 16.1 19.4 G04CA Alpha -adrenoreceptor antagonists 10.54 11.18 11.87 76 87 838 90 834 13.7 0.00 18 25 21 0.0 0.0 G04CA02 tamsulosin (0.4 mg) 7.30 7.59 7.85 8.28 8.32 52 615 55 027 57 371 60 594 61 807 10.1 11.5 G04CA03 terazosin (5 mg) 0.07 0.06 0.05 0.05 0.06 509 421 395 350 294 0.1 0.1 G04CA52 tamsulosin and dutasteride (1 caps) 3.14 3.43 3.84 4.39 4.64 21 617 24 463 27 008 30 043 31 685 4.2 5.9 G04CA53 tamsulosin and solifenacin (1 caps) 0.03 0.08 0.13 0.17 0.20 348 703 1 134 1 407 1 627 0.1 0.3 G04CB Testosterone -5-alpha reductase inhibitors 2.70 2.64 2.60 2.44 2.45 17 492 17 414 17 467 17 248 17 473 3.4 3.3 G04CB01 finasteride (5 mg) 2.57 2.52 2.50 2.35 2.36 16 687 16 763 16 869 16 698 16 960 3.2 3.2 G04CB02 dutasteride (0.5 mg) 0.13 0.12 0.10 0.09 0.08 846 686 637 705 562 0.2 0.1 henholdsvis 39 % og 57 % av all DDD i gruppe H. Reseptregisteret viser at i 2020 fikk rundt 9 % av minst ett legemiddel fra 73 Figure 4.7.1 Proportion of the population (prevalence ) who had dispensed at leas t one glucocorticosteroid (H02AB) according to age groups salget n\u00e6r doblet fra 2000 til 2020) f\u00e5r utlevert et thyre oideapreparat. 020406080100 0 - 9 years 10 - 19 years 20 - 39 years 40 - 69 years 70 years and aboveProportion () of the population age groups2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 74 Figure. 4.7.2. Proportion of the population (prevalence ) w ho had dispensed a thyroid preparation (H03AA) according to age groups in selected years. Source: Norwegian Prescription Database 020406080100120140 Women Men Women Men Women Men 0-29 years 30-59 years 60 years and aboveProportion () of the population2008 2012 2016 2020 75 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 1.85 1.92 1.86 1.91 1.76 26 687 27 881 27 530 26 181 25 468 5.1 4.7 H01A ANTERIOR 0.49 2 091 2 133 2 178 2 203 2 2 133 2 148 2 189 0.4 0.4 H01AC01 somatropin (2 U) 0.47 0.51 0.51 0.52 0.48 2 046 2 083 2 130 2 148 2 189 0.4 0.4 (2 anterior pituitary lobe hormones and analogues 0.01 0.01 0.01 0.01 0.01 40 42 41 50 50 0.0 0.0 H01AX01 pegvisomant (10 mg) 0.01 0.01 0.01 0.01 0.01 40 42 41 50 50 0.0 0.0 H01B POSTERIOR PITUITARY LOBE HORMONES 1.03 1.07 1.01 1.05 0.95 18 399 19 303 18 603 17 326 16 2.2 2.0 H01BA02 desmopressin 662 11 982 026 10 971 2.2 2.0 H01BB Oxytocin and analogues 0.20 0.22 0.16 0.18 0.16 6 737 7 320 6 607 5 302 5 889 1.3 1.1 H01BB02 oxytocin (15 U) 0.20 0.22 0.16 0.18 0.16 6 737 7 320 6 607 5 302 5 889 1.3 1.1 H01C HYPOTHALAMIC HORMONES 0.34 0.33 0.33 0.32 0.32 6 487 6 745 7 042 6 954 6 671 1.2 1.2 H01CA Gonadotropin -releasing hormones 0.13 0.10 0.10 0.08 0.06 2 954 2 632 2 483 2 184 1 652 0.6 0.3 H01CA02 nafarelin (0.4 mg) 0.13 0.10 0.10 0.08 0.06 2 954 2 632 2 483 2 184 1 652 0.6 0.3 H01CB Somatostatin and analogues 0.20 0.21 0.21 0.22 0.23 927 944 987 997 1 119 0.2 0.2 H01CB02 octreotide (0.7 mg) 0.13 0.13 0.12 0.11 0.12 616 617 607 576 665 0.1 0.1 H01CB03 lanreotide (3 mg) 0.07 0.08 0.09 0.10 0.11 329 351 397 445 464 pasireotide (1.2 mg) 0.00 0.00 0.00 0.00 0.00 11 13 17 0.0 0.0 H01CC Anti -gonadotropin - releasing hormones 0.01 0.02 0.02 0.02 0.02 3 082 3 650 4 053 4 233 4 309 0.6 0.8 H01CC01 ganirelix (0.25 mg) 0.01 0.02 0.02 0.02 0.02 3 011 3 071 3 495 3 844 4 073 0.6 0.8 H01CC02 cetrorelix (0.25 mg) 0.00 0.00 0.00 FOR SYSTEMIC USE 19.77 19.86 19.76 19.87 18.65 233 853 240 115 227 790 42.4 19.76 19.87 18.65 233 616 240 195 242 827 256 114 42.4 H02AA Mineralocorticoids 0.40 0.42 0.42 563 1 612 1 632 0.3 0.3 H02AA02 fludrocortisone (0.1 mg) 0.40 0.42 0.42 0.42 0.44 1 490 1 546 1 18.21 233 414 255 887 227 587 44.8 42.4 H02AB01 betamethasone (1.5 mg O,P/0.4 mg P (depot)) 1.29 1.23 1.20 1.17 1.07 2 982 3 476 3 984 4 301 3 008 0.6 0.6 H02AB02 dexamethasone (1.5 mg) 2.47 2.69 2.84 3.06 3.19 8 837 10 446 11 688 13 801 14 724 1.7 2.7 76 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 H02AB04 methylprednisolone (7.5 mg O/20 mg P) 1.19 1.06 0.93 0.81 0.77 9 093 7 919 6 941 6 095 5 043 1.7 H02AB06 prednisolone (10 mg) 13.21 13.19 13.17 11.97 181 577 178 348 34.8 33.2 H02AB07 prednisone (10 mg) 0.02 0.02 0.01 0.01 0.01 294 268 114 69 133 0.1 0.0 H02AB08 triamcinolone (7.5 mg) 0.46 0.45 0.43 0.45 0.41 35 086 34 710 32 421 35 504 29 624 6.7 5.5 H02AB09 hydrocortisone (30 mg) 0.22 0.24 0.25 0.26 0.25 827 948 989 1 090 1 148 0.2 0.2 H02AB10 cortisone (37.5 mg) 0.50 0.49 0.49 0.52 0.53 3 130 3 254 3 351 3 418 3 522 0.6 0.7 H02AB13 deflazacort (15 mg) 0.01 0.01 0.01 0.01 0.01 51 55 59 64 66 0.0 0.0 H02B CORTICOSTEROIDS FOR SYSTEMIC 0 0 0.0 0.0 H02CA Anticorticosteroids 10 <5 0.00 0.00 0.00 0.00 THERA PY 27.02 26.12 27.55 27.68 27.44 212 089 216 220 398 224 401 228 888 40.7 42.6 H03A THYROID PREPARATIONS 26.30 25.38 26.73 26.83 26.56 207 170 211 335 214 677 218 325 222 434 39.7 41.4 H03AA Thyroid hormones 26.30 25.38 26.73 26.83 26.56 207 170 211 335 214 677 218 325 222 434 39.7 41.4 H03AA01 levothyroxine sodium mg) 25.22 24.25 25.41 25.34 25.29 205 630 209 382 028 220 221 39.4 41.0 H03AA02 liothyronine sodium (0.06 mg) 0.35 0.40 0.41 0.56 0.50 7 273 8 412 9 883 10 348 10 764 1.4 2.0 H03AA05 thyroid gland preparations 0.73 0.73 0.91 0.93 0.78 3 407 4 144 4 885 5 081 4 874 0.7 0.9 H03B ANTITHYROID PREPARATIONS 0.72 0.74 0.82 0.85 0.88 7 103 7 525 8 175 8 617 9 079 1.4 1.7 H03BA Thiouracils 0.12 0.10 0.11 0.12 559 552 570 601 0.1 0.1 propylthiouracil g) 0.12 0.10 0.11 0.12 0.11 557 552 570 601 0.1 imidazole derivatives 0.61 0.63 0.70 0.73 0.77 6 729 7 157 7 814 8 246 8 687 1.3 1.6 H03BB01 carbimazole (15 mg) 0.61 0.63 0.70 0.73 0.77 6 729 7 157 7 814 8 246 8 687 1.3 1.6 H04 PANCREATIC HORMONES 0.02 0.01 0.01 0.02 0.01 5 588 5 427 5 353 5 693 4 945 1.1 0.9 H04A GLYCOGENOLYTIC HORMONES 0.02 0.01 0.01 0.02 0.01 5 588 5 427 5 353 5 693 4 945 1.1 0.9 H04AA Glycogenolytic hormo nes 0.02 0.01 0.01 0.02 0.01 5 588 5 427 5 353 5 693 4 945 1.1 0.9 H04AA01 glucagon (1 mg) 0.02 0.01 0.01 0.02 0.01 5 588 5 427 5 353 5 693 4 945 1.1 0.9 H05 CALCIUM HOMEOSTASIS 0.22 0.25 0.25 0.26 0.28 1 827 2 096 2 139 2 239 2 351 0.4 0.4 H05A PARATHY ROID HORMONES AND ANALOGUES 0.11 0.14 0.14 0.14 0.14 931 1 151 1 133 1 179 1 201 0.2 0.2 H05AA Parathyroid hormones and analogues 0.11 0.14 0.14 0.14 0.14 931 1 151 1 133 1 179 1 201 0.2 0.2 H05AA02 teriparatide (20 mcg) 0.11 0.14 0.14 0.13 0.14 931 1 15 1 1 123 1 149 1 170 0.2 0.2 H05AA03 parathyroid hormone (0.1 mg) 0.00 0.00 0.00 0.00 0 <5 22 31 32 0.0 0.0 77 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 H05B ANTI -PARATHYROID AGENTS 0.11 0.11 0.12 0.12 0.14 896 945 1 006 1 060 1 150 0.2 0.2 H05BA Calcitonin preparations Other anti -parathyroid agents 0.12 0.12 937 782 887 0.1 0.2 H05BX02 paricalcitol (2 mcg) 0.03 0.03 0.03 0.03 0.03 341 333 336 361 350 0.1 0.1 78 4.8 J u like virussykdommer. Midler mot HIV og hepatitt B og C mid 7,9 % av de 6 % m\u00e5lt i dose r (DDD) i 2020 i av di redusert i en rapport Tidsskrift den norske legeforening 1). En et urinveisantiseptikum som brukes kun s om profylakse. Fra 2019 til 2020 er andel barn i en kraftig nedg ang i antibiotikabruk fra 2019 til 2020. Toppen som sees ved 19 -\u00e5rs alder i figuren kvinner anti biotika fra 2019 til 2020 ikke like stor, kun 7 % hos personer over 75 Vaksiner of users (prevalence ) of antibacterials for systemic use (ATC group J01, excl. methenamine) in 2019 and 20 20 by age and gender. Source: Norwegian Prescription Database Antibakterielle midler til systemisk bruk Fra re antibiotikabruken med 30 % m \u00e5lt i DDD fra 2012 til utgangen av 2020. Figur 4.8.1 viser at legemidler n\u00e5r en ser bort f ra metenamin. I tid trolig p\u00e5 grunn av smittevernsrestriksjonene under koronapandemien. 0 5 10 15 20 25 30 35 40 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75+Proportion (%) of the population AgeWomen 2019 Women 2020 Men 2019 Men 2020 80 Reseptregisteret viser at vel 20 % av norske kvinner og handlingsplanen mot antibiotikaresistens i helsetjenesten 1). Fenoksymetylpenicillin sto for 21 % av antibiotikareseptene og i underkant som ble hyppigst forskrevet i Reseptregisteret i 20 20 og stod for mer enn 50 % av antibiotikareseptene. Figur forekomst av resistens og antall brukere er mer enn hal vert i 2020 i forhold til 2018 . Den utbredt bruk siste \u00e5rene midler 50 % fra 2018 til 2019, mens \u00f8kningen bare var p\u00e5 vel 1 % sist e \u00e5r. En rapport om bruk av antivirale resistens i Norge utgis \u00e5rlig (RAVN -rapporten) 5). 81 Figure 4.8. 2 Sales of antibacterials for systemic use (J01) in 200 1-2020 The total of J01 includ shown specifically in the figure. Source: Norwegian Drug Wholesales Statistics 1) Blix et al. Bruk of Antivirals and the Occurrence of Antiviral Resistance in Norway 2019 , Folkehelseinstituttet (Ravn - rapporten ) 0510152025 2001 inhabitant/day YearJ01 J01A J01C J01E Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC lev el name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 J ANTIINFECTIVES FOR SYSTEMIC USE J01 ANTIBACTERIALS FOR SYSTEMIC USE 16.94 109 722 1 063 315 1 026 347 1 046 173 945 212.8 166.2 J01A TETRACYCLINES 3.16 3.01 2.86 2.96 2.65 168 809 159 385 152 178 158 962 127 057 32.4 23.7 J01AA Tetracyclines 3.16 3.01 2.86 2.96 2.65 168 809 159 385 152 178 158 962 127 057 32.4 23.7 J01AA02 doxycycline (0.1 g) 1.82 1.69 1.61 1.67 1.38 131 272 122 266 115 437 121 112 89 307 25.2 16.6 J01AA04 lymecycline (0.6 g) 0.94 0.95 0.93 0.98 1.08 23 337 24 396 24 801 26 525 29 660 4.5 5.5 J01AA06 oxytetracycline (1 g) 0.00 0.00 0.00 0.00 J01AA07 tetracycline (1 g) 0.40 0.36 0.32 0.31 0.19 16 804 15 267 14 240 13 852 11 001 3.2 2.1 J01AA08 minocycline (0.2 g) 0.00 0.00 0.00 0.00 0.00 0.0 J01C BETA -LACTAM ANTIBACTERIALS, PENICILLINS 7.35 6.99 6.87 7.12 6.05 750 891 730 187 713 977 735 182 624 024 144.0 116.3 J01CA Penicillins with extended spectrum 2.62 2.47 2.46 2.53 2.22 311 008 298 397 299 136 303 783 265 361 59.7 49.4 J01CA01 ampicillin (6 g) 0.04 0.04 0.05 0.05 0.05 62 54 66 55 54 0.0 0.0 J01CA04 amoxicillin (1.5 g) 0.88 0.87 0.84 0.89 0.65 125 992 119 990 117 652 118 029 81 768 24.2 15.2 J01CA08 pivmecillinam (0.6 g) 1.69 1.56 1.57 1.58 1.52 198 004 190 781 194 102 199 160 194 072 38.0 36.2 J01CA11 mecillinam (1.2 g) 0.01 0.01 0.00 0.00 0.00 16 18 6 14 8 0.0 0.0 Beta -lactamase sensiti ve penicillins 3.73 3.61 3.43 3.56 2.77 404 417 394 483 373 327 388 028 296 199 77.6 55.2 J01CE01 benzylpenicillin (3.6 g) 0.23 0.23 0.24 0.23 0.23 149 166 209 214 221 0.0 0.0 J01CE02 phenoxymethylpenicillin (2 g) 3.50 3.38 3.18 3.33 2.53 404 289 394 344 373 170 387 854 295 977 0.00 0.00 0.00 resistant penicillins 0.90 0.84 0.90 0.93 0.95 105 128 103 589 681 109 543 111 626 20.2 20.8 J01CF01 dicloxacillin (2 g) 0.74 0.70 0.74 0.76 0.78 103 820 103 272 109 423 111 476 19.9 20.8 J01CF02 cloxacillin (2 g) 0.17 0.13 0.16 0.17 0.16 1 624 379 105 123 164 0.3 0.0 J01CF05 flucloxacillin (2 g) 0.00 0.00 0.00 0.00 0.00 47 73 79 0.0 J01CR Combinations of penicillins, incl. beta - lactamase inhibitors 0.10 0.08 0.10 0.11 1 017 1 652 2 829 4 595 6 0.2 1.1 J01CR02 amoxicillin and beta - lactamase inhibitor (1.5 g) 0.01 0.02 0.03 0.04 0.05 916 1 588 2 762 4 519 5 972 0.2 1.1 J01CR 05 piperacillin and beta - lactamase inhibitor (14 g) 0.09 0.05 0.05 0.05 0.06 104 66 70 83 78 0.0 0.0 J01D OTHER BETA -LACTAM ANTIBACTERIALS 0.42 0.38 0.39 0.37 0.37 14 827 13 449 12 545 12 151 11 048 2.8 2.1 J01DB First -generation cephalosporins 0.20 0.17 0.18 0.17 0.16 13 968 12 546 11 728 11 322 10 272 2.7 1.9 J01DB01 cefalexin (2 g) 0.10 0.09 0.09 0.07 0.07 13 951 12 529 11 708 11 311 10 252 2.7 1.9 J01DB03 cefalotin (4 g) 0.09 0.08 0.07 0.00 0.02 19 17 22 7 14 0.0 0.0 J01DB04 cefazolin (3 g) 0.01 0.03 0.09 0.08 0 0 0 5 8 0.0 0.0 J01DC Second -generation cephalosporins 0.04 0.03 0.03 0.03 0.02 97 72 75 68 69 0.0 0.0 J01DC02 cefuroxime (0.5 g O/3 g P) 0.04 0.03 0.03 0.03 0.02 97 72 75 68 69 0.0 0.0 83 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC lev el name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 J01DD Third -generation cephalosporins 0.15 0.15 0.16 0.15 0.14 740 785 717 711 636 0.1 0.1 J01DD01 cefotaxime (4 g) 0.12 0.12 0.12 0.12 0.11 363 305 169 191 167 0.1 0.0 J01DD02 ceftazidime (4 g) 0.01 0.01 0.01 0.01 0.01 68 75 55 34 53 0.0 0.0 J01DD04 ceftriaxone (2 g) 0.02 0.02 0.02 0.02 0.03 312 412 494 484 414 0.1 0.1 J01DF Monobactams 0.00 0.00 0.00 10 15 0.0 0.0 J01DH Carbapenems 0.03 0.03 0.03 0.03 0.03 73 86 71 67 101 0.0 0.0 J01D H02 meropenem (3 g) 0.03 0.02 0.02 0.02 0.03 58 63 53 49 74 0.0 0.0 J01DH03 ertapenem (1 g) 0.00 0.00 0.00 0.00 15 121 601 131 238 126 390 23.4 23.6 J01EA Trimethoprim and derivatives 0.38 0.35 0.34 0.36 0.33 69 823 68 123 68 64 614 13.4 J01EA01 0.38 823 68 123 66 0.47 0.49 0.53 0.57 0.57 57 183 58 807 64 637 69 732 67 941 11.0 12.7 J01EE01 sulfamethoxazole and trimethoprim 0.47 0.49 0.53 0.57 0.57 57 183 58 807 64 637 69 732 67 941 11.0 12.7 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 1.33 1.18 1.05 1.04 0.80 217 006 187 736 163 672 158 725 112 41.6 20.9 J01FA Macrolides 1.04 0.93 0.80 0.80 0.57 168 977 145 999 123 073 118 620 74 487 32.4 13.9 J01FA01 erythromycin (2 g O/1 g O,P) 0.60 0.54 0.44 0.45 0.29 92 247 82 929 67 903 66 917 39 866 17.7 7.4 J01FA02 spiramycin (3 g) 0.00 0.00 0.00 0.00 0.00 1 1 065 884 J01FA06 roxithromycin (0.3 0.13 0.11 0.11 0.09 18 856 15 730 13 281 12 498 9 481 3.6 1.8 J01FA10 azithromycin (0.3 g) 0.30 0.26 0.24 0.24 0.19 61 238 49 933 43 855 40 980 25 945 11.7 4.8 J01FF Lincosamides 0.28 0.25 0.25 0.25 0.23 53 932 46 587 44 857 44 181 40 809 10.3 7.6 J01FF01 clindamycin (1.2 g O/1.8 g P) 0.28 0.25 0.25 0.25 0.23 53 9 32 46 587 44 857 44 181 40 809 10.3 7.6 J01G AMINOGLYCOSIDE ANTIBACTERIALS 0.08 0.09 0.09 0.10 0.10 216 0.0 0.0 J01GB Other aminoglycosides 0.08 0.09 0.09 0.10 0.10 215 222 185 198 173 0.0 0.0 J01GB01 tobramycin (0.24 g P/ 0.3 g inhal.s ol./ 0.112 g inhal.powder) 0.02 0.02 0.01 0.01 0.01 168 172 140 158 138 0.0 0.0 J01GB03 gentamicin (0.24 g) 0.06 0.07 0.08 0.09 0.09 32 32 33 29 (1 g) 0.00 0.00 0.00 0.00 12 QUINOLONE ANTIBACTERIA LS 0.53 0.45 0.41 0.36 0.30 53 197 45 649 42 078 37 406 32 425 10.2 6.0 J01MA Fluoroquinolones 0.53 0.45 0.41 0.36 0.30 53 197 45 649 42 078 37 406 32 425 10.2 6.0 84 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC lev el name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 J01MA01 ofloxacin (0.4 g) 0.01 0.01 0.01 0.01 0.01 1 083 941 832 849 709 0.2 0.1 J01MA02 ciprofloxacin (1 g O/0.8 g P) 0.51 0.43 0.39 0.33 0.28 51 047 43 221 39 388 34 464 29 819 9.8 5.6 J01MA12 levofloxacin (0.5 g) 0.00 0.00 0.00 0.00 83 82 78 0.0 0.0 J01MA14 moxifloxacin (0.4 g) 0.01 0.01 0.01 0.01 0.01 1 247 1 600 1 939 2 154 1 935 0.2 0.4 J01X OTHER 756 63 796 12.6 11.9 J01XA Glycopeptide antibacterials 0.02 0.02 0.02 0.02 0.02 47 43 43 47 32 0.0 0.0 J01XA01 vancomycin (2 g) 0.02 0.02 0.02 0.02 0.02 47 42 43 47 32 0.0 0.0 J01XB Polymyxins 0.01 0.01 0.01 0.01 0.01 111 111 104 126 144 0.0 0.0 J01XB01 colistin (3 MU inhal/9 MU P) 0.01 0.01 0.01 0.01 0.01 111 111 104 126 144 0.0 0.0 J01XC Steroid antibacterials 0.00 0.00 0.00 (1.5 0.00 326 359 32 0.1 0.0 J01XD Imidazole derivatives 0.03 0.04 0.04 0.04 0.04 30 27 31 36 44 0.0 0.0 J01XD01 metronidazole (1.5 g) 0.03 0.04 0.04 0.04 0.04 30 27 31 36 44 0.0 0.0 J01XE Nitrofuran derivatives 0.31 0.28 0.25 6.3 J01XX08 linezolid (1.2 g) 0.01 0.01 0.01 0.01 0.01 305 314 339 340 301 0.1 0.1 J01XX09 daptomycin 0.00 8 25 DDD/1000 inhabitants/Year 2016 2017 2018 2019 2020 g) 1.68 1.69 1.56 1.91 2.07 401 365 348 382 483 0.1 0.1 J02AC03 voriconazole (0.4 g) 2.83 2.27 2.31 3.10 2.57 105 97 96 111 108 0.0 0.0 J02AC04 posaconazole (0.3 g) 2.93 2.74 2.71 3.19 4.32 120 106 111 139 178 0.0 isavuconazole (0.2 g) 0.08 0.34 0.73 1.83 0 <5 16 31 73 0.0 0.0 85 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/1000 inhabitants/Year 2016 2017 2018 2019 2020 J02AX Other antimycotics for systemic use 2.80 2.68 2.72 3.06 3.94 10 10 20 20 20 0.0 0.0 J02AX04 (0.1 g) 1.47 0.96 1.71 1.99 2.63 5 J04 ANTIMYCOBACTERIALS 88.47 82.37 76.99 79.01 75.36 1971 1998 1938 1923 1914 0.4 0.4 J04A DRUGS FOR TREATMENT derivatives 0.01 0.02 0.03 0.00 0.01 <5 0 0 0 0 - 0.0 J04AA01 4-aminos alicylic acid (12 g) 0.01 0.02 0.03 0.00 0.01 <5 0 0 0 0 - 0.73 0.38 0.0 J04AB05 rifapentine (0.11 g) 7.15 6.59 6.20 6.87 7.16 272 319 322 349 377 0.1 0.1 J04AB30 capreomycin (1 g) 0.01 0.00 0.00 0.00 10.34 9.74 8.99 9.20 9.55 336 378 J04AC01 isoniazid (0.3 g) 10.34 9.74 8.99 9.20 9.55 336 414 0.1 J04AD Thiocarbamide derivatives 0.29 0.68 0.35 0.18 0.05 6 11 <5 - J04AD01 protionamide (0.75 g) 0.29 0.68 0.35 0.18 0.05 6 11 9 6 <5 0.0 - J04AK Other drugs for treatment of tuberculosis 5.91 5.11 5.03 4.76 4.51 204 177 160 152 139 0.0 0.0 J04AK01 pyrazinamide (1.5 g) 1.25 0.93 0.96 0.88 0.84 46 40 40 28 34 ethambutol (1.2 g) 4.66 3.89 3.82 3.68 3.59 181 162 145 142 122 0.0 J04AK05 mg) 0.29 0.25 <5 0 0.0 0.0 J04AM Combinations of drugs for treatment of tuberculosis 18.19 13.37 11.60 10.84 10.03 529 UD/4 UD) 14.33 10.19 8.81 0.1 J04AM05 rifampicin, 1.23 1.08 pyrazinamide, ethambutol a nd isoniazid (4 UD) 1.85 1.95 1.71 1.48 1.51 101 128 126 97 105 0.0 0.0 J04B DRUGS FOR TREATMENT OF LEPRA 29.11 28.96 27.79 31.56 27.85 475 485 473 500 for treatment of lepra 29.11 28.96 27.79 31.56 475 485 J04BA01 clofazimine (0.1 g) 0.11 0.43 0.44 0.40 0.37 5 9 6 9 10 dapsone (50 mg) 29.00 28.53 27.34 31.16 27.48 470 476 467 491 454 0.1 0.1 86 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabita nts/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/1000 inhabitants/Year 2016 2017 2018 2019 2020 0.07 0.02 0.03 <5 <5 6 <5 0.17 0.26 0.11 0.18 0.25 - - - - - - - J05AB14 valganciclovir (0.9 g) 8.33 9.78 8.47 9.67 8.16 377 439 409 472 384 0.1 0.1 J05AB16 remdesivir (0.1 g) 0.40 - - - - - - - J05AD Phosphonic acid derivatives 0.21 0.21 0.16 0.24 0.17 0 0 0 0 <5 0.0 - J05AD01 foscarnet (6.5 g) 0.21 0.21 0.16 0.24 0.17 0 0 0 0 (1.8 g) 0.20 0.08 <5 <5 0 0 0 - 0.0 J05AE03 ritonavir g) 2.99 1.94 1.29 0.93 0.76 605 399 269 184 g) 34.18 20.00 12.92 8.63 228 149 108 0.1 0.0 J05AE10 darunavir (1.2 g) 8.45 6.18 4.89 3.95 3.61 200 148 124 94 83 0.0 0.0 J05AF Nucleoside 0.69 0.48 0.41 0.24 14 19 15 18 10 0.0 0.0 J05AF05 lamivudine (0.3 g) 3.20 2.70 3.41 9.54 5.12 84 75 103 208 162 J05AF06 abacavir (0.6 g) 3.44 3.37 2.91 2.36 2.14 dipivoxil (10 mg) 0.34 0.29 0.14 <5 <5 <5 - J05AF09 emtricitabine 23.95 21.53 410 410 367 376 0.1 0.1 J05AF11 telbivudine (0.6 g) 0.05 <5 0 0 0 0 - 0.0 J05AF13 tenofovir alafenamide (25 mg) 4.20 6.15 4.35 4.60 0 121 130 80 80 0.0 reverse transcriptase inhibitors 13.99 11.26 11.73 J05AG01 nevirapine (0.4 g) 7.46 5.94 5.04 5.53 4.76 126 99 89 83 75 0.0 0.0 J05AG03 efavirenz (0.6 g) 3.92 2.50 2.24 1.97 1.24 76 46 38 36 25 0.0 0.0 J05AG04 etravirine (0.4 g) 1.67 1.22 1.18 1.07 1.21 28 24 18 20 19 0.0 0.0 J05AG05 rilpivirine (25 mg) 0.94 1.60 3.27 13.03 10.54 19 31 85 239 188 0.0 0.0 J05AG06 doravirine (0.1 g) 0.06 0.44 0 0 0 <5 9 0.0 0.0 87 Norwegian Drug Wholesales Statistics Norwegian Presc ription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/1000 inhabitants/Year 2016 2017 2018 2019 2020 J05AH Neuraminidase inhibitors 4.50 8.36 6.61 8.02 2153 1923 3571 2987 2214 0.4 0.4 J05AH01 zanamivir (20 mg) 0.01 0.00 25 0 0 0 0 0.0 0.0 J05AH02 oseltamivir (0.15 g) 4.92 4.50 8.36 6.61 8.02 2129 19.06 413 793 606 1.25 0.52 0.42 754 380 88 36 28 0.1 0.0 J05AP05 simeprevir (0.15 g) 0.08 0.03 5 <5 0 0 0 0.0 0.0 J05AP07 daclatasvir (60 mg) 3.86 0.54 235 47 0 0 0 0.1 0.0 J05AP08 sofosbuvir (0.4 g) 6.33 1.24 0.05 - J05AP09 dasabuvir (0.5 g) 4.77 1.17 0.60 0.03 299 105 54 5 0 0.1 0.0 J05AP51 sofosbuvir and ledipasvir (1 UD) 4.18 0.46 1.15 6.99 29 620 0.1 0.1 J05AP53 ombitasvir, paritaprevir and ritonavir (2 UD) 4.92 1.20 0.61 0.03 312 107 55 6 0 0.1 0.0 J05AP54 elbasvir and grazoprevir (1 UD) 18.13 14.27 3.23 990 glecaprevir pibrentasvir (3 UD) 0.01 0.42 0.32 <5 30 27 33 0.0 0.0 J05AR Antivirals for treatment 3.53 2.39 1.74 104 64 46 30 0.0 0.0 J05AR02 lamivudine and abacavir (1 UD) 10.22 7.35 9.75 25.89 131 469 2.75 1.72 1.37 259 104 52 37 25 0.1 0.0 J05AR10 lopinavir and ritonavir (0.8 g) 6.62 4.18 2.63 2.32 2.16 145 89 62 43 46 0.0 0.0 J05AR13 941 1178 0.2 0.2 88 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of indivi duals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/1000 inhabitants/Year 2016 2017 2018 2019 0.31 0.82 bictegravir (1 UD) 309 0.1 J05AR21 dolutegravir and rilpivirine (1 UD) 0.35 4.79 0 14 11 9 0.0 0.0 J05AR24 lamivudine, tenofovir disoproxil and doravirine (1 UD) 0.10 0 5 69 0.0 0.0 J05AR25 lamivudine and dolutegravir (1 UD) 1.18 28.05 0 0 Other antivirals 0.57 0.42 0.47 0.52 0.0 J05AX05 inosine pranobex (3 g) 0.30 0.19 0.17 0.14 0.14 18 13 9 5 <5 0.0 - J05AX09 maraviroc (0.6 g) 0.27 0.23 0.30 0.23 0.34 7 6 7 6 5 0.0 0.0 J05AX18 letermovir (0.48 g) 0.15 0.34 0 0 0 6 10 0.0 0.0 89 4.9 L Antineoplastiske og immunmodulerende midler L01 Antineoplastiske legemiddelstatistikk utgj\u00f8r (m\u00e5lt flere pasienter kan tilbys interferon beta (L03AB) og glatiramer acetate (L03AX13) tilgjengelige, nye legemidlene Figure Sales of drugs in ATC -groups L03 and L04 indicated for treatment of multiple sclerosis; interferon beta (L03AB -07, 08 Source: Norwegian D rug Wholesales Statistics. 00,20,40,60,811,2 2001 2003 2005 2007 2009 2011 2013 /day Year 91 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 gram of active ingredient/year ATC 2016 2017 2018 2019 2020 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS 8 784 9 955 10 466 11 488 13 111 1.7 2.4 L01A ALKYLATING AGENTS 1 242 1 247 1 252 1 326 1 267 0.2 0.2 L01AA Nitrogen mustard analogues 649 599 541 622 587 0.1 0.1 L01AA01 cyclophosphamide 18 539 18 728 17 952 19 088 18 073 214 223 227 304 275 0.0 0.1 L01AA02 chloram bucil 54 41 35 35 32 106 84 79 68 64 0.0 0.0 L01AA03 melphalan 153 148 125 150 141 215 175 144 155 155 0.0 0.0 L01AA06 ifosfamide 11 382 10 943 10 786 11 105 10 104 - - - - - - - L01AA07 trofosfamide 1 680 1 668 1 700 1 348 1 355 119 123 98 104 99 0.0 0.0 L01AA09 bendamustine 556 447 484 546 479 <5 <5 0 - 0.0 L01AB Alkyl sulfonates 5 <5 7 5 11 0.0 0.0 L01AB01 busulfan 52 64 80 54 51 5 <5 7 5 11 0.0 0.0 L01AB02 treosulfan 2 196 2 577 2 947 4 061 5 776 - - - - - - - L01AC Ethylene imines - - - - - - - L01AC01 thiotepa 10 12 21 16 21 - - - - - - - L01AD Nitrosoureas 126 125 117 122 119 0.0 0.0 L01AD01 carmustine 55 50 38 47 40 L01AD02 lomustine 156 158 129 143 145 126 125 117 122 119 0.0 0.0 L01AD04 streptozocin 349 248 203 144 142 - - - - - - - L01AX Other alkylating agents 526 593 659 645 622 0.1 0.1 L01AX03 temozolomide 4 205 5 181 5 879 5 575 5 325 525 593 659 645 622 0.1 0.1 L01AX04 dacarbazine 1 182 1 134 1 001 960 847 <5 0 0 0 0 - 0.0 L01B ANTIMETABOLITES 1920 2625 3200 4344 25 17 <5 <5 0.0 - L01BA01 1) methotrexate 6 427 8 463 6 399 9 825 7 334 41 25 17 <5 <5 0.0 - L01BA04 pemetrexed 1 646 1 210 1 256 2 566 3 818 <5 0 0 0 0 - 0.0 L01BB Purine analogues 519 500 510 498 442 0.1 0.1 L01BB02 mercaptopurine 5 904 6 181 6 048 5 931 5 507 463 459 473 449 403 0.1 0.1 L01BB03 tioguanine 142 95 106 135 75 36 43 53 56 36 0.0 0.0 L01BB04 cladribine 2 3 3 4 3 - - - - - - - L01BB05 fludarabine 97 87 90 110 110 54 38 35 45 38 0.0 0.0 L01BB06 clofarabine 0 0 1 1 - - - - - - - L01BC Pyrimidine analogues 1 357 2 002 2 098 2 701 3 901 0.3 0.7 L01BC01 cytarabine 9 322 8 455 8 918 8 671 8 888 <5 5 <5 <5 <5 - - L01BC02 fluorouracil 58 829 61 98 7 64 85 6 69 35 7 76 328 116 98 68 166 742 0.0 0.1 L01BC05 gemcitabine 12 382 14 024 14 189 14 062 14 866 13 15 0 0 0 0.0 0.0 1) Metotrexat tabletter t i L04AX03 92 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 gram of active ingredient/year ATC 2016 2017 2018 2019 2020 L01BC06 capecitabine 223 728 215 430 209 256 253 557 257 007 1 184 1 215 1 175 1 292 1 303 0.2 0.2 L01BC07 azacitidine 669 811 827 969 <5 - - L01BC08 decitabine 16 33 33 26 25 0 <5 0 0 0 0.0 0.0 L01BC52 fluorouracil, combinations 1 20 23 34 52 43 651 784 1 171 1 773 0.0 0.3 L01BC53 tegafur, combinations 30 24 36 28 72 <5 6 5 5 11 - 0.0 L01BC59 trifluridine, combinations 78 268 258 339 0 24 74 73 92 0.0 0.0 L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS 1 365 1 250 1 216 990 903 0.3 0.2 L01CA Vinca alkaloids and analogues 893 792 765 528 347 0.2 0.1 L01CA01 vinblastine 23 22 21 18 17 - - - - - - - L01CA02 vincristi ne 13 13 12 13 12 <5 <5 0 0 0 - 0.0 L01CA04 vinorelbine 578 529 485 399 260 890 789 765 528 347 0.2 0.1 L01CA05 vinflunine 60 61 14 1 13 - - - - - - - L01CB Podophyllotoxin derivatives 433 430 438 444 544 0.1 0.1 L01CB01 etoposide 3 749 3 627 3 630 3 844 4 123 433 430 438 444 544 0.1 0.1 L01CB02 teniposide 22 22 14 3 - - - - - - - L01CD Taxanes 25 15 <5 <5 <5 0.0 - L01CD01 paclitaxel 4 559 4 459 4 121 4 630 4 665 16 9 <5 <5 0 0.0 0.0 L01CD02 docetaxel 898 909 867 995 903 9 6 0 <5 <5 0.0 - L01CD04 cabazitaxel 3 10 34 38 48 - - - - - - - L01CE Topoisomerase 1 (TOP1) inhibitors 29 22 18 19 24 0.0 0.0 L01CE01 topotecan 2 1 1 1 2 23 17 18 19 24 0.0 0.0 L01CE02 irinotecan 3 416 3 671 3 443 3 574 3 855 6 5 0 0 0 0.0 0.0 L01CX Other plant alkaloids and natural products - - - - - - - L01CX01 trabectedin 0.3 0.3 0.4 0.3 0.3 - - - - - - - L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES 16 14 6 0 0 0.0 0.0 L01DA Actinomycines - - - - - - - L01DA01 dactinomycin 0.2 0.2 0.3 0.2 0.2 - - - - - - - L01DB Anthracyclines and related substances 15 14 <5 0 0 0.0 0.0 L01DB01 doxorubicin 601 564 575 678 672 <5 6 <5 0 0 - 0.0 L01DB02 daunorubicin 52 52 60 44 52 - - - - - - - L01DB03 epirubi cin 1 315 1 127 1 006 988 1 013 10 7 0 0 0 0.0 0.0 L01DB06 idarubicin 6 6 5 5 5 <5 <5 <5 0 0 - 0.0 L01DB07 mitoxantrone 5 4 3 3 3 - - - - - - - L01DB11 pixantrone 1 1 1 - - - - - - - 93 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 gram of active ingredient/year ATC 2016 2017 2018 2019 2020 L01DC Other cytotoxic antibiotics <5 0 <5 0 0 - 0.0 L01DC01 bleomycin 50 550 47 250 42 450 39 300 32 985 <5 0 <5 0 0 - 0.0 L01DC03 mitomycin 51 53 57 60 63 0 0 <5 0 0 0.0 0.0 L01E PROTEIN KINASE INHIBITORS 2 366 2 925 3 227 3 641 3 839 0.5 0.7 L01EA BCR-ABL tyrosine 0.2 L01EA01 imatinib 62 640 62 232 63 186 68 466 68 142 539 577 577 607 601 0.1 0.1 L01EA02 dasatinib 1 740 2 039 2 379 2 601 2 941 80 95 106 123 127 0.0 0.0 L01EA03 nilotinib 16 940 16 475 17 110 17 972 15 665 106 108 113 108 97 0.0 0.0 L01EA04 bosutinib 406 274 882 1 462 2 173 6 5 15 19 22 0.0 0.0 L01EA05 ponatinib 51 92 120 145 156 7 14 16 17 18 0.0 0.0 L01EB Epidermal growth factor receptor (E GFR) tyrosine kinase inhibitors 200 205 198 169 164 0.0 0.0 L01EB01 gefitinib 2 130 1 815 4 035 4 710 3 390 42 36 93 95 64 0.0 0.0 L01EB02 erlotinib 2 868 3 227 2 084 1 298 898 131 138 86 48 40 0.0 0.0 L01EB03 afatinib 264 294 201 236 150 48 49 38 37 21 0.0 0.0 L01EB04 osimertinib 10 120 209 264 0 <5 6 9 15 0.0 0.0 L01EB07 dacomitinib 1 248 0 0 0 L01EC B-Raf serine -threonine kinase (BRAF) 170 179 173 162 205 0.0 0.0 L01EC01 vemurafenib 7 190 4 140 3 454 7 620 6 263 38 23 20 50 43 0.0 0.0 L01EC02 dabrafenib 5 592 6 480 6 400 5 115 5 369 144 164 162 126 158 0.0 0.0 L01EC03 encorafenib 126 1 884 0 0 0 6 48 0.0 0.0 L01ED Anaplastic lymphoma kinase (ALK) inhibitors 63 65 71 81 103 0.0 0.0 L01ED01 crizotinib 4 302 4 521 3 807 2 367 3 033 54 54 39 24 26 0.0 0.0 L01ED02 ceritinib 1 823 2 273 1 508 743 880 18 21 13 8 8 0.0 0.0 L01ED03 alectinib 1 378 5 242 15 187 17 942 0 9 32 55 64 0.0 0.0 L01ED04 brigatinib 8 396 0 0 0 <5 13 0.0 0.0 L01ED05 lorlatinib 27 - - - - - - - L01EE Mitogen -activated protein kinase (MEK) inhibitors 106 157 159 154 186 0.0 0.0 L01EE01 trametinib 24 44 44 35 37 106 155 156 126 150 0.0 0.0 L01EE02 cobimetinib 1 40 52 151 149 <5 10 10 41 34 - 0.0 L01EE03 binimetinib 28 422 0 0 0 6 43 Cyclin -dependent kinase (CDK) 0.0 0.1 L01EF01 palbociclib 1 129 6 147 7 520 7 090 8 851 86 442 463 426 545 0.0 0.1 L01EF02 ribociclib 7 59 4 20 668 18 791 0 0 143 317 228 0.0 0.0 L01EF03 abemaciclib 540 0 0 0 0 16 0.0 0.0 94 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 gram of active ingredient/year ATC 2016 2017 2018 2019 2020 L01EG Mammalian target of rapamycin (mTOR) 239 241 L01EG02 everolimus 396 304 284 335 305 296 238 210 239 241 0.1 0.0 L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors 30 18 6 14 10 0.0 0.0 L01EH01 lapatinib 4 305 2 373 1 323 1 155 840 30 18 6 14 10 0.0 0.0 L01EJ Janus -associated kinase (JAK) inhibitors 143 213 262 320 353 0.0 0.1 L01EJ01 ruxolitinib 1 010 1 404 1 773 2 014 2 283 143 213 262 320 353 0.0 0.1 L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors 66 43 24 25 78 0.0 0.0 L01EK01 axitinib 111 68 44 38 84 66 43 24 23 71 0.0 0.0 L01EK03 tivozanib 0.1 0.5 0 0 0 <5 7 0.0 0.0 L01EL Bruton's tyrosine kinase (BTK) inhibitors 153 0.1 L01EL01 ibrutin ib 10 387 14 045 19 324 22 408 24 952 115 153 207 234 270 0.0 0.1 L01EM Phosphatidylinositol -3- kinase (Pi3K) inhibitors 26 26 27 23 21 0.0 0.0 L01EM01 idelalisib 1 251 978 1 401 1 368 1 107 26 26 27 23 21 0.0 0.0 L01EX Other protein kinase inhibitors 604 704 790 947 976 0.1 0.2 L01EX01 sunitinib 1 003 848 1 229 1 030 760 192 177 253 187 139 0.0 0.0 L01EX02 sorafenib 6 899 4 838 5 174 7 146 5 242 90 76 74 90 68 0.0 0.0 L01EX03 pazopanib 22 512 22 806 16 614 20 970 20 034 201 212 159 225 203 0.0 0.0 L01EX04 vandetanib 174 159 78 33 585 665 706 64 77 59 68 73 0.0 0.0 L01EX07 cabozantinib 249 566 898 1 213 1 170 33 78 135 172 162 0.0 0.0 L01EX08 lenvatinib 13 15 43 49 135 5 7 14 25 85 0.0 0.0 L01EX09 nintedanib 5 280 9 339 13 311 19 167 22 350 84 132 194 276 320 0.0 0.1 L01EX10 midostaurin 73 62 186 0 0 <5 5 19 0.0 0.0 L01EX14 entrectinib 108 0 0 0 0 <5 0.0 - L01X OTHER ANTINEOPLASTIC AGENTS 2 407 2 585 2 61 0 2 911 3 260 0.5 0.6 L01XA Platinum compounds 20 19 0 <5 0 0.0 0.0 L01XA01 cisplatin 631 618 600 607 552 - - - - - - - L01XA02 carboplatin 6 105 6 058 5 979 6 296 6 261 6 7 0 0 0 0.0 0.0 L01XA03 oxaliplatin 1 864 1 899 1 835 1 978 2 151 14 12 0 <5 0 0.0 0.0 95 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 gram of active ingredient/year ATC 2016 2017 2018 2019 2020 L01XB Methylhydrazines 105 126 94 102 109 0.0 0.0 L01XB01 procarbazine 663 680 503 680 683 105 126 94 102 109 0.0 0.0 L01XC Monoclonal antibo dies 238 216 115 63 37 0.1 0.0 L01XC02 rituximab 13 305 13 552 14 155 13 660 13 655 177 161 55 11 10 0.0 0.0 L01XC03 trastuzumab 6 232 6 794 6 798 6 221 6 135 28 21 34 21 14 0.0 0.0 L01XC06 cetuximab 1 090 1 223 1 166 993 1 131 0 0 <5 0 0 0.0 0.0 L01XC07 bevacizumab 3 902 4 030 3 997 4 227 4 650 12 7 <5 <5 <5 0.0 - L01XC08 panitumumab 838 849 813 880 895 <5 5 0 0 0 - 0.0 L01XC10 ofatumumab 32 27 4 - - - - - - - L01XC11 ipilimumab 10 27 37 81 105 <5 <5 - - L01XC12 brentuximab ve dotin 9 23 24 30 29 - - - - - - - L01XC13 pertuzumab 837 1 055 1 085 1 491 2 873 0 <5 <5 0 0 0.0 0.0 L01XC14 trastuzumab emtansine 9 70 169 165 199 - - - - - - - L01XC15 obinutuzumab 14 53 226 330 337 - - - - - - - L01XC17 nivolumab 472 1 027 1 663 2 074 3 263 19 19 21 23 6 - - L01XC18 pembrolizumab 327 885 1 017 1 315 2 <5 <5 <5 <5 0.0 - L01XC21 ramucirumab 14 34 12 30 16 - - - - - - - L01XC24 daratumumab 28 515 2 533 3 251 5 408 0 0 <5 <5 <5 0.0 - L01XC28 bermekimab 52 992 - - - - - - - L01XC31 avelumab 360 516 544 - - - - - - - L01XC32 atezolizumab 1 667 3 038 2 946 - - - - - - - L01XC33 cemiplimab 4 - - - - - - - L01XD Sensitizers used in photodynamic/radiation therapy 5 <5 47 193 176 0.0 0.0 L01XD03 methyl aminolevulinate 1 325 1 259 1 026 1 140 1 358 5 <5 37 141 175 0.0 0.0 L01XD04 aminolevulinic acid 158 289 490 453 430 0 0 11 53 <5 0.0 - L01XF Retinoids for cancer treatment 28 43 31 32 28 0.0 0.0 L01XF01 tretinoin 98 178 114 133 157 15 32 22 24 19 0.0 0.0 L01XF03 bexarotene 1 275 1 035 998 720 885 13 11 9 8 9 0.0 0.0 L01XG Proteasome inhibitors 31 36 38 34 84 0.0 0.0 L01XG01 bortezomib 32 34 38 45 51 30 33 35 32 44 0.0 0.0 L01XG02 carfilzomib 35 105 314 334 420 <5 <5 0 0 0 - 0.0 L01XG03 ixazomib 0.0 0.2 0.2 1.5 0 0.0 0.0 L01XH Histone deacetylase (HDAC) 25 26 12 12 13 0.0 0.0 L01XH03 panobinostat 9 10 4 4 6 25 26 12 12 13 0.0 0.0 L01XJ Hedgehog pathway inhibitors 12 22 21 25 21 0.0 0.0 L01XJ01 vismodegib 202 340 307 361 491 12 22 21 25 21 0.0 0.0 96 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 gram of active ingredient/year ATC 2016 2017 2018 2019 2020 L01XK Poly (ADP -ribose) polymerase (PARP) inhibitors 27 53 62 69 241 0.0 0.0 L01XK01 olaparib 2 822 7 750 8 893 8 372 21 409 27 53 62 69 196 0.0 0.0 L01XK02 niraparib 1 000 0 0 0 0 47 0.0 L01XX Other antineoplastic L01XX01 amsacrine 39 61 37 28 46 - - - - - - - L01XX02 asparagi nase 3 200 2 850 3 640 2 380 940 - - - - - - - L01XX05 hydroxycarbamide 453 570 475 390 512 300 550 520 581 770 1757 1866 2009 2163 2254 0.3 0.4 L01XX23 mitotane 9 600 7 300 4 750 5 800 6 550 15 14 13 15 13 0.0 0.0 L01XX24 pegaspargase 1 916 1 695 1 216 390 258 - - - - - - - L01XX27 arsenic trioxide 4 8 3 6 13 - - - - - - - L01XX35 anagrelide 102 104 103 108 113 206 218 215 224 242 0.0 0.1 L01XX41 eribulin 2 2 1 1 1 - - - - - - - L01XX52 venetoclax 1 605 2 094 6 782 0 0 9 45 120 0.0 0.0 DDD/10 00 inhabitants/year 2016 2017 2018 2019 2020 L02 ENDOCRINE THERAPY 2 256 2 298 2 247 2 358 2 315 28869 31639 32537 33413 34285 5.5 6.4 L02A HORMONES 545 554 10640 10832 11026 11251 2.0 2.1 L02AB Progestogens 6 6 7 5 7 138 130 162 144 150 0.0 0.0 L02AB01 megestrol (0.16 g) 6 6 7 5 7 138 130 162 144 150 0.0 0.0 L02AE Gonadotropin releasing hormone L02AE01 buserelin (1 .2 mg) 2 2 1 1 0 387 335 252 127 34 0.1 0.0 L02AE02 leuprorelin (0.134 mg depot inj./ 0.06 mg depot inj./0.1 mg P) 1 1 1 1 1 241 479 573 670 890 0.1 0.2 L02AE05 histrelin (0.137 mg) - - - - - - - L02B HORMONE ANTAGONISTS AND RELATED AGENTS 1 696 1 744 1 702 1 804 5.2 L02BA Anti -estrogens 304 333 337 347 365 4 958 5 439 5 544 5 675 5 745 1.0 1.1 L02BA01 tamoxifen (20 mg) 272 288 287 301 318 4 612 4 963 5 062 5 214 5 295 0.9 1.0 L02BA03 fulvestrant (8.3 mg) 32 45 50 46 47 376 522 521 487 485 0.1 0.1 L02BB Anti -androgens 741 737 681 721 651 6 985 7 007 7 020 6 884 6 818 1.3 1.3 L02BB01 flutamide (0.75 g) 4 4 3 2 1 85 82 64 55 46 0.0 0.0 L02BB03 bicalutamide (50 mg) 705 694 634 672 599 6 116 6 041 5 945 5 762 5 605 1.2 1.0 L02BB04 enzalutamide (0.16 g) 32 39 44 47 51 938 1 093 1 18 8 1 219 1 296 0.2 0.2 L02BB05 apalutamide 0 0 0 0 16 0.0 0.0 97 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/1000 inhabitants/year 2016 2017 2018 2019 2020 L02BB06 darolutamide 0 0 0 0 <5 0.0 - L02BG Aromatase inhibitors 584 614 630 685 701 10 626 12 995 13 880 14 668 15 462 2.0 2.9 L02BG03 anastrozole (1 mg) 50 41 34 35 28 843 757 652 574 527 0.2 0.1 L02BG04 letrozole (2.5 mg) 480 521 542 593 613 9 079 11 537 12 524 13 348 14 136 1.7 2.6 L02BG06 exemestane (25 mg) 54 52 54 57 60 1 015 974 1 041 1 078 1 206 0.2 0.2 L02BX Other hormone antagonists and related agents 67 60 54 51 50 1 401 1 273 1 180 1 147 1 125 0,3 0,2 L02BX02 degarelix (2.7 mg) 46 44 40 38 39 872 837 786 778 827 0.2 0.2 L02BX03 abiraterone (1 g) 21 16 14 13 11 581 473 430 398 319 0.1 0.1 L03 IMMUNOSTIMULANTS 200 177 168 164 174 6 819 6 431 6 432 6 510 7 080 1.3 1.3 L03A IMMUNOSTIMULANTS 200 177 168 164 174 6 819 6 431 6 432 6 510 7 080 1.3 1.3 L03AA Colony stimulating factors 4 909 4 775 4 932 5 169 5 769 0.9 1.1 L03AA02 filgrastim (0.35 mg) 4 4 4 4 4 583 588 594 671 633 0.1 0.1 L03AA13 pegfilgrastim (0.3 mg) 55 61 23 47 83 3 605 3 947 1 811 3 208 5 206 0.7 1.0 L03AA14 lipegfilgrastim (0.3 mg) 13 5 45 24 1 956 370 3 086 1 997 111 0.2 0.0 L03AB Interferons 1 210 952 763 668 676 0.2 0.1 L03AB03 interferon gamma (40 mcg) 1 1 1 1 1 13 10 9 8 9 0.0 0.0 L03AB04 interferon alfa -2a (2 MU) 1 1 0 19 21 0 0 0 0.0 0.0 L03AB05 interferon alfa -2b (2 MU) 1 1 1 1 1 36 40 27 22 12 0.0 0.0 L03AB07 interfer on beta -1a (4.3 mcg) 55 44 37 33 28 461 372 323 273 233 0.1 0.0 L03AB08 interferon beta -1b (4 MU) 12 9 6 5 4 211 134 95 65 57 0.0 0.0 L03AB10 peginterferon alfa -2b (7.5 mcg) 3 2 2 1 1 51 50 40 28 33 0.0 0.0 L03AB11 peginterferon alfa -2a (26 mcg) 7 5 5 6 8 315 214 184 203 276 0.1 0.1 L03AB13 peginterferon beta -1a (8.9 mcg) 3 3 2 2 2 149 135 100 75 70 0.0 0.0 L03AX Other immunostimulants 723 722 761 685 642 0.1 0.1 L03AX03 BCG vaccine (1.8 mg) 8 8 8 9 11 13 5 8 5 8 0.0 0.0 L03AX13 glatiram er acetate (20 mg) 36 33 34 31 30 710 717 753 680 634 0.1 0.1 L04 IMMUNOSUPPRESSANTS 4 906 5 229 5 471 5 746 6 192 64 946 68 190 71 244 74 825 77 919 12.5 14.5 L04A IMMUNOSUPPRESSANTS 4 906 5 229 5 471 5 746 6 192 64 946 68 190 71 244 74 825 77 919 12.5 14.5 L04AA Selective immunosuppressants 678 712 736 732 740 10 333 10 851 11 856 12 234 12 371 2.0 2.3 L04AA06 mycophenolic acid (2 g) 225 233 238 248 249 4 925 5 164 5 375 5 473 5 654 0.9 1.1 L04AA10 sirolimus (3 mg) 12 12 12 12 13 272 295 297 293 312 0.1 0.1 L04AA13 leflunomide (20 mg) 104 102 98 81 107 2 225 2 256 2 238 2 121 2 013 0.4 0.4 L04AA18 everolimus (1.5 mg) 52 49 53 54 50 487 481 508 480 458 0.1 0.1 L04AA23 natalizumab (10 mg) 58 58 60 61 55 0 <5 <5 0 <5 0.0 - L04AA24 abatacept (27 mg) 11 11 10 9 8 258 283 268 215 188 0.1 0.0 98 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/1000 inhabitants/year 2016 2017 2018 2019 2020 L04AA25 eculizumab (64 mg) 18 18 18 22 22 0.0 0.0 L04AA26 belimumab (25 mg) 3 3 3 4 5 - - - - - - - L04AA27 fingo limod (0.5 mg) 79 82 82 77 69 1 329 1 411 1 380 1 263 1 104 0.3 0.2 L04AA28 belatacept (12.5 mg) 0 1 1 1 2 <5 0 <5 <5 <5 - - L04AA29 tofacitinib (10 mg) 1 24 33 24 0 87 835 672 481 0.0 0.1 L04AA31 teriflunomide (14 mg) 73 78 80 80 75 1 362 1 427 1 465 1 358 1 272 0.3 0.2 L04AA32 apremilast (60 mg) 1 1 1 0 0 35 27 15 6 11 0.0 0.0 L04AA33 vedolizumab (5.4 mg) 38 61 78 96 106 0 0 0 0 14 0.0 0.0 L04AA34 alemtuzumab (0.13 mg) 23 22 21 9 1 - - - - - - - L04AA36 ocrelizumab (3.29 mg) 0 1 1 - - - - - - - L04AA37 baricitinib (4 mg) 1 2 16 31 0 28 56 553 793 0.0 0.1 L04AA40 cladribine (0.34 mg) 14 39 50 0 0 182 510 649 0.0 0.1 L04AB Tumor necrosis factor alpha (TNF -) inhibitors 1 671 1 814 1 979 2 187 2 415 15 647 16 505 16 764 20 473 23 506 3,0 4,4 L04AB01 etanercept (7 mg) 279 329 377 343 342 5 737 7 350 8 196 7 228 7 203 1.1 1.3 L04AB02 infliximab (3.75 mg) 801 920 1 086 1 127 1 160 0 <5 <5 <5 6 0.0 0.0 L04AB04 adalimumab (2.9 mg) 257 256 255 500 740 4 448 4 376 4 430 10 828 14 580 0.9 2.7 L04AB05 certolizumab pegol (14 mg) 214 195 157 131 100 4 262 3 646 2 990 2 577 2 010 0.8 0.4 L04AB06 golimumab (1.66 mg) 120 114 104 86 73 1 848 1 684 1 514 1 308 1 071 0.4 0.2 L04AC Interleukin inhibitors 129 173 197 197 346 1 848 2 673 3 062 3 002 3 779 0.4 0.7 L04AC01 daclizumab (5 mg) 1 0 0 14 5 0 0 0.0 0.0 L04AC03 anakinra (0.1 g) 8 9 8 10 13 189 197 208 270 323 0.0 0.1 L04AC05 ustekinumab (0.54 mg) 67 69 79 78 226 830 814 805 752 1 190 0.2 0.2 L04AC07 tocilizumab (20 mg) 37 41 42 38 39 521 608 618 543 561 0.1 0.1 L04AC08 canakinumab (2.7 mg) 2 2 4 4 5 23 24 37 37 42 0.0 0.0 L04AC10 secukinumab (10 mg) 16 51 64 64 59 371 1 102 1 430 1 368 1 277 0.1 0.2 L04AC12 brodalumab (15 mg) 0 3 4 0 0 15 85 80 0.0 0.0 L04AC13 ixekizumab (2.9 mg ) 1 18 0 0 0 22 398 0.0 0.1 L04AC18 risankizumab (1.67 mg) 0 0 0 0 57 0.0 0.0 L04AD Calcineurin inhibitors 298 310 320 337 338 6 203 6 274 6 449 6 612 6 685 1.2 1.3 L04AD01 ciclosporin (0.25 g) 125 118 110 108 101 3 130 2 954 2 893 2 788 2 654 0.6 0.5 L04AD02 tacrolimus (5 mg) 173 192 210 229 237 3 132 3 383 3 628 3 886 4 092 0.6 0.8 L04AX Other immunosuppressants 2 130 2 220 2 239 2 293 2 353 43 579 45 478 47 018 48 044 48 615 8.4 9.1 L04AX01 azathioprine (0.15 g) 320 312 300 276 283 8 280 8 280 8 214 8 003 7 498 1.6 1.4 L04AX02 thalidomide (0.1 g) 4 2 1 1 1 200 90 63 63 37 0.0 0.0 L04AX03 methotrexate (2.5 mg) 1 777 1 865 1 890 1 967 2 014 33 357 35 139 36 511 37 749 38 707 6.4 7.2 L04AX04 lenalidomide (10 mg) 23 33 39 39 44 612 810 987 957 1 088 0.1 0.2 L04AX05 pirfenidone (2.4 g) 3 3 4 5 6 69 78 98 120 170 0.0 0.0 99 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 DDD/1000 inhabitants/year 2016 2017 2018 2019 2020 L04AX06 pomalidomide (3 mg) 3 4 5 5 5 130 178 191 202 211 0.0 0.0 L04AX07 dimethyl fumarate (0.48 g) 68 63 62 63 60 1 235 1 160 1 213 1 180 1 111 0.2 0.2 100 4.10 M Muskler og ned tid. i Proportion of the populations (prev alence %) of most prescribed antirheumatic products, non -steroids (NSAIDs, M01A) in 2016 - 2020. Source: Norwegian Prescription Midle r til behandling av bensykdommer (M05) Reseptregisteret til behandling av I 2020 fi kk 8 % av alle kvinner over 65 forebygging behandling \u00f8kt fra 12 % i 2004 til n\u00e6r 20 % i 2020. Kalsium og vitamin D stadig 17 \u00e5r minst minst en resept i - EtoricoxibProportion (%) of the populatiom2016 2017 2018 2019 2020 102 Figure 4.10.2 Sales of Calcium/vitamin D (A12A), bisphosphonates, plain and comb. (M05BA and M05BB), denosumab (M05BX04) and other drugs with the Norway (G03CX01 tib olone, G03XC01 raloxifene, H05AA02 teriparatide) to elderly women years) in Norway for the years 2004 -2020. Source: Norwegian Prescription Database 1) https://legemiddelverket.no/nyheter/nye- anbefalinger -for-diklofenak 02468101214161820 020406080100120140160180200 2004 2006 2008 2010 2012 2014 2016 2018 2020year Proportion (%) women above 65 year with at least one prescriptionDDD/1,000 inhabitants, women above 65 yearCalcium/Vit D Bisphosphonate Denosumab Other treatment for osteoporosis All treatment for osteoporosis 103 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 M MUSCULO 734 158.0 153.1 M01AB Acetic acid derivatives and related substances 8.18 7.75 7.16 6.74 6.39 349 105 341 (0.1 g) 0.07 0.06 0.06 0.07 0.08 1 220 1 282 1 302 1 466 1 445 0.2 0.3 M01AB02 sulindac (0.4 g) 7.25 6.85 6.31 5.92 5.62 330 952 323 120 307 380 290 645 273 256 63.5 50.9 M01AB15 ketorolac (30 mg) 0.03 0.03 0.04 0.04 0.04 18 25 48 35 34 0.0 0.0 M01AB55 diclofenac, combinations (0.1 g) 0.83 0.80 0.75 0.71 0.65 19 774 19 896 18 774 17 808 17 450 3.8 3.3 M01AC Oxicams 1.36 1.19 1.07 0.73 0.79 35 293 31 649 27 443 23 545 20 431 6.8 3.8 M01AC01 piroxicam (20 mg) 0.86 0.75 0.69 0.56 0.57 28 375 25 189 21 552 19 409 17 861 5.4 3.3 M01AC06 meloxicam (15 mg) 0.50 0.44 0.38 0.17 0.22 7 051 6 577 5 991 4 349 2 732 1.4 0.5 M01AE Propionic acid 4.06 4.07 4.21 105 672 99 739 94 127 93 013 90 76 0 20.3 16.9 M01AE03 ketoprofen (0.15 g) 0.54 0.49 0.45 0.43 0.39 4 252 3 766 3 559 3 432 3 280 0.8 0.6 M01AE14 dexibuprofen (0.8 g) 0.00 0.00 0.00 0.00 (75 mg) 0.00 0.00 0.00 0.00 26 6 M01AE52 naproxen and esomeprazole (0.5 g) 7.93 9.17 9.96 11.04 12.27 123 511 142 741 154 156 173 107 190 454 23.7 35.5 M01AG Fenamates 0.01 0.01 0.01 0.01 0.01 454 494 484 616 712 0.1 0.1 M01AG02 tolfenamic acid (0.3 g) 0.01 0.01 0.01 0.01 0.01 454 494 484 616 712 0.1 0.1 M01AH Coxibs 4.26 4.71 4.99 5.55 5.90 96 791 101 372 104 774 112 423 121 232 18.6 22.6 M01AH01 celecoxib (0.2 g) 0.82 0.86 0.88 0.99 1.04 14 296 14 719 14 942 16 566 18 170 2.7 3.4 M01AH04 parecoxib (60 mg) 0.01 0.01 0.01 0.01 <5 4.54 4.84 83 452 87 661 90 828 97 099 104 488 16.0 19.5 M01AX Other antiinflammatory and antirheumatic agents, non -steroids 3.85 3.69 3.38 2.99 2.85 31 596 30 244 28 000 24 546 23 046 6.1 4.3 M01AX01 nabumetone (1 g) 0.21 0.20 0.17 0.16 0.15 2427 2175 1935 1753 1728 0.5 0.3 M01AX05 glucosamine 2.70 25322 0.00 0.00 0.00 0.02 64 49 35 29 22 0.0 0.0 M01CB Gold preparations 0.01 0.00 0.00 0.00 0.02 59 42 29 22 14 0.0 M01CB01 sodium aurothiomalate (2.4 mg) 0.00 0.00 0.00 0.00 0.02 24 13 11 6 auranofin (6 mg) 0.00 0.00 0.00 0.00 18 16 14 ne and similar agents 0.00 0.00 0.00 0.00 0.00 5 7 6 7 8 0.0 0.0 104 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 M01CC01 penicillamine (0.5 g) 0.00 0.00 0.00 0.00 0.00 RELAXANTS 0.81 0.86 0.84 0.89 0.88 8 272 8 991 10 310 11 347 12 178 1.6 2.3 M03B MUSCLE RELAXANTS, CENTR ALLY ACTING AGENTS 0.67 0.73 0.72 0.76 5 868 5 883 6 164 6 358 6 670 1.1 1.2 M03BA Carbamic acid esters 0.05 0.05 0.04 0.04 0.04 495 421 401 387 386 0.1 0.1 M03BA02 carisoprodol (1.4 g) 0.05 0.05 0.04 0.04 0.04 495 421 401 387 383 0.1 0.1 M03BX Other centrally acting agents 0.62 0.68 0.67 0.72 0.72 5 347 5 430 5 716 5 892 6 169 1.0 1.2 M03BX01 baclofen (50 mg O) 0.61 0.66 0.66 0.71 0.71 5 269 5 357 5 637 5 819 6 085 1.0 1.1 M03BX02 tizanidine (12 mg) 0.01 0.02 0.01 0.01 0.01 105 103 108 105 114 0.0 0.0 M04 ANTIGOUT PREPARATIONS 4.50 4.95 4.87 4.96 5.62 56 374 59 343 61 965 64 438 67 951 10.8 12.7 M04A ANTIGOUT PREPARATIONS 4.50 4.95 4.87 4.96 5.62 56 374 59 343 61 965 64 438 67 951 10.8 12.7 M04AA Preparations inhibiting uric acid production 3.80 4.22 4.23 4.20 4.88 50 525 53 155 55 688 58 024 61 235 9.7 11.4 M04AA01 allopurinol (0.4 g) 3.76 4.18 4.15 4.11 4.79 50 261 52 795 55 177 57 435 60 599 9.6 11.3 M04AA03 febuxostat (80 mg) 0.03 0.05 0.08 0.09 arations increasing uric acid excretion 0.20 0.20 0.19 0.19 0.19 1 878 1 788 1 752 1 710 1 666 0.4 0.3 M04AB01 probenecid (1 g) 0.20 0.20 0.19 0.19 0.19 1 878 1 788 1 748 1 702 1 662 0.4 0.3 M04AC Preparations with no effect on uric acid metabolism 0.50 0.53 0.45 0.57 0.55 8 293 9 200 9 576 9 870 10 709 1.6 2.0 M04AC01 colchicine (1 mg) 0.50 0.53 0.45 0.57 0.55 8 293 9 200 9 576 9 870 10 709 1.6 2.0 M05 DRUGS FOR TREATMENT OF BONE DISEASES 9.78 9.52 9.43 9.43 9.34 63 305 64 868 66 175 67 014 66 357 12.1 12.4 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 9.78 9.52 9.43 9.43 9.34 63 305 64 868 66 175 67 014 66 357 12.1 12.4 M05BA Bisphosphonates 7.98 7.75 7.56 7.33 7.07 57 490 57 746 57 407 56 785 54 962 11.0 10.2 M05BA04 alendronic acid (10 mg ) 7.88 7.65 7.46 7.24 6.99 52 152 51 864 50 714 49 788 47 792 10.0 8.9 M05BA06 ibandronic acid (5 mg O/6 mg P) 0.04 0.04 0.03 0.03 0.03 618 597 556 488 441 0.1 0.1 M05BA07 risedronic acid (5 mg) 0.05 0.04 0.04 0.04 0.03 327 309 280 264 218 0.1 0.0 M05B A08 zoledronic acid (4 mg) 0.01 0.02 0.02 0.02 0.02 4 921 5 613 6 475 6 856 7 057 0.9 1.3 M05BX Other drugs affecting bone structure and mineralization 1.80 1.77 1.87 2.11 2.27 6 410 7 906 9 608 10 998 12 145 1.2 2.3 M05BX04 denosumab (0.33 mg) 1.80 1.77 1.87 2.11 2.27 6 410 7 906 9 608 10 998 12 134 1.2 2.3 105 4.11 N Nervesystemet Grossistbasert legemiddelgruppen m\u00e5lt i 15 % av befolkningen utlevert et NSAID, 10 % Figure 4.11: Proportion of the population (prevalence, %) havin g dispensed various analgesics in the period 2016 - 2020. Anti -inflammatory drugs N\u00f8kkeltall. Grossistbasert m\u00e5lt inng\u00e5r i mest, of the populationM01A N02A N02B Year 107 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N 4.14 4.04 48 789 57 193 62 111 67 118 69 247 9.4 12.9 N02AA01 morphine (0.03 g P/0,1 g O) 1.11 1.08 1.06 1.12 1.09 7 951 8 200 8 068 8 722 9 513 1.5 1.8 N02AA 03 hydromorphone (20 mg O) 0.24 0.19 0.18 0.18 0.17 137 123 60 12 16 0.0 0.0 N02AA05 oxycodone (75 mg O) 2.20 2.40 2.42 2.49 2.44 40 730 48 755 53 411 57 732 59 135 7.8 11.0 N02AA08 dihydrocodeine (0.15 g) 0.01 0.01 0.01 0.01 0.01 42 37 34 39 34 0.0 0.0 N02AA55 oxycodone and naloxone 0.28 0.30 0.32 0.33 0.33 6 521 7 246 7 726 8 380 8 978 1.3 1.7 N02AB Phenylpiperidine derivatives 1.56 1.50 1.46 1.43 1.36 12 920 12 405 11 975 11 564 10 687 2.5 2.0 N02AB01 ketobemidone (50 mg) 0.11 0.08 0.08 0.07 0.07 4 146 3 604 3 241 2 889 2 675 0.8 0.5 N02AB02 pethidine (0.4 g) 0.03 0.02 0.02 0.02 0.00 1 112 948 976 856 264 0.2 0.1 N02AB03 fentanyl (1.2 mg TD/0.6 mg N/SL) 1.43 1.40 1.36 1.34 1.29 8 058 8 180 8 036 8 070 7 961 N02AD benzomorphan derivatives 0.00 0.00 0.00 0.00 (0.2 g) 0.00 0.00 0.00 0.00 derivatives 0.73 0.78 0.77 0.77 0.77 18 354 18 403 17 999 17 972 18 047 3.5 3.4 N02AE01 buprenorphine (1.2 mg) 0.73 0.78 0.77 0.77 0.77 18 354 18 403 17 999 17 972 18 047 3.5 3.4 N02AG Opioids in combination with antispasmodics 0.04 0.05 0.05 0.05 0.05 1 719 1 688 1 546 1 511 1 619 0.3 0.3 N02AG02 ketobemidone and antispasmodics 0.04 0.05 0.05 0.05 0.05 1 719 1 688 1 546 1 511 1 619 0.3 0.3 N02AJ Opioids in combination with non -opioid analgesics 9.24 8.41 8.04 8.28 7.98 369 279 63.8 7.88 361 371 351 291 339 937 345 968 338 N02AJ07 codeine and acetylsalicylic acid 0.00 89 0.0 N02AJ13 tramadol and paracetamol 0.14 0.09 0.10 0.11 0.10 10 761 6 698 6 878 7 354 5 778 2.1 1.1 N02AX Other opioids 4.42 4.56 4.46 4.38 4.17 217 509 228 155 799 221 267 214 647 41.7 40.0 712 225 038 209 796 41.4 39.1 N02AX06 tapentadol (0 .4 g) 0.11 0.16 0.19 0.20 0.20 2 822 4 613 5 304 5 970 6 638 0.5 1.2 0.16 0.13 0.13 0.18 0.18 1 086 1 261 1 195 1 258 1 237 0.2 0.2 N02BA01 acetylsalicylic acid 0.16 0.13 0.13 0.18 0.18 1 082 1 257 1 191 1 254 1 232 0.2 Pyrazolones 1.45 1.35 1.27 1.17 1.03 1 318 1 550 1 551 1 521 1 449 0.3 0.3 0.00 0.00 0.00 0.0 N02BB51 phenazone, combinations excl. psycholeptics 1.45 1.35 1.27 1.17 1.02 1 269 1 485 1 492 1 602 090 641 037 91.9 119.4 108 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 analgesics and antipyretics 0.32 0.04 0.04 0.06 0.06 326 472 541 841 945 0.1 0.2 N02BG10 cannabinoids 0.32 0.04 0.04 0.06 0.06 326 472 540 0.1 0.2 4.09 4.28 4.36 N02CA72 ergotamine, combinations with psycholeptics 0.00 0.00 287 240 (5HT1) agonists 3.70 3.87 3.91 4.02 4.20 103 715 111 321 114 871 121 160 126 349 19.9 23.5 N02CC01 sumatriptan (50 mg O/ 6 mg P/ 20 mg N) 1.58 1.70 1.72 1.79 1.85 51 695 58 093 59 990 64 377 67 553 9.9 12.6 N02CC02 naratriptan (2.5 mg) 0.07 0.07 0.09 0.09 0.09 2 242 2 485 2 847 3 171 3 427 0.4 0.6 N02CC03 zolmitriptan (2.5 mg) 0.78 0.81 0.79 19 321 19 838 20 513 3.9 3.8 N02CC04 rizatriptan (10 mg) 0.71 0.73 0.75 0.80 0.81 30 355 31 217 32 744 34 523 36 170 5.8 6.7 N02CC05 almotriptan (12.5 mg) 0.07 0.07 0.08 0.07 0.07 2 916 2 934 3 023 3 214 3 413 0.6 0.6 N02CC06 eletriptan (40 mg) 0.48 0.48 0.48 0.48 0.52 12 796 13 275 13 651 14 317 14 946 2.5 2.8 N02CC07 frovatriptan (2.5 mg) 0.00 0.00 0.00 0.00 N02CD Calcito nin gene -related peptide (CGRP) antagonists 0.02 0.16 1.28 0 0 399 1 488 6 626 0.0 1.2 N02CD01 erenumab (2.5 mg) 0.02 0.16 1.01 0 0 399 1 468 5 276 0.0 1.0 N02CD02 galcanezumab (4 mg) 0.00 0.08 0 0 0 <5 991 0.0 0.2 N02CD03 fremanezumab (7. 5 mg) 0.00 0.20 0 0 0 82 2 103 0.0 0.4 N02CX Other antimigraine preparations 0.39 0.41 0.43 0.43 0.08 4 762 4 844 5 343 5 489 1 675 0.9 0.3 N02CX01 pizotifen (1.5 mg) 0.01 0.01 0.00 0.00 0.00 50 45 35 31 31 0.0 0.0 N02CX02 clonidine (0.1 mg) 0.39 0.41 0.43 0.43 0.07 4 714 4 802 5 308 5 458 1 644 0.9 0.3 N03 ANTIEPILEPTICS 16.95 17.58 17.90 18.51 19.17 127 262 131 955 136 191 142 623 148 772 24.4 27.7 N03A ANTIEPILEPTICS 16.95 17.58 17.90 18.51 19.17 127 262 131 955 136 191 142 623 148 772 24.4 27.7 N03AA Barbiturates and derivatives 0.51 0.49 0.46 0.34 0.44 2 087 2 006 1 901 1 825 1 743 0.4 0.3 N03AA02 phenobarbital (0.1 g) 0.49 0.47 0.44 0.32 0.43 1 744 1 630 1 519 1 387 1 287 0.3 0.2 N03AA03 primidone (1.25 g) 0.02 0.02 0.02 0.02 0.02 355 385 391 445 464 0.1 0.1 N03AB Hydantoin derivatives 0.23 0.21 0.19 0.18 0.16 1 281 1 118 1 022 981 914 0.3 0.2 N03AB02 phenytoin (0.3 g) 0.22 0.21 0.19 0.18 0.16 1 281 1 118 1 022 981 914 0.3 0.2 N03AD Succinimide derivatives 0.02 0.02 0.03 0.03 0.03 266 289 294 305 341 0.1 0.1 N03AD01 ethosuximide (1.25 g) 0.02 0.02 0.03 0.03 0.03 266 289 294 305 341 0.1 0.1 N03AE Benzodiazepine derivatives 0.33 0.28 0.25 0.23 0.21 8 702 7 198 6 416 5 885 5 459 1.7 1.0 N03AE01 clonazepam (8 mg) 0.33 0.28 0.25 0.23 0.21 8 702 7 198 6 416 5 885 5 459 1.7 1.0 109 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N03AF Carboxamide derivatives 1.79 1.74 1.70 1.75 1.68 15 310 14 894 14 432 14 218 13 844 2.9 2.6 N03AF01 carbamazepine (1 g) 1.17 1.11 1.03 0.99 0.93 12 256 11 495 10 461 9 734 9 310 2.4 1.7 N03AF02 oxcarbazepine (1 g) 0.50 0.50 0.50 0.55 0.53 2 703 2 968 3 388 3 732 3 669 0.5 0.7 N03AF03 rufinamide (1.4 g) 0.02 0.01 0.01 0.01 0.01 94 90 83 78 79 0.0 0.0 N03AF04 eslicarbazepine (0.8 g) 0.10 0.12 0.15 0.19 0.21 461 590 783 955 1 031 0.1 0.2 N03AG Fatty acid derivatives 1.79 1.79 1.79 1.79 1.78 15 249 15 197 15 073 14 939 14 785 2.9 2.8 N03AG01 valproic acid (1.5 g) 1.78 1.78 1.78 1.78 1.77 15 167 15 118 15 015 14 859 14 684 2.9 2.7 N03AG03 aminobutyric acid (1 g) 0.00 0.00 0.00 0.00 14 8 17 36 0.0 0.0 N03AG04 vigabatrin (2 g) 0.01 0.01 0.01 0.01 0.01 85 87 78 90 92 0.0 0.0 N03AG06 tiagabine (30 mg) 0.00 0.00 0.00 0.00 0.00 Other antiepileptics 12.28 13.04 13.50 14.19 14.87 97 526 104 042 109 602 117 023 124 154 18.7 23.1 N03AX03 sultiame (0.4 g) 0.02 0.03 0.03 0.03 0.03 277 323 343 347 366 0.1 0.1 N03AX09 lamotrigine (0.3 g) 4.18 4.36 4.38 4.54 4.68 29 235 30 145 30 746 31 739 32 428 5.6 6.0 N03AX10 felbamat (2.4 g) 0.00 0.00 0.00 0.00 topir amate (0.3 g) 0.30 0.31 0.31 0.32 0.32 4 174 4 617 4 814 5 751 6 207 0.8 1.2 N03AX12 gabapentin (1.8 g) 2.76 2.97 3.23 3.58 3.93 39 417 42 711 46 051 50 467 55 381 7.6 10.3 N03AX14 levetiracetam (1.5 g) 1.52 1.60 1.68 1.76 1.82 9 244 9 761 10 306 10 896 11 324 1.8 2.1 N03AX15 zonisamide (0.2 g) 0.17 0.17 0.16 0.17 0.18 639 623 611 604 663 0.1 g) 3.15 3.46 3.49 3.58 21 852 23 571 24 468 24 994 25 906 4.2 4.8 N03AX17 stiripentol (1 g) 0.01 0.01 0.01 0.01 0.01 30 33 34 40 40 0.0 0.0 N03AX18 lacosamide (0.3 g) 0.10 0.12 0.13 0.16 0.17 625 703 770 935 1 027 0.1 0.2 N03AX21 retigabine (0.9 g) 0.00 0.00 0 0.0 - N03AX22 perampanel (0.9 g) 0.04 0.04 0.04 0.05 0.05 303 360 361 406 426 0.1 0.1 N03AX23 brivaracetam (8 mg) 0.01 0.04 0.06 0.08 0.09 89 201 289 347 403 0.0 0.1 N03AX24 cannabidiol - - - 0.00 0.00 0 0 0 14 118 - -parkinson drugs 4.16 4.22 4.28 22 23 693 24 380 4.1 4.5 N04A Anticholinergic agents 0.17 0.16 0.15 0.15 0.14 2 119 2 071 1 990 1 906 1 868 0.4 0.4 N04AA Tertiary amines 0.17 0.16 0.15 0.15 0.14 2 103 2 055 1 979 1 899 1 860 0.4 0.4 N04AA01 trihexyphenidyl (10 mg) 0.01 0.01 0.01 0.01 0.01 52 54 39 48 43 0.0 0.0 N04AA02 biperiden (10 mg) 0.16 0.15 0.14 0.14 0.13 2 049 2 000 1 939 1 852 1 818 0.4 0.3 N04AA04 0.00 0.00 0.00 0.00 0.00 0.00 N04B Dopaminergic agents 3.99 4.06 4.13 4.17 4.15 19 443 20 262 21 150 21 850 22 569 3.7 4.2 N04BA Dopa and dopa derivatives 1.58 1.62 1.74 1.84 1.86 9 663 10 093 10 586 10 900 11 028 1.9 2.1 N04BA02 levodop a and decarboxylase inhibitor (0.6 g) 1.25 1.30 1.42 1.51 1.54 9 055 9 513 10 003 10 328 10 509 1.7 2.0 N04BA03 levodopa, decarboxylase inhibitor and comt inhibitor (0.45 g) 0.33 0.32 0.32 0.32 0.32 1 392 1 387 1 380 1 314 1 278 0.3 0.2 110 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N04BB Adamantane derivatives 0.03 0.03 0.03 0.03 0.02 191 207 178 175 169 0.0 0.0 N04BB01 amantadine (0.2 g) 0.03 0.03 0.03 0.03 0.02 191 207 178 175 169 0.0 0.0 N04BC Dopamine agonists 1.19 1.18 1.16 1.13 1.10 12 849 13 281 13 773 14 142 14 632 2.5 2.7 0.61 0.59 0.56 0.53 0.49 2 957 2 923 2 914 2 800 2 716 0.6 0.5 N04BC05 pramipexole (2.5 mg) 0.47 0.49 0.49 0.50 0.51 9 577 10 013 10 581 11 126 11 665 1.8 2.2 N04BC06 cabergoline (3 mg) 0.01 0.01 0.00 91 80 61 0 0 0.0 - N04BC07 apomorphine (20 mg) 0.02 0.02 0.02 0.03 0.03 45 62 60 66 60 0.0 0.0 N04BC09 rotigotine (6 mg) Monoamine oxidase B inhibitors 1.19 1.21 1.19 1.16 1.15 4 134 4 304 4 302 4 171 4 130 0.8 0.8 N04BD01 selegiline (5 mg) 0.84 0.85 0.85 0.83 0.80 2 400 2 439 2 465 2 376 2 373 0.5 0.4 N04BD02 rasagiline (1 mg) 0.34 0.34 0.33 0.34 1 778 1 887 1 807 1 768 1 747 0.3 0.3 N04BD03 safinamide (75 mg) 0.00 0.01 0.02 0.01 0.01 10 101 86 68 56 0.0 0.0 N04BX Other dopaminergic agents 0.02 0.02 0.02 0.02 0.02 127 142 157 141 158 0.0 0.0 N04BX01 tolcapone (0.45 g) 0.00 0.00 0.00 0.00 6 5 5 0.0 0.0 N04BX02 entacapone (1 g) 0.02 0.02 0.02 0.02 0.02 118 134 151 136 153 0.0 0.0 N05 PSYCHOLEPTICS 71.14 69.59 68.18 70.25 22.8 25.2 N05AA Phenothia zines with aliphatic side -chain 0.19 0.17 0.15 0.14 0.13 16 472 15 331 13 921 10 482 7 107 3.2 1.3 N05AA01 chlorpromazine (0.3 g O,R/0.1 g P) 0.01 0.01 0.01 0.00 0.00 168 202 202 176 133 0.0 0.0 N05AA02 levomepromazine (0.3 g O/0.1 g P) 0.18 0.16 0.15 0.13 0.12 16 313 15 135 13 727 10 312 6 979 3.1 1.3 N05AB Phenothiazines with piperazine structure 0.31 0.29 0.27 0.27 0.24 9 382 9 108 8 691 8 394 7 892 1.8 1.5 N05AB02 fluphenazine O/1 mg P) (30 mg O/ 10 mg P/ 7mg P (dep)) 0.26 0.24 0.23 0.22 0.20 1 659 1 577 1 507 1 454 1 320 0.3 0.3 N05AB04 prochlorperazine (0.1 g O,R/50 mg P) 0.05 0.04 0.04 0.04 0.04 7 715 7 529 7 186 6 936 6 575 1.5 with piperidine structure 0.00 0.00 0.00 26 0.00 0.00 pipotiazine 0.00 0.00 <5 <5 0 0 Butyrophenone derivatives 0.23 0.22 0.20 0.18 0.18 3 998 3 835 3 628 3 750 4 385 0.8 0.8 N05AD01 haloperidol (8 mg O,P/ 3.3 mg P (depot)) 0.22 0.21 0.19 0.18 0.18 3 987 3 822 3 608 3 740 4 376 0.8 0.8 N05AD03 melperon (0.3 g) 0.00 0.00 0.00 0.00 18 10 7 0.0 0.0 N05AD08 droperidol (2.5 mg) 0.01 0.01 0.01 0.01 0.01 <5 <5 5 0 <5 - - N05AE Indole derivatives 0.18 0.17 0.19 0.20 0.19 1 013 1 006 1 091 1 186 1 172 0.2 0.2 N05AE03 sertindole (16 mg) 0.02 0.01 0.01 0.01 0.01 96 79 72 65 55 0.0 0.0 111 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N05AE04 ziprasidone (80 mg O/40 mg P) 0.12 0.11 0.11 0.11 0.10 639 586 550 560 505 0.1 0.1 N05AE05 lurasidone (60 mg) 0.04 0.05 0.06 0.08 0.09 291 347 476 576 620 Thioxanthene derivatives 1.01 0.95 0.87 0.83 0.80 20 308 19 329 17 745 16 803 16 237 3.9 3.0 N05AF01 flupentixol (6 mg O/4 mg P) 0.22 0.21 0.19 0.19 0.18 3 744 3 486 3 171 3 025 2 860 0.7 0.5 N05AF03 chlorprothixene (0.3 g O/50 mg P) 0.36 0.34 0.31 0.28 0.27 14 499 13 822 12 619 11 908 11 640 2.8 2.2 N05AF05 zuclopenthixol (30 mg O,P/ 15 mg P (depot)) 0.43 0.40 0.37 0.36 0.35 2 561 2 470 2 314 2 208 2 080 0.5 0.4 N05AG Diphenylbutylpiperidine derivatives 0.01 0.01 0.01 0.01 0.01 112 104 101 103 96 0.0 0.0 N05AG02 pimozide (4 mg) 0.01 0.01 0.01 0.01 0.01 109 101 97 100 93 0.0 0.0 831 92 641 12.4 17.3 N05AH02 clozapine (0.3 g) 0.60 0.60 0.60 0.59 0.58 2 610 2 651 2 700 2 718 2 773 0.5 0.5 N05AH0 3 olanzapine (10 mg) 3.03 3.01 2.97 3.05 3.08 16 990 17 421 17 673 18 174 18 823 3.3 3.5 N05AH04 quetiapine (0.4 g) 2.65 2.82 2.89 3.02 3.09 47 818 55 638 63 126 69 337 74 652 9.2 13.9 N05AH05 asenapine (20 mg) 0.00 0.00 29 29 <5 0 0.0 - 692 717 0.1 0.1 N05AN Lithium 1.21 1.18 1.17 1.19 1.17 7 570 7 628 7 639 7 797 7 798 1.5 1.5 N05AN01 lithium (24 mmol) 1.21 1.18 1.17 1.19 1.17 7 570 7 628 7 639 7 797 7 798 1.5 1.5 N05AX Other antipsychotics 1.77 1.78 1.80 1.84 1.89 14 612 14 943 14 999 15 532 16 022 2.8 3.0 N05AX08 risperidone (5 mg (depot)) 0.67 0.64 0.62 0.62 0.61 8 305 8 141 8 040 8 225 8 302 1.6 1.6 N05AX12 aripiprazole (15 mg) 0.82 0.85 0.87 0.90 0.93 5 910 6 375 6 530 6 825 7 142 1.1 1.3 N05AX13 paliperidone (15 mg) 0.29 0.30 0.31 0.32 0.33 887 936 973 1 013 1 035 0.2 0.2 N05AX15 cariprazine (3 mg) 0.00 0.01 0 0 0 11 49 - 0.0 N05AX16 brexpiprazole (3 mg) 0.00 0.01 0 0 0 0.0 N05B Anxiolytics 14.01 13.10 12.41 12.03 11.96 258 101 252 244 452 238 570 49.5 44.5 233 577 229 065 223 642 220 145 212 671 44.8 39.6 N05BA01 diazepam (10 mg) 5.81 5.44 5.02 5.18 4.93 105 594 100 854 106 454 87 023 20.3 16.2 N05BA02 mg) 5.68 5.39 5.20 4.71 4.85 137 340 136 950 135 936 131 846 133 364 26.3 24.9 N05BA06 lorazepam (2.5 mg) 0.03 0.03 0.04 0.04 0.05 98 142 148 164 202 0.0 0.0 N05BA08 bromazepam clobazam (20 mg) 0.12 0.13 0.13 0.14 0.14 836 896 936 1 042 1 088 0.2 0.2 N05BA12 alprazolam (1 mg) 1.01 0.89 0.84 0.81 0.82 2 895 2 587 2 409 2 494 2 435 0.6 0.5 N05BB Diphenylmethane derivatives 1.17 1.05 1.02 0.98 1.01 31 107 29 71 6 29 178 29 986 31 966 6.0 6.0 N05BB01 hydroxyzine (75 g) 1.17 1.05 1.02 0.98 1.01 31 107 29 716 29 178 29 986 31 966 6.0 6.0 112 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N05BE Azaspirodecanedione derivatives 0.18 0.17 0.16 0.16 0.16 2 248 2 119 2 053 2 138 2 122 0.4 0.4 N05BE01 buspirone (30 mg) 0.18 0.17 0.16 0.16 0.16 2 248 2 119 2 053 2 138 2 122 0.4 0.4 N05C HYPNOTICS AND SEDATIVES 45.85 45.19 44.55 46.80 46.82 431 014 435 943 446 899 457 195 82.7 85.2 N05CC Aldehydes and derivatives - - - - - 7 13 12 13 13 0.0 0.0 N05CC01 chloral h ydrate - - - - - 7 13 12 13 13 0.0 0.0 N05CD Benzodiazepine derivatives 3.12 2.94 2.76 2.67 2.34 26 877 26 433 25 703 25 482 25 412 5.2 4.7 N05CD01 flurazepam (30 mg) 0.00 0.00 0.00 0.00 7 10 0.0 0.0 N05CD02 nitrazepam (5 mg) 2.73 2.57 2.41 2.32 1.78 20 328 19 139 17 915 17 146 15 978 3.9 3.0 N05CD03 flunitrazepam (1 mg) 0.14 0.11 0.10 0.09 0.08 790 645 559 516 470 0.2 0.1 N05CD05 triazolam (0.25 mg) 0.01 0.01 0.01 0.01 0.01 62 49 49 43 64 0.0 0.0 N05CD08 midazolam (15 mg) 0.24 0.24 0.24 0.25 0.47 6 217 7 125 7 702 8 300 9 479 1.2 1.8 N05CF Benzodiazepine related drugs 33.71 32.06 30.65 31.18 30.36 355 844 350 093 345 212 344 766 343 760 68.3 51.8 N05CF02 zolpidem (10 mg) 5.91 5.81 5.78 5.88 6.21 70 628 70 841 72 358 74 824 76 477 13.6 14.3 N05CH 8.83 10.02 10.97 12.78 13.93 82 748 94 753 101 660 114 056 132 406 15.9 24.7 N05CH01 melatonin (2 mg) 8.83 10.02 10.97 12.78 13.93 82 748 94 753 101 660 114 056 132 406 15.9 24.7 N05CM Other hypnotics and sedatives 0.18 0.17 0.16 0.16 0.18 2 122 1 961 1 948 1 849 1 865 0.4 0.4 N05CM02 clomethiazole (1.5 g) 0.16 0.15 0.14 0.14 0.13 1 945 1 835 1 824 1 707 1 727 0.4 0.3 N05CM05 scopolamine (0.9 mg) 0.00 - - - 0.00 65 41 25 19 10 0.0 0.0 N05CM06 propiomazine (25 mg) 0.01 0.01 0.01 0.01 0.01 105 77 97 121 129 0.0 0.0 N05CM09 Valerianae radix - - - - - 9 9 <5 0 0 0.0 0.0 N05CM11 bromides - - - - - 0 0 <5 <5 0 0.0 0.0 N05CM18 dexmedetomidine (1 mg) 0.01 0.01 0.01 0.01 0.03 - - - - - - - N06 PSYCHOANALEPTICS 70.64 71.26 70.64 73.65 69 403 70 267 71 208 75 288 79 933 13.3 14.9 N06AA02 imipramine (0.1 g) 0.00 0.00 0.00 0.00 18 9 0.0 0.0 N06AA04 clomipramine (0.1 g) 0.21 0.19 0.17 0.17 0.15 2 216 2 122 1 953 1 835 1 734 0.4 0.3 N06AA05 opipramol (0.15 g) 0.00 0.00 0.00 0.00 8 11 0.0 0.0 N06AA06 trimipramine (0.15 g) 0.27 0.26 0.24 0.20 0.23 8 128 7 521 7 105 6 628 6 383 1.6 (0.105 mg) 2.72 2.73 2.68 2.93 3.03 55 869 57 811 59 417 64 298 69 184 10.7 12.9 N06AA10 nortriptyline (75 mg) 0.15 0.14 0.14 0.15 0.15 2 251 2 143 2 422 2 476 2 596 0.4 0.5 N06AA12 doxepin (0.1 0.12 0.11 0.09 0.08 0.08 1 641 1 454 inhibitors 37.32 761 35.7 34.4 N06AB03 fluoxetine (20 mg) 2.52 2.36 2.29 2.25 2.44 12 232 12 055 11 817 12 097 12 609 2.4 2.4 N06AB04 citalopram (20 mg) 3.71 3.41 3.11 2.89 2.70 20 210 18 571 17 008 15 942 14 953 3.9 2.8 113 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N06AB05 paroxetine (20 mg) 2.54 2.42 2.30 2.22 2.14 13 122 12 510 12 050 11 570 11 139 2.5 2.1 N06AB06 sertraline (50 mg) 7.49 7.94 8.06 8.79 9.47 32 444 34 076 35 157 38 158 41 412 6.2 7.7 N06AB08 fluvoxamine (0.1 g) 0.09 0.09 0.08 (10 mg) 20.97 20.42 19.61 19.74 19.52 112 762 110 559 107 724 108 124 108 644 21.6 20.2 N06AF Monoamine oxidase inhibitors, non -selective 0.01 0.02 0.02 0.01 0.01 89 93 97 87 78 0.0 0.0 N06AF03 phenelzine (60 mg) 0.01 0.01 0.01 0.01 0.01 85 88 89 83 66 0.0 0.0 N06AF04 tranylcypromine (60 mg) 0.00 0.00 0.00 0.00 6 26 0.0 N06AG Monoamine oxidase A inhibitors 0.13 0.12 0.11 0.10 0.10 668 634 569 540 517 0.1 0.1 N06AG02 moclobemide (0.3 g) 0.13 0.12 0.11 0.10 0.10 668 634 569 540 517 0.1 0.1 N06AX Other antidepressants 16.67 17.08 17.26 18.33 18.63 112 616 115 819 118 416 123 086 127 200 21.6 23.7 N06AX01 oxitriptan - - - - - 95 90 78 58 69 0.0 0.0 N06AX02 tryptophan - - - - - 32 17 18 26 36 0.0 0.0 N06AX03 mianserin (60 mg) 1.52 1.44 1.29 1.34 1.14 24 219 23 176 22 034 21 432 19 304 4.7 3.6 N06AX05 trazodone (0.3 g) 0.00 0.00 0.00 0.00 (0.4 g) 0.00 0.00 0.00 0.00 mirtazapine (30 mg) 5.58 5.68 5.83 6.25 6.32 43 265 45 123 46 334 48 445 53 692 8.3 10.0 N06AX12 bupropion (0.3 g) 1.09 1.12 1.10 1.13 1.18 12 100 11 958 11 934 12 103 12 309 2.3 2.3 N06AX14 tianeptine (37.5 mg) 0.00 0.00 0.00 0.00 0.0 N06AX16 venlafaxine (0.1 g) 7.18 7.13 7.01 7.14 7.17 32 903 32 906 32 734 33 226 33 851 6.3 6.3 N06AX18 reboxetine (8 mg) 0.03 0.03 0.03 0.02 0.02 286 263 262 197 213 0.1 0.0 N06AX21 duloxetine (60 mg) 0.63 0.68 0.77 0.88 0.93 5 361 6 119 7 206 8 096 8 623 1.0 1.6 N06AX22 agomelatine (25 mg) 0.00 0.00 0.00 0.00 0.0 N06AX26 vortioxetine (10 mg) 0.64 1.00 1.24 1.56 1.85 5 041 7 126 8 703 10 809 12 134 1.0 2.3 N06AX27 esketamine (0.008 g) 0.00 - - - - - - - N06B Psychostimulants, agents used for adhd and nootropics 9.90 10.83 11.43 12.69 13.63 42 365 45 899 48 609 52 711 58 257 8.1 10.9 N06BA Centrally acting sympathomimetics 9.87 10.79 11.40 12.65 13.60 41 988 45 520 48 281 52 382 57 916 8.1 10.8 N06BA01 amfetamine (15 mg) 0.12 0.14 0.13 0.13 0.16 315 348 327 335 358 0.1 0.1 N06BA02 dexamfetamine (15 mg) 0.75 0.83 0.90 0.97 1.06 2 282 2 589 2 861 3 233 3 712 0.4 0.7 N06BA04 methylphenidate (30 mg) 7.85 8.20 8.23 8.48 8.40 35 618 37 698 38 784 40 246 42 445 6.8 7.9 N06BA07 modafinil (0.3 g) 0.06 0.07 0.08 (80 mg) 0.27 0.26 0.25 0.28 0.27 3 669 3 707 3 621 3 812 3 900 0.7 0.7 N06BA12 lisdexamfetamine (30 mg) 0.80 1.29 1.82 2.70 3.63 3 908 5 884 8 217 11 933 15 889 0.8 3.0 N06BC Xanthine derivatives 0.02 0.01 0.01 0.01 0.01 304 300 269 263 263 0.1 0.1 N06BC01 caffeine (0.4 g) 0.02 0.01 0.01 0.01 0.01 304 300 269 263 263 0.1 0.1 N06BX Other psychostimulants and nootropics 0.02 0.03 0.02 0.02 0.02 92 98 78 85 104 0.0 0.0 N06BX03 piracetam (2.4 g) 0.02 0.02 0.02 0.02 0.02 75 81 64 71 94 0.0 0.0 N06BX13 idebenone (0.9 g) 0.00 0.00 0.00 0.00 0.00 17 17 14 14 10 0.0 0.0 114 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N06C N06D Anti -dementia drugs 3.16 3.16 3.05 3.03 2.90 15 233 15 281 15 356 15 138 14 525 2.9 2.7 N06DA Anticholinesterases 2.28 2.32 2.25 2.24 2.18 12 572 12 630 12 729 12 570 12 175 2.4 2.3 N06DA0 2 donepezil (7.5 mg) 1.47 1.50 1.45 1.48 1.43 7 360 7 449 7 546 7 569 7 273 1.4 1.4 N06DA03 rivastigmine (9 mg) 0.78 0.79 0.77 0.74 0.72 5 344 5 380 5 404 5 214 5 258 1.0 1.0 N06DA04 galantamine (16 mg) 0.04 0.03 0.02 0.02 0.03 193 172 139 131 152 0.0 0.0 N06DX Other anti -dementia drugs 0.87 0.84 0.80 0.79 0.72 3 821 3 818 3 685 3 540 3 233 0.7 0.6 N06DX01 Memantine (20 mg) 0.87 0.84 0.80 0.79 0.72 3 821 3 818 3 685 3 540 3 233 0.7 0.6 N07 Other nervous system drugs 12.48 12.91 12.88 13.12 14.03 40 271 38 745 37 138 35 785 36 316 7.7 6.8 N07A Parasympathomimetics 0.15 0.17 0.17 0.18 0.19 837 874 928 991 1 053 0.2 0.2 N07AA Anticholinesterases 0.14 0.15 0.15 0.16 0.17 692 737 770 825 882 0.1 0.2 N07AA02 pyridostigmine (0.18 g) 0.12 0.13 0.13 0.14 0.15 688 733 767 818 873 0.1 0.02 0.02 0.02 0.02 carbachol (6 mg O/0 .5 mg P) 0.00 9 0 0 0 0 0.0 - N07AB02 bethanechol (45 mg) 0.00 0.00 <5 - 0.0 N07AX Other parasympathomimetics 0.01 0.02 0.02 0.02 0.02 139 137 158 165 170 0.0 0.0 N07AX01 pilocarpine (15 mg) 0.01 0.01 0.02 0.02 0.02 135 130 152 159 165 0.0 0.0 N07AX03 cevimeline (90 mg) 0.00 0.00 0.00 6 6 5 used in addictive disorders 11.98 12.38 12.34 12.55 13.45 36 830 35 133 33 382 31 851 32 167 7.1 6.0 N07BA Drugs used in nicotine depen dence 7.87 8.34 8.39 8.60 9.35 16 961 16 000 14 702 13 546 14 250 3.3 2.7 N07BA01 Nicotine (14 mg TD/30 mg gum) 7.40 7.90 7.99 8.23 8.96 1 191 1 168 1 284 1 287 1 390 0.2 0.3 N07BA03 Varenicline (2 mg) 0.47 0.45 0.40 0.37 0.39 15 833 14 902 13 507 12 32 9 12 935 3.0 2.4 N07BB Drugs used in alcohol dependence 0.50 0.47 0.44 0.41 0.46 12 143 11 498 11 158 10 729 10 495 2.3 2.0 N07BB01 disulfiram (200 mg) 0.39 0.37 0.34 0.31 0.35 4 247 4 146 4 003 3 788 3 797 0.8 0.7 N07BB03 acamprosate (2 g) 0.02 0.02 0.02 0.02 0.02 472 435 384 374 394 0.1 0.1 N07BB04 naltrexone (50 mg) 0.08 0.07 0.07 0.08 0.08 6 840 6 483 6 407 6 332 6 156 1.3 1.2 N07BB05 nalmefene (18 mg) 0.01 0.01 0.01 0.01 0.01 921 695 583 488 413 0.2 0.1 N07BC Drugs used in opioid dependence 3.60 3.56 3.50 3.54 3.64 8 010 7 933 7 791 7 829 7 697 1.5 1.4 N07BC01 buprenorphine (8 mg) 1.03 1.09 1.15 1.17 1.33 3 168 3 321 3 485 3 607 3 633 0.6 0.7 N07BC02 methadone (25 mg) 2.06 2.02 1.97 2.02 1.99 3 424 3 346 3 295 3 330 3 315 0.7 0.6 N07BC05 levome thadone (15 mg) 0.01 0.01 0.02 0.03 0.06 14 16 16 51 100 0.0 0.0 115 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 N07BC51 buprenorphine, combinations (8 mg) 0.51 0.44 0.37 0.33 0.26 2 018 1 774 1 455 1 286 1 101 0.4 0.2 N07C Antivertigo preparations 0.11 0.11 0.11 g) 0.05 0.05 0.05 0.05 0.05 336 353 359 351 386 0.1 0.1 N07XX04 sodium oxybate (7.5 mg) 0.02 0.02 0.02 0.02 0.02 116 142 141 151 168 0.0 0.0 N07XX05 amifampridine (40 mg) 0.00 0.00 0.00 0.00 13 18 20 0.0 0.0 N07XX06 tetrabenazine (0.1 g) 0.01 0.01 0.01 0.01 0.01 41 44 57 48 53 0.0 0.0 N07XX07 fampridine (20 mg) 0.28 0.28 0.30 - 0.0 N07XX11 pitolisant (18 mg) 0.00 0.01 0.01 0 6 29 51 61 - 0.0 N07XX59 dextromethorphan, combinations 0.00 0.00 0.00 0.00 0 8 9 8 5 0.0 0.0 116 4.12 P Antiparasit\u00e6re midler, insekticider og insektmidler P01 eroral metronidazol P har v\u00e6rt relativt stabilt i perioden 2016 - 2020, nedgang i ko ronapandemien. Antall brukere gikk fra vel 35 000 i 2019 til vel 15 000 i 2020. Legemidler til behandling av skabb Forekomsten -doblet seg til 2020, viser tall fra al. Increase of 2018. Euro Surveill. 2019;24(23):pii =190020. https://doi.org/10.2807/1560 -7917.ES.2019.24.23.190020 117 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 P ANTIPARASITIC REPELLENTS P01 ANTIPROTOZOALS 0.81 0.81 0.78 0.79 0.75 87 278 86 800 87 630 87 487 67 629 16.7 12.6 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 0.23 0.22 0.21 0.22 0.21 55 655 53 658 52 535 52 598 52 607 10.7 9.8 P01AB Nitroimidazole derivatives 0.23 0.22 0.21 0.22 0.21 55 655 53 655 52 529 52 596 52 602 10.7 9.8 P01AB01 metronidazole (2 g) 0.23 0.22 0.21 0.22 0.21 55 641 53 649 52 508 52 591 52 (2 g) 0.00 0.00 0.00 0.00 P01B ANTIMALARIALS 0.58 0.59 0.57 0.57 0.54 32 165 33 624 35 594 35 394 15 299 6.2 2.9 P01BA Aminoquinolines 0.46 0.45 0.44 0.44 0.50 6 288 6 280 6 298 6 308 7 394 1.2 1.4 P01BA01 chloroquine (0.5 g) 0.00 0.00 0.00 0.00 9 P01BA02 hydroxychloroquine (0.516 g) 0.45 0.45 0.44 0.44 0.50 6 258 6 260 6 279 6 286 7 374 1.2 1.4 P01BA03 primaquine (15 mg) 0.00 0.00 0.00 0.00 10 15 19 0.0 0.0 P01BB Biguanides 0.12 0.13 0.12 0.13 0.04 23 563 25 145 27 088 27 080 7 282 4.5 1.4 P01BB51 proguanil, combinations 0.12 0.13 0.12 0.13 0.04 23 563 25 144 27 088 27 080 7 282 4.5 1.4 P01BC Methanolquinolines 0.01 0.01 0.01 0.01 0.00 2 436 2 323 2 336 2 110 667 0.5 0.1 P01BC01 quinine (1.5 g) 0.00 0.00 0.00 g) 5 2 083 1 901 467 0.4 0.1 derivatives, combinations 0.00 0.00 0.00 0.00 16 14 lumefantrine (0.28 g) 0.00 0.00 0.00 6 13 16 14 8 LEISHMANIASIS - P02 ANTHELMINTICS 0.17 0.17 0.17 0.19 0.20 3 066 3 231 3 438 6 332 14 895 0.6 2.8 P02B ANTITREMATODALS 0.00 0.00 0.00 derivatives and related substances 0.00 0.00 0.00 0.00 65 56 63 (3 g) 0.00 0.00 0.00 0.00 63 83 39 0.0 0.0 P02C ANTINEMATODAL AGENTS 0.17 0.17 0.17 0.19 0.20 2 991 3 167 3 370 6 234 14 843 0.6 2.8 P02CA Benzimidazole derivatives 0.16 0.17 0.16 0.17 0.17 2 626 2 696 2 457 2 535 2 261 0.5 0.4 P02CA01 mebendazole (0.2 g) 0.16 0.17 0.16 0.17 0.17 2 261 2 294 2 065 2 026 1 764 0.4 0.00 0.00 0.01 0.03 2.3 P02C F01 ivermectin mg) 0.00 0.00 0.01 0.03 324 769 3 0.00 0.00 0.00 (0.35 g) 0.00 0.00 0.00 0.00 0.00 174 177 167 180 184 0.0 0.0 118 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 0.00 Salicylic acid derivatives 0.00 0.00 0.00 0.00 0.00 22 22 16 (2 g) 0.00 0.00 0.00 0.00 0.00 22 22 16 24 26 0.0 0.0 number of packages ATC 2016 2017 2018 2019 2020 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES 209 82 741 140 293 3 211 3 561 3 681 4 977 6 019 0.6 1.1 P03A ECTOPARASITICIDES, INCL. SCABICIDES 68 693 50 164 741 140 293 3 211 3 561 3 681 4 977 6 019 0.6 1.1 P03AA Sulfur containing products 0 0 0 0 165 0.0 0.0 P03AA54 disulfiram, combinations 863 0 0 0 0 165 0.0 0.0 P03AC Pyrethrines, incl. synthetic compounds 38 983 41 770 46 007 80 644 128 787 3 148 3 507 3 622 4 837 5 420 0.6 1.0 P03AC04 permethrin 38 983 41 770 46 007 80 644 128 787 3 148 3 507 3 622 4 837 5 420 0.6 1.0 P03AX Other ectoparasiticides, incl. scabicides 29 710 8 394 1 202 2 097 11 506 69 71 73 187 557 0.0 0.1 P03AX01 benzyl be nzoate 33% 399 485 1 202 2 097 11 506 37 44 73 187 557 0.0 0.1 P03AX03 malathion 29 311 7 909 32 27 0 0 0 0.0 0.0 119 4.13 er spesielt utgj\u00f8r henholdsvis 28 %, % og 39 % av solgt DDD innen gruppen R. I 2020 var det en (32 % \u00f8kning m\u00e5lt i DDD fra 2019). Derimot har det v\u00e6rt en nedgang p\u00e5 ca. n\u00e6r 140 000 i 2020, nesten en halvering. Nedgangen inhalasjonspreparatene til i DDD ble n\u00e6r tredoblet fra 2016 til 2020. Figure 4.13 Sales of inhalation products for the treatm ent of obstructive lung disease (R03A and R03B) in 2016- 2020. Source: beta-2- adrenoreceptor agonists Anticholinergics (R03AK)Adrenergics in 2017 2018 2019 2020 Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS 57.03 62.20 63.12 67.56 65.97 428 436 518 254 488 287 82.2 91.0 R01A DECONGESTANTS AND 60.75 61.76 66.12 64.94 366 599 395 882 2 698 0.7 0.5 R01AA05 oxymetazoline (0.4 mg) 1.02 1.00 0.88 0.88 0.91 2 047 1 563 2 241 2 388 1 641 0.4 R01AA07 xylometazoline (0.8 mg) 32.77 36.63 37.41 38.17 1 745 1 063 0.3 0.2 R01AB Sympathomimetics, combinations excl. corticosteroids 2.05 1.99 1.83 1.90 1.46 480 435 382 403 325 0.1 0.1 R01AB06 xylometazoline (0.8 mg) 2.05 1.99 1.83 1.90 1.46 480 435 382 403 325 0.1 0.1 R01AC Antiallergic agents, excl. corticosteroids 0.96 1.08 0.98 1.11 1.21 42 169 46 164 45 902 50 805 52 188 8.1 9.7 R01AC01 cromoglicic acid (40 mg) 0.16 0.16 0.06 7 457 7 607 4 927 <5 0 1.4 R01AC02 levocabastine (0.6 mg) 0.80 0.92 0.92 1.11 1.21 34 878 38 774 41 371 50 803 52 6.7 9.7 R01AD 0.00 0.00 0.0 R01AD05 budesonide (0.2 mg) 2.31 2.21 2.02 2.30 1.10 25 023 25 004 20 345 18 032 13 112 4.8 2.4 R01AD08 fluticasone (0.2 mg) 1.83 1.81 1.65 1.63 1.98 21 199 21 209 20 342 21 776 21 798 4.1 4.1 R01AD09 mometasone (0.2 mg) 9.31 9.62 10.11 10.73 11.09 161 114 171 090 176 302 190 474 183 890 30.9 34.3 R01AD11 triamcinolone (0.22 mg) 0.31 0.30 0.28 0.28 0.29 6 023 5 719 5 523 5 608 5 208 1.2 1.0 R01AD1 2 fluticasone furoate (0.11 mg) 3.45 3.64 3.55 3.79 3.93 87 374 92 014 91 495 98 912 99 053 16.8 18.5 R01AD58 fluticasone, combinations 1.77 2.45 3.02 3.94 4.77 42 588 55 895 67 754 90 619 100 731 8.2 18.8 R01AX Other nasal preparations 0.02 0.02 0.02 0.03 0.03 1 482 1 923 2 047 2 123 2 021 0.3 0.4 R01AX03 ipratropium bromide (0.24 mg) 0.02 0.02 0.02 0.03 0.03 585 791 910 1 024 1 042 0.1 0.2 R01AX06 mupirocin - - - - - 899 1 134 1 137 1 099 979 0.2 0.2 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 1.22 1.44 1.36 1.44 1.02 97 245 105 358 106 140 112 359 71 332 18.7 13.3 R01BA Sympathomimetics 1.22 1.44 1.36 1.44 1.02 97 245 105 358 106 140 112 359 71 332 18.7 13.3 R01BA01 phenylpropanolamine (0.1 g) 1.22 1.44 1.36 1.44 1.02 97 241 105 358 106 140 112 359 71 332 18.7 13.3 R02 THROAT PREPARATIONS 1.18 1.07 1.14 1.16 0.73 860 959 718 859 448 0.2 0.1 R02A THROAT PREPARATIONS 1.18 1.07 1.14 1.16 0.73 860 959 718 859 448 0.2 0.1 R02AA Antiseptics 0.28 0.24 0.17 0.05 0.00 113 242 174 104 24 0.0 0.0 R02AA03 dichlorobenzyl alcohol (6 tab) 0.28 0.24 0.17 0.05 0.00 113 242 174 104 24 0.0 0.0 R02AX Other throat preparations 0.90 0.83 0.97 R02AX01 flurbiprofen (44 mg) 0.05 0.09 0.15 0.17 0.12 14 90 105 166 134 0.0 0.0 R02AX0 3 benzydamine (9 mg) 0.85 0.74 0.82 0.94 0.60 735 639 456 603 294 0.1 0.1 123 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 66.33 67.59 67.21 68.63 68.86 448 102 429 661 422 712 75.9 78.8 R03AA Alpha - and beta - adrenoreceptor agonists 0.01 0.01 0.01 0.01 0.00 68 52 55 32 35 0.0 0.0 R03AA01 epinephrine 0.01 0.01 0.01 0.01 0.00 68 52 55 32 35 0.0 0.0 R03AC Selective 12.38 12.32 12.88 12.62 255 957 270 499 274 667 288 784 278 831 49.1 52.0 R03AC03 terbutaline (2 mg a erosol/powder/ 20 mg solution) 1.47 1.35 1.24 1.32 1.30 27 455 25 686 23 882 22 509 22 127 5.3 4.1 R03AC04 fenoterol (0.6 aerosol/powder/ 40 mg solution) 0.00 0.00 0.00 0.00 0.00 11 11 13 mg aerosol/powder 0.87 0.85 0.82 0.79 0.79 8 185 8 238 8 111 7 881 7 684 1.6 1.4 10 958 9 400 9 088 2.2 1.7 R03AC18 indacaterol (0.15 mg) 1.02 0.86 0.74 0.63 0.54 6 114 5 163 4 402 3 775 3 279 1.2 0.6 R03AC19 olodaterol (5 mcg inhal sol) 0.10 0.11 0.11 0.12 0.13 927 1 029 1 070 1 114 1 058 0.2 0.2 R03AK Adrenergics in combination 202 475 37.0 37.7 R03AK06 salmeterol and fluticasone 9.68 8.90 8.29 7.56 7.42 83 967 78 843 73 829 70 729 68 863 16.1 12.8 R03AK07 formoterol and budesonide 8.06 7.66 7.45 7.19 7.16 80 791 78 736 75 828 73 355 73 159 15.5 13.6 a nd beclometasone 1.20 1.61 1.90 2.19 2.49 13 249 17 061 20 625 23 854 27 015 2.5 5.0 R03AK10 vilanterol and fluticasone furoate 2.29 3.08 3.56 3.97 4.33 20 372 26 166 30 322 34 015 35 810 3.9 6.7 R03AK11 4 482 767 5 039 5 065 0.8 0.9 R03AL Adrenergics in combination with anticholinergics 2.22 2.92 3.91 5.21 5.84 17 031 22 168 28 395 35 286 39 146 3.3 7.3 R03AL03 vilanterol and umeclidinium bromide 0.55 0.81 1.02 1.20 1.25 4 546 6 634 8 310 9 174 9 261 0.9 1.7 R03AL04 indacaterol and glycopyrronium bromide 1.06 1.04 1.00 0.89 0.77 7 618 7 435 6 766 5 956 5 184 1.5 1.0 R03AL05 formoterol and aclidinium R03AL06 olodaterol and tiotropium bromide 0.32 0.70 0.98 1.27 1.35 3 086 5 969 7 631 9 040 9 686 0.6 1.8 R03AL07 formoterol and glycopyrronium bromide 0.03 0.10 0 0 0 0.0 0.2 R03AL08 vilanterol, umeclidinium bromide and fluticasone furoate 0.16 0.65 0.86 0 0 1 802 5 167 6 208 0.0 1.2 R03AL09 formoterol, glycopyrronium bromide and beclometasone 0.02 0.39 0.85 1.22 0 337 3 221 6 270 8 637 0.0 1.6 124 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, 488 31.1 29.2 R03BA Glucocorticoids 7.48 7.97 7.66 7.74 7.82 99 473 103 028 102 567 103 183 98 962 19.1 18.4 R03BA01 beclometasone (0.8 mg) 0.14 0.14 0.13 0.14 0.13 3 652 3 817 3 889 3 860 3 74 3 0.7 0.7 R03BA02 budesonide (0.8 mg) 1.53 1.43 1.31 1.24 1.20 17 063 16 579 15 784 15 185 14 685 3.3 2.7 R03BA05 fluticasone (0.6 mg) 2.62 2.64 2.58 2.52 2.50 64 979 67 460 67 035 67 778 63 315 12.5 11.8 R03BA07 mometasone (0.4 mg) 0.05 0.04 0.04 0.04 0.04 392 348 348 331 314 0.1 0.1 R03BA08 ciclesonide (0.16 mg) 3.15 3.72 3.60 3.81 3.95 15 260 16 702 17 330 17 635 413 2.9 13.01 12.99 12.38 12.19 11.38 69 233 69 67 424 64 526 13.3 12.0 R03BB01 ipratropium brom ide (0.12 mg powder/aerosol/ 0.3 mg 6.47 6.52 6.22 6.15 5.89 30 118 30 696 31 013 31 498 31 183 5.8 5.8 R03BB04 tiotropium bromide (10 mcg) 5.70 5.46 5.15 5.16 4.69 38 667 37 851 36 258 34 299 31 957 7.4 6.0 R03BB05 aclidinium bromide (0.644 m g) 0.36 0.37 0.33 0.28 0.25 3 048 2 929 2 575 2 210 1 915 0.6 0.4 R03BB06 glycopyrronium bromide (44 mcg) 0.27 0.25 0.22 0.19 0.16 1 905 1 705 1 506 1 283 1 089 0.4 854 3 072 3 589 3 22 8 2 973 0.4 0.6 R03BC Antiallergic agents, excl. corticosteroids 0.01 0.00 0.00 28 25 0.0 0.0 R03BC01 cromoglicic acid (40 mg aerosol/ 80 mg powder/solution) 0.01 0.00 0.00 0.00 210 10 28 35 25 0.0 0.0 R03C ADRENERGICS FOR SYSTEMI C USE 0.19 0.16 0.11 0.08 0.07 13 869 4 772 3 574 2 585 1 401 2.7 0.3 R03CA Alpha - and beta - adrenoreceptor agonists 0.11 0.10 0.08 0.07 0.07 4 389 3 636 2 746 2 232 1 192 0.8 0.2 R03CA02 ephedrine (50 mg) 0.11 0.10 0.08 0.07 0.07 4 389 3 636 2 746 2 232 1 192 0.8 0.2 R03CC Selective beta -2- adrenoreceptor agonists 0.08 0.06 0.03 0.01 0.00 9 634 1 161 845 360 215 1.9 0.0 R03CC02 salbutamol (12 mg) 0.01 0.00 0.00 0.00 0.00 483 377 286 147 0.7 0.0 R03CC03 terbutaline (15 mg) 0.05 0.04 0.02 0.00 0.00 6 105 536 342 73 69 1.2 0.0 R03CC12 bambuterol (20 mg) 0.01 0.01 0.01 145 150 145 0 0 0.0 0.0 R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 5.48 5.41 5.46 5.56 5.79 39 686 39 924 39 923 40 875 41 798 7.6 7.8 R03DA Xanthines 0.47 0.43 0.37 0.32 0.28 2 316 2 017 1 874 1 611 1 376 0.4 0.3 R03DA04 theophylline (0.4 g) 0.47 0.43 0.37 0.32 0.28 2 305 2 006 1 865 1 604 1 370 0.4 0.00 0.00 0.00 0.00 receptor antagon ists 4.75 4.66 4.73 4.80 5.01 36 321 36 373 36 185 36 955 37 585 7.0 7.0 R03DC01 zafirlukast (40 mg) 0.00 0.00 0.00 0.00 15 13 14 0.0 0.0 R03DC03 montelukast (10 mg) 4.75 4.65 4.72 4.80 5.01 36 306 36 357 36 171 36 942 37 571 7.0 7.0 R03DX Other systemic drugs for obstructive airway diseases 0.26 0.32 0.37 0.43 0.50 2 147 2 691 3 066 3 636 4 277 0.4 0.8 R03DX05 omalizumab (16 mg) 0.12 0.15 0.17 0.21 0.25 1 122 1 519 1 812 2 214 2 702 0.2 0.5 R03DX07 roflumilast (0.5 mg) 0.14 0.15 0.15 0.14 0.14 977 997 981 946 837 0.2 0.2 125 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 R03DX08 reslizumab (7.1 mg) 0.00 0.01 0.00 0.00 0 <5 17 12 9 0.0 0.0 R03DX09 mepolizumab (3.6 mg) 0.01 0.02 0.04 0.06 0.10 61 197 247 443 704 0.0 0.1 R03DX10 benralizumab (0.54 mg) 0.00 0.01 0.01 0 0 34 78 89 0.0 0.0 R05 COUGH AND COLD PREPARATIONS 10.95 10.47 10.53 10.45 7.86 390 932 389 149 385 381 487 215 314 75.0 40.1 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 7.93 7.70 7.69 7.61 6.29 103 679 101 730 98 301 96 031 68 101 19.9 12.7 R05CA Expectorants 1.48 1.43 1.27 1.19 0.78 6 010 5 064 4 035 4 005 2 220 1.2 0.4 R05CA10 combinations 1.48 1.43 1.27 1.19 0.78 6 007 5 064 4 035 4 005 2 220 1.2 0.4 R05CB Mucolytics 6.45 6.27 6.42 6.42 5.51 98 519 97 444 95 095 92 861 66 347 18.9 12.4 R05CB0 1 acetylcysteine g O/1.6 g inhal.sol.) 4.83 4.94 4.38 94 871 93 303 773 88 822 63 833 18.2 11.9 R05CB02 bromhexine (24 mg) 1.60 1.51 1.47 1.45 1.10 4 300 4 689 4 927 4 487 2 733 0.8 0.5 R05CB13 dornase alfa (desoxyribonuclease) (2.5 mg ) 0.02 0.02 0.02 0.02 0.03 156 165 182 191 192 0.0 0.0 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 2.50 2.25 2.31 2.31 1.29 275 066 273 933 271 087 268 764 137 971 52.8 25.7 R05DA Opium alkaloids and derivatives 2.50 2.25 2.31 2.31 1.29 275 066 273 933 271 087 268 764 137 971 52.8 25.7 R05DA01 ethylmorphine (50 mg) 1.38 1.34 1.29 1.26 0.67 266 227 265 341 262 533 259 897 130 0.00 g) 0.09 0.08 0.08 0.08 0.09 7 015 6 853 6 7 181 6 961 1.4 1.3 R05DA07 noscapine (0.125 g) 1.01 0.81 0.92 0.95 0.52 2 177 2 270 2 102 2 463 1 426 0.4 0.3 R05DA20 combinations 0.02 0.02 0.02 0.01 0.01 2 532 2 369 2 265 2 048 938 0.5 0.2 R05F COUG H SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 0.52 0.52 0.53 0.53 0.29 55 023 55 933 56 948 57 425 28 492 10.6 5.3 R05FA Opium derivatives and expectorants 0.52 0.52 0.53 0.53 0.29 55 023 55 933 56 948 57 425 28 492 10.6 5.3 R05FA02 opium derivatives and expectorants 0.52 0.52 0.53 0.53 0.29 55 023 55 933 56 948 57 425 28 492 10.6 5.3 R06 ANTIHISTAMINES 123.3 149.5 R06AA Aminoalkyl ethers 0.04 0.15 0.19 0.23 0.24 2 581 8 784 9 372 10 235 11 210 0.5 2.1 R06AA02 diphenhydramine (2 mg) 0.00 0.00 0.00 0.00 27 19 21 0.0 0.0 R06AA09 doxylamine (25 mg) 0.03 0.15 0.19 0.23 0.24 2 535 8 741 9 303 10 186 11 152 0.5 2.1 R06AA52 diphenhydramine, combinations - - - - - 17 20 14 0 0 0.0 0.0 R06AB Substituted alk ylamines 0.19 0.16 0.16 0.14 0.15 5 868 5 347 4 573 4 299 3 796 1.1 0.7 R06AB02 dexchlorpheniramine (6 mg) 0.19 0.16 0.16 0.14 0.15 5 868 5 347 4 573 4 299 3 796 1.1 0.7 R06AD Phenothiazine 4.16 4.09 4.15 4.64 72 539 72 702 74 78 98 5 82 606 13.9 15.4 R06AD01 alimemazine (30 mg) 3.07 2.98 2.96 3.04 3.39 66 312 66 923 68 855 73 109 75 902 12.7 14.1 R06AD02 promethazine (25 mg) 1.26 1.18 1.13 1.12 1.26 6 799 6 324 6 186 6 438 8 187 1.3 1.5 126 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 R06AE Piperazine derivatives 34.89 35.30 35.64 37.43 39.22 285 298 541 304 698 54.8 56.8 R06AE03 cyclizine (0.1 g) 0.16 0.17 0.03 0.01 0.06 1 076 1 098 475 93 379 0.2 0.1 R06AE05 meclozine (50 mg) 0.65 0.76 0.86 0.86 0.73 3 378 3 838 4 355 5 046 5 352 0.7 1.0 R06AE07 cetirizin e (10 mg) 34.00 34.29 34.68 36.49 38.36 281 412 286 302 293 295 298 940 54.0 55.7 R06AE09 levocetirizine (5 mg) 0.07 0.08 0.07 0.07 0.07 600 612 602 609 634 0.1 0.1 R06AX Other antihistamines for systemic use 30.75 33.84 35.88 41.21 311 620 343 951 418 445 448 527 59.8 mg) 0.00 0.00 0.00 0.00 20 14 R06AX13 loratadine (10 mg) 6.05 5.97 5.77 5.88 6.00 55 508 54 389 52 598 53 363 52 756 10.7 9.8 R06AX17 ketotifen (2 mg) 0.00 0.00 0.00 0.00 11 10 (10 mg) 1.82 1.97 1.97 2.19 2.39 11 836 12 808 13 182 14 694 15 789 2.3 2.9 R06AX26 fexofenadine (12 mg) 5.14 5.56 5.80 6.59 7.44 39 227 42 308 44 851 50 127 55 468 7.5 10.3 R06AX27 desloratadine (5 mg) 17.72 20.33 22.34 26.55 29.71 212 900 243 334 267 222 311 465 337 003 40.8 62.8 R06AX28 rupatadine (10 0.00 33 0.0 R07 OTHER RESPIRATO RY SYSTEM PRODUCTS 0.00 0.01 0.01 0.01 0.01 39 49 57 65 62 0.0 0.0 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 0.00 0.01 0.01 0.01 0.01 39 49 57 65 62 0.0 0.0 R07AX Other respiratory system products 0.00 0.01 0.01 0.01 0.01 26 41 45 49 48 0.0 0.0 R07AX02 ivacaftor (0.3 g) 0.00 0.00 0.00 0.00 17 ivacaftor and lumacaftor (4 tab) 0.00 0.00 0.00 0.01 0.01 15 28 30 32 32 0.0 127 4.14 S DDD og er har fastsatt inkludert hovedtabellen . *** rundt 69 000 i 2016 til rundt 105 i Med inkludert i hovedtabel len. Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 S SENSORY 109.8 112.3 S01A ANTIINFECTIVES - - - - - 240 135 243 441 238 057 243 137 195 321 46.1 36.4 S01AA Antibiotics - - - - - 236 834 239 977 234 634 239 489 192 352 45.4 35.8 S01AA01 chloramphenicol - - - - - 187 623 193 942 193 285 200 108 163 886 36.0 30.5 S01AA11 gentamicin - - - - - 31 17 24 22 27 0.0 0.0 S01AA12 tobramycin - - - - - 1 413 1 293 1 260 1 076 913 0.3 0.2 S01AA13 fusidic acid - - - - - 51 375 48 485 41 986 38 966 25 653 9.9 4.8 S01AA26 azithromycin - - - - - 5 796 5 330 4 876 4 564 3 101 1.1 0.6 S01AA30 combinations of different antibiotics - - - - - 6 263 6 446 8 651 9 932 10 937 1.2 2.0 S01AD Antivirals - - - - - 3 300 3 375 3 300 3 191 2 734 0.6 0.5 S01AD03 aciclovir - - - - - 3 300 3 374 3 299 3 188 2 732 0.6 0.5 S01AE Fluoroquinolones - - - - - 2 926 3 082 3 016 3 346 2 691 0.6 0.5 S01AE03 ciprofloxacin - - - - - 2 926 3 082 3 016 3 346 2 689 0.6 0.5 S01AX Other antiinfectives - - - - - <5 5 7 13 <5 - - S01AX18 povidone -iodine - - - - <5 <5 <5 10 0 - 0.0 S01B ANTIINFLAMMATORY AGENTS - - - - - 62 824 67 149 70 182 77 071 75 793 12.1 14.1 S01BA Corticosteroids, plain - - - - - 42 473 48 920 53 707 61 287 60 334 8.2 11.2 S01BA01 dexamethasone - - - - - 29 392 36 013 37 430 41 254 39 466 5.6 7.4 S01BA02 hydrocortisone - - - - - 0 60 4 618 7 419 7 953 0.0 1.5 S01BA04 prednisolone - - - - - 16 479 17 943 18 288 20 193 20 520 3.2 3.8 S01BA 07 fluorometholone - - - - - 25 17 16 16 16 0.0 0.0 S01BA09 clobetasone - - - - - 12 14 13 13 14 0.0 0.0 S01BA13 rimexolone - - - - - 2 440 83 0 0 0 0.5 0.0 S01BC Antiinflammatory agents, non -steroids - - - - - 27 895 28 399 29 078 30 564 29 740 5.4 5.5 S01BC03 diclofenac - - - - - 7 688 7 732 7 782 9 009 8 869 1.5 1.7 S01BC10 nepafenac - - - - - 15 204 17 423 17 753 18 092 17 091 2.9 3.2 S01BC11 bromfenac - - - - - 5 400 3 545 4 061 3 938 4 045 1.0 0.8 S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION - - - - - 49 893 43 762 43 174 40 541 39 750 9.6 7.4 S01CA Corticosteroids and antiinfectives in combination - - - - - 49 893 43 762 43 174 40 541 39 750 9.6 7.4 S01CA01 dexamethasone and antiinfectives - - - - - 49 893 43 762 43 174 40 5 41 39 750 9.6 7.4 S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS 19.42 19.02 19.38 19.28 19.50 74 978 76 099 868 78 507 78 885 14.4 14.7 S01EA Sympathomimetics in glaucoma therapy 0.71 0.70 0.65 0.67 0.66 4 901 4 787 4 647 4 752 4 802 0.9 0.9 S01EA03 apraclonidine 0.01 0.01 0.01 0.01 0.01 169 205 178 224 237 0.0 0.0 S01EA05 brimonidine 0.70 0.69 0.64 0.66 0.65 4 772 4 633 4 492 4 571 4 620 0.9 0.9 129 Norwegian Drug Wholesales Statistics Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 S01EB Parasympathomimetics 0.04 0.04 0.04 0.04 0.04 917 910 841 858 804 0.2 0.2 S01EB01 pilocarpine (0.4 m l) 0.04 0.04 0.04 0.04 0.04 917 910 841 858 804 0.2 0.2 S01EC 1.90 2.02 2.13 2.23 12 539 13 374 13 984 14 820 14 684 2.4 2.7 S01EC01 acetazolamide (0.75 g) 0.09 0.11 0.11 0.13 0.11 1 687 2 065 2 107 2 253 1 726 0.3 0.3 S01EC02 diclofenamide (0.1 g) 0.00 0.00 0.00 0 0 7 10 11 0.0 0.0 S01EC03 dorzolamide (0.3 ml) 0.38 0.43 0.46 0.52 0.60 2 840 3 152 3 443 3 777 4 292 0.5 0.8 S01EC04 brinzolamide (0.2 ml) 1.17 1.08 1.14 1.06 1.06 7 486 7 290 7 108 7 205 6 851 1.4 1.3 S01EC54 brinzolamide, combinations 0.20 0.28 0.31 0.43 0.46 1 554 2 062 2 594 2 936 3 151 0.3 0.6 S01ED Beta blocking agents 10.48 10.21 10.40 10.19 10.40 51 182 51 703 52 160 53 151 53 778 9.8 09 8 20 510 20 267 19 563 4.1 3.6 S01ED02 betaxolol 0.14 0.12 0.11 0.10 0.08 834 5.15 5.50 5.68 5.88 31 281 32 044 33 251 34 694 35 904 6.0 6.7 S01EE Prostaglandin analogues 6.34 6.17 6.27 6.26 6.17 38 866 38 665 38 696 39 101 38 996 7.5 7.3 S01EE01 latanoprost 3.95 3.88 3.86 3.90 3.97 24 533 24 257 24 309 24 369 25 4.7 4.7 S01EE03 bimatoprost 0.43 0.41 0.41 0.43 0.41 2 380 2 444 2 425 2 604 2 564 0.5 0.5 S01EE04 travoprost 0.81 0.65 0.69 0.51 5 206 4 520 4 026 3 633 3 231 1.0 0.6 S01EE05 tafluprost 1.16 1.24 1.31 1.36 1.28 7 675 8 197 8 698 9 384 9 177 1.5 1.7 S01F MYDRIATICS AND CYCLOPLEGICS - - - - - 5 556 4 995 4 918 5 061 4 912 1.1 0.9 S01FA Anticholinergics - - - - - 5 540 4 976 4 910 5 048 4 885 1.1 0.9 S01FA01 atropine - - - - - 1 553 1 336 1 120 1 075 1 245 0.3 0.2 S01FA04 cyclopentolate - - - - - 4 059 3 749 3 907 4 006 3 444 0.8 0.6 S01FA06 tropicamide - - - - - 128 86 93 156 461 0.0 0.1 S01FA54 cyclopentolate, combinatio ns - - - - - <5 9 - 0.0 S01FB Sympathomimetics excl. antiglaucoma preparations - - - - - 46 51 30 37 46 0.0 0.0 S01FB01 phenylephrine - - - - - 46 51 30 37 46 0.0 0.0 S01G DECONGESTANTS AND ANTIALLERGICS - - - - - 185 939 201 407 202 111 236 257 232 735 35.7 43.4 S01GA Sympathomimetics used as decongestants - - - - - 19 535 20 161 19 732 23 417 21 838 3.8 4.1 S01GA01 naphazoline - - - - - 5 12 11 21 11 0.0 0.0 S01GA52 tetryzoline, combinations - - - - - 19 530 20 152 19 723 23 400 21 828 3.8 4.1 S01GX Other antiallergics - - - - - 169 762 185 118 186 024 218 054 215 693 32.6 40.2 S01GX01 cromoglicic acid - - - - - 23 034 23 718 22 328 25 368 22 358 4.4 4.2 S01GX02 levocabastine - - - - - 87 921 97 537 98 785 114 471 114 971 16.9 21.4 S01GX0 6 emedastine - - - - - 398 413 430 497 507 0.1 0.1 S01GX08 ketotifen - - - - - 21 391 23 557 24 107 30 054 29 636 4.1 5.5 S01GX09 olopatadine - - - - - 41 694 45 550 45 756 55 332 55 087 8.0 10.3 130 Norwegian Drug Wholesales Statistics Norwegian Pre scription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 S01H LOCAL ANESTHETICS - - - - - 122 111 123 135 164 0.0 0.0 S01HA Local anesthetics - - - - - 122 111 123 135 164 0.0 0.0 S01HA02 oxybuprocaine - - - - - 97 85 100 99 127 0.0 0.0 S01HA03 tetracaine - - - - - 12 13 16 20 11 0.0 0.0 S01HA04 proxymetacaine - - - - - 14 13 10 17 29 0.0 0.0 S01J DIAGNOSTIC AGEN TS - - - - - 27 32 31 36 28 0.0 0.0 S01JA Colouring agents - - - - - 27 32 31 36 28 0.0 0.0 S01JA01 fluorescein - - - - - 26 31 30 33 26 0.0 0.0 S01X OTHER OPHTHALMOLOGICALS - - - - - 69 033 79 807 88 992 98 296 105 619 13.2 19.7 S01XA Other ophthalmol ogicals - - - - - 69 033 79 807 88 992 98 296 105 619 13.2 19.7 S01XA03 sodium chloride, hypertonic - - - - - 34 39 63 105 113 0.0 0.0 S01XA18 ciclosporin - - - - - 1 823 2 697 3 881 4 252 4 807 0.4 0.9 S01XA20 artificial tears and other indifferent pre parations - - - - - 68 604 79 216 87 932 97 241 104 551 13.2 19.5 S01XA21 mercaptamine - - - - - 0 6 10 10 10 0.0 0.0 S01XA25 lifitegrast - - - - - 0 0 6 26 17 0.0 0.0 S02 OTOLOGICALS - - - - - 22 510 20 226 22 925 28 871 31 582 4.3 5.9 S02A ANTIINFECT IVES - - - - - 5 536 5 224 4 987 4 676 3 669 1.1 0.7 S02AA Antiinfectives - - - - - 5 536 5 224 4 987 4 676 3 669 1.1 0.7 S02AA01 chloramphenicol - - - - - 11 0 0 0 0 0.0 0.0 S02AA03 boric acid - - - - - 8 20 5 <5 <5 0.0 - S02AA15 ciprofloxacin - - - - - 5 520 5 204 4 983 4 672 3 668 1.1 0.7 S02B CORTICOSTEROIDS - - - - - 7 855 1 355 1 429 6 083 9 797 1.5 1.8 S02BA Corticosteroids - - - - - 7 855 1 355 1 429 6 083 9 797 1.5 1.8 S02BA07 betamethasone - - - - - 7 855 1 355 1 429 4 440 6 369 1.5 1.2 S02BA08 fluocinolone acetonide - - - - - 0 0 0 1 703 3 524 0.0 0.7 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION - - - - - 10 163 14 369 17 171 19 308 19 597 2.0 3.7 S02CA Corticosteroids and antiinfectives in combination - - - - - 10 163 14 369 17 171 19 308 19 597 2.0 3.7 S02CA02 flumetasone and antiinfectives - - - - - 62 59 <5 42 44 0.0 0.0 S02CA05 fluocinolone acetonide and antiinfectives - - - - - 10 104 14 314 17 169 19 270 19 554 1.9 3.6 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS - - - - - 74 436 74 488 73 693 73 385 63 919 14.3 11.9 S03B CORTICOSTEROIDS - - - - - 0 0 0 0 8 0.0 0.0 S03BA CORTICOSTEROIDS 0 0 0 0 8 0.0 0.0 S03BA03 betamethasone - - - - - 0 0 0 0 8 0.0 0.0 131 Norwegian Drug Wholesales Statistics Norwe gian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBIN ATION - - - - - 74 436 74 488 73 693 73 385 63 916 14.3 11.9 S03CA Corticosteroids and antiinfectives in combination - - - - - 74 436 74 488 73 693 73 385 63 916 14.3 11.9 S03CA01 dexamethasone and antiinfectives - - - - - 10 956 10 854 9 588 8 414 5 562 2.1 1.0 S03CA04 hydrocortisone and antiinfectives - - - - - 65 134 65 319 65 569 66 243 59 331 12.5 11.1 132 4.15 V Varia V01 Allergener som under andre DDD data \u00e5rene; 1569 pakninger i 2000 ti l 68 990 pakninger i 2020. Utvalget av preparater til hyposensibilisering Norwegian Prescription Database DDD/1000 inhabitants/day Number of individuals Prevalence (per 1000) per year ATC ATC level name (DDD value) 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2020 Numbers of packages/year ATC 2016 2017 2018 2019 2020 V VARIOUS V01 ALLERGENS 12 876 14 582 16 203 18 981 23 711 2.5 4.4 V01A ALLERGENS 33 987 38 110 44 034 52 573 68 990 12 876 14 582 16 20 3 18 981 23 711 2.5 4.4 V01AA Allergen extracts 33 987 38 110 44 034 52 573 68 990 12 876 14 582 16 203 18 981 23 711 2.5 4.4 V01AA02 grass pollen 21 435 24 275 27 020 30 772 36 573 9 845 11 002 12 021 13 800 16 263 1.9 3.0 V01AA03 house dust mites 935 2 052 3 776 5 914 7 053 514 933 1 544 2 180 2 710 0.1 0.5 V01AA05 tree pollen (bj\u00f8rk) 9 665 10 232 11 260 13 039 22 243 5 791 6 259 6 585 7 227 10 703 1.1 2.0 V01AA07 insects 511 510 552 623 670 149 144 136 144 157 0.0 0.0 V01AA10 flowers 82 36 151 164 43 <5 10 32 35 0.0 0.0 V01AA11 animals 1 359 1 041 1 390 2 074 2 287 555 513 581 712 809 0.1 0.2 DDD/1000 inhabitants/day 2016 2017 2018 2019 2020 PRODUCTS 0.29 0.30 0.33 0.40 0.48 3 528 3 866 4 205 4 719 5 210 0.7 1.0 V03A ALL OTHER THERAPEUTIC PRODUCTS 0.29 0.30 0.33 0.40 0.48 3 528 3 866 4 205 4 719 5 210 0.7 1.0 V03AB Antidotes - - - - - 120 82 122 87 98 0.0 0.0 V03AC Iron chelating agents - - - - - 139 144 157 188 205 0.0 0.0 V03AC01 deferoxamine - - - - - 30 31 26 26 32 0.0 0.0 V03AC02 deferiprone - - - - - 22 21 23 25 30 0.0 0.0 V03AC03 deferasirox - - - - - 105 109 122 158 169 0.02 0.03 V03AE Drugs for treatment of hyperkalemia sulfonate (45 g) 0.03 0.03 0.03 0.02 0.01 881 951 876 683 376 0.17 0.07 V03AE02 sevelamer (6.4 g 0.14 0.14 0.15 0.16 0.16 1862 1987 2014 2126 2228 0.36 0.42 V03AE03 lanthanum carbonate (2.25 g) 0.07 0.07 0.07 0.07 0.07 644 562 590 592 649 0.12 0.12 V03AE04 calcium acetate and magnesium carbonate (6 oxyhydroxide (1.5 g) 0.00 0.01 0.01 0.01 0.01 63 122 115 119 120 0.01 0.02 V03AE09 patiromer calcium (8.4 g) 0.02 0.07 0.07 0 747 606 0.00 0.11 V03AE10 sodium 0.08 61 61 38 35 41 0.01 0.01 V03AF 01 mesna 9 10 12 8 5 (60 mg) 0.06 0.06 0.06 52 51 26 27 rasburicase (14 mg) 0.00 0.00 0.00 0.00 0.00 - - - - - - - V03AG Drugs for treatment of hypercalcemia - - - - 0.01 371 579 736 865 1030 0.07 0.19 V03AG05 g) 0.01 371 579 736 865 og dagligvaregrossister. : m\u00e5ned. til dags dato et som s\u00e5kalt datasikkerheten v\u00e6rt tilgjengelig 1994 Finland Danmark, og siden legemidler for vernepliktige yrkesskad e (hjemlet i Lov fo \u00a7 10 (ICD -10) eller Internat ional Classification of Primary ATC/DDD- systemet anbefalt av WHO og 1982 opprettet koordineringssenter ved Norsk medisinaldepot ( WHO Col laborating Centre ) med tilknytning til WHOs Europakontor med medlemmer fra 12 ulike land. Bakgrunnen for opprettelse av DD D er at statistikk angitt i verdi (kroner) eller classification and DDD assignment (https://www. whocc .no/filearchive/publications/2021_guidelines_web.pdf ) for mer informasjon. 1) Sommerschild et al. Data resource profile: Norwegian Drug and Pharmacoepidemiology . 2021;29(1 137 Folkemengde i Norge 201 6-2020 (per 1. januar) Year 2016 2018 2018 2019 2020 Population 5 236 624 5 276 847 5 311 797 5328212 5 367 580 Men Women 2020 2 706 562 2 661 018 Kilde: Statistisk sentralbyr\u00e5 N, Ribu L, Vistad I, Helseth S. Associations between menopausal hormone therapy and sleep disturbance in women during the menopausal transition and post -menopause: data from the Norwegian prescription database and the HUNT study. BMC Womens Health 2020;20(1):64. Apalset EM, Lunde A, V, Tell GS. Initiation of anti -osteoporotic drugs in high -risk female patients starting glucocorticoid treatment: a population study in Norway. Arch Handal M, Hauge LJ, Reichborn -Kjennerud T, Skurtveit S. Incidence of diagnosed pediatric anxiety disorder s and use of prescription drugs: a nation -wide registry study. Eur Child Adolesc Psychiatry. 2020;29(8):1063 -73 Berge Andreassen BK, Stenehjem JS, Heir T, Furu K, Juzeniene A, et al. Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry -Based Case - Control Study. Epidemiol 2020;12:193 -202. \u00d8, Juzeniene A, et al. Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case - Control Study. 2020;12:1389 E, et al. Metformin use and lung cancer survival: a population -based st udy in Norway. Br J Cancer 2021;124(5):1018 -1025. B\u00f8dkergaard K, Selmer A, Skovlund E, St\u00f8vring H. Using the waiting time distribution with random index dates to estimate prescription durations in the presence of seas onal stockpiling. Pharmacoepidemiol Drug 2020;29(9):1072 J, Furu K. Incidence of malformations after early pregnancy exposure to modafinil in Sweden -Diaz S, Huybrec hts K, Kieler H, Leinonen M, Li J, Reutfors R, Schaffer A, Selmer R, Yu Y, Zoega H, Karlstad \u00d8. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006 -2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf 2020 ;29(8):913 - 22. Cohen JM, Selmer R, Furu K, Karlstad \u00d8. Interrupted time series analysis to assess changes in prescription filling aroun d conception and implications for exposure misclassification. Pharmacoepidemiol Drug Urinary with anxiety and depression: the impact of psychotropic drugs in a cross -sectional study from the Norwegian HUNT study. BMC Psychiatry Hjellvik V. Prescription of analgesics to long -term survivors of cancer in early adulthood, adolescence, and childhood in Norway: a national cohort study. Pain 2020;161(5):1083 -91. Gravningen K, Field N, Blix HS, Asfeldt A M, Sm\u00e5brekke L. Non -prescription purchase of antibiotics during travel abroad among a general adult population in Norway: Findings from the seventh Tromso Study. B. A possible effect of montelukast on neurological aging examined by the use of register data. Int J Clin Pharm 2020. Hansen AB, Baste V, Hetlevik O, Haukene s I, Smith - Sivertsen T, Sabine R. General practitioners' drug treatment for depression by patients' educational level: registry -based study. BJGP Open 2021;5(2):BJGPO.2020.0122. Harris GE, Wood M, Nordeng H. Modeling exposures of medications used episodic ally during pregnancy: Triptans as a motivating example. Pharmacoepidemiol Drug Saf -9. Hjorth S, Wood M, Tauqeer F, Nordeng H. Fertility treatment and oral contraceptive discontinuation for identification of pregnancy planning in routinely collected health data - an application to analgesic and antibiotic utilisation. Langhammer A, S\u00f8gaard AJ, et al. Proton pump inhibitors and fracture risk. The HUNT study, Norway. Osteoporos Int 2020;31(1):109 - 18. Hold\u00f8 I, Bramness JG, Handal M, Hansen BH, Hjellvik V, Skurtveit S. Association Between Prescribed Hypnotics in Infants and Toddlers and Later ADHD: A Large Cohort Study from Norway. Child Psychiatry Hum Dev 2020 . Hovland R, Bremer S, Frigaard C, Henjum S, EM, Kristiansen IS. Effect of a pharmacist -led intervention on adherence among patients with a first- time prescription for a cardiovascular medicine: a randomized controlled trial in Norwegian pharmacies. The impact of hospitalisation to geriatric wards on the use of medications and potentially inappropriate medications - a health register study. BMC Geriatr 2020;20(1):190. Jortveit J, Halvorsen S, Langorgen J. ionwide 139 Study of Neuropsychiatric Comorbidity and M edicines Use in Children With Autism Spectrum Disorder in Norway. Frontiers in Psychiatry 2020. Kjekshus VHR, Schuster P. Adherence to oral anticoagulant treatment and risk factor assessment six months aft er DC - conversion of atrial fibrillation. Scand Card iovasc J 2020;54(3):179 -185. Kieler Odsbu I, N\u00f8rgaard M, \u00d6zt\u00fcrk B, Bateman V, Skurtveit S, Handal M. In utero opioid exposure and risk of infections in childhood: A multinational Nordic cohort study. Phar macoepidemiol Drug Ariansen I, Langhammer A, Wisloff T, et al. Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources. International Journal of C opd 2020;15:323 -34. Pasternak K, C, Svanstr\u00f6m H, Ueda P. Use of sodium -glucose co - transporter 2 inhibito rs and risk of serious renal events: Scandinavian cohort study. BMJ. 2020;369:m1186 \u00d8degaard KM, Hallen J, Lirhus SS, Melberg HO, Halvorsen S. Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016. ESC Heart Fail 2020;7(4):1917 -26. \u00d8rbeck B, -Kjennerud T, Pripp AH, et al. Child and Parental Characteristics of Medication Use f or Attention -Deficit/Hyperactivity Disorder. J Child Adolesc JG, Hansen BH, Lien L. The Use of Sleep Medication in Youth Residential Care. J Child Adolesc Psychopharmacol 2020; 30(5):335 -41. Raknes G, Sm\u00e5brekke L. No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a Nafstad P, et al. Is the Association of Early Day Care Attendance with Childhood Asthma Explained by Underlying Susceptibility? Epidemiology 2020;31(3):451 - 8. Reigstad MM, IK. Validation of Assisted Rep roductive Technology in the Medical Birth Registry of Norway Versus the Norwegian Prescription Databas e. Epidemiology 2020;31(5):681 -6. Reutfors L, Schaffer A, Schink T, Wan g Z, Yu Y, Zoega H, Br\u00f6ms G. Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophr Res 2020;220:106 -15. Rognli EB, Bram ness JG, von Soest T. Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, E, Eriksson R. Sex and age differences among tramadol users in three Nordic countries. Dan Med J 2020;67(7):A06190336. Siffel C, Page M, Maxwell T, Thun B, Kolb N, Rosenlund M, et al. Patterns of Lisdexamfetamine Dimesylat e Use in Children, Adolescents, and Adults with Attention -Deficit/Hyperactivity Disorder in Europe. J Child Adolesc Psychopha rmacol 2020;30(7):439 -47. Skow MAH, Vik I, H\u00f8ye S. Antibiotic switch after treatment with UTI antibiotics in male patients. Infect Dis 2020;52(6):405 -12. Skurtveit S, Hjellvik V, Sakshaug S, Borchgrevink PC, vold A. The prevalence and incidence of glaucoma in Norway 2004 - 2018: A nationwide population -based study. PLoS ONE [Electron Haavik J, Klungs\u00f8yr K. Sex differences in parent -offspring recurrence of attention -deficit/hyperactivity disorder. J Child Psychol Psychiatry 2020. St\u00f8er NC, Botter i E, Thoresen GH, Karlstad \u00d8, Weiderpass E, Friis S, Potteg\u00e5rd A, Andreassen BK. Drug use and cancer risk: a drug -wide association study (DWAS) in Frank AS, Haug L S, Nordeng H. Thyroid hormone replacement therapy in pregnancy and motor function, communication skills, and behavior of preschool children: The Norwegian Mother, Father, and Child Cohort Study. Pharmacoepidemiol Drug Saf 2021;30(6):716 -726. KA, et al. Dispensations of benzodiazepines, z hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. BMC Health Serv Res 202 Aas C, Johansson KA, Fadnes LT. Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013 -2017): a prospective cohort study. BMC Health Serv Res 2020;20(1):668. JH, I, Chalabianloo F, Halm\u00f8y A, et al. Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway 2015 to 2017. BMC Psychiatry 2020;20 I, Chalabianloo F, Reutfors J, et al. Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register -based prospective cohort study in Norway and Sweden from 2015 to 2017. BMJ Op en 2020;10(8):e036860. Wie B\u00f8rsheim A, Engeland A, Gilhus NE. Epilepsy and autoimmune diseases: Comorbidity in a national patient cohort. Seizure. 2020;75:89 -95. W\u00e6rholm AC, Meland E, Kjome RLS. Can subjective well - being and body concern in adolescence pr edict prescribed medication in adulthood? Findings from the Nord - Tr\u00f8ndel ag Health Study and the Norwegian Prescription Database. Scandinavian Journal of Public Health 2020;48(5):559 -66. Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, et al. Uptake and predictors of direct -acting antiviral treatment for hepatiti s C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev F, et al. On the path towards u niversal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017. BMJ Open 2020;10(8):e036355. 140 2019 Andreassen BK, St\u00f8er NC, Martinsen JI, Ursin G, Weiderpass E, Thoresen GH, et al. Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry - based study. BMJ Open 2019;9(4):e028504. Amato E, Dansie HH, Soleng A. Increase of scabies infestations, Nor Euro Surveill. 2019 doi: 10.2807/1560 - PG, Johannessen SI, Landmark CJ. Safety aspects of antiepileptic drugs -a population -based study of adverse effects relati ve to changes in utilisation. Eur J Clin Pharmacol 2019;75(8):1153 -60. Benko MC, C, Fungie G, Bordas R, Blix HS. Cross -national comparison of paediatric antibiotic use in Norway, Portugal K, Juzeniene A, et al. Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a pr otocol for a prospective case - control study. BMJ Open 2019;9(2):e025246. Bergene EH, Nordeng H, Ro TB, Steinsbe kk A. Register - based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatr 2019;108(4):699 Skurtveit S. Tramadol use in Norway: A register -based population study. Pharmacoepidemiol Drug Saf 2019;28(1):54 -61. Bramness JG, von Soest T. A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults. BMC Pulmonary Medi cine 2019;19(1):52. Cesta Y, Antidiabetic medicati on use during pregnancy: an international utilization study. BMJ Open Diabetes Research and Care. 2019 Nov 1;7(1). https://drc.bmj.com/content/7/1/e000759 Diaz E, Omland G, Hannestad Y, Ruths S. Use of hormonal contraceptives among immigrant women and thei r daughters in Norway: Data from the Engedal K, Blix HS. Drug Use before and after Initiating Treatment with Acetylcholinesterase Inhibito rs. Dementia and Geriatric Cognitive Disorders Extra 2019;9(1):196 -206. Ekman J, Skjeldestad FE. Do Norwegian providers comply with national recommendations when prescribing combined oral contraceptives to starters? A cohort study. BMJ 2019;9(11):e02 NH, P, Skovlund E, et al. Agreement between self -reported and registry -based use of sleep medications and tranquilizers. Pharmacoepidemiol Drug Saf 2019;28(10):1336 -43. Evensen JU, Bull H, Martinsen EW, Ueland T, et al. Exploring the potential cost -effectiveness of a vocational rehabilitation program for individuals with schizophrenia in a high -income welfare society. BMC Psychiatry 2019;19:140 Fog AF, Straand J, Engedal K, Blix HS. Drug use differs by care level. A cross -sectional comparison between older people living at home or in a nursing home in Oslo, Norway. BMC Geriatrics 2019;19(1):49. Frank AS, Lupattelli A, Brandlistuen RE, Nordeng H. Maternal Thyroid Hormone Replacement Th erapy Exposure and Language and Communication Skills of Offspring at 8 Years of Age. JAMA netw 2019;2(10):e1912424. Frank AS, Lupattelli A, Matteson DS, Meltzer HM, Nordeng H. Thyroid hormone replacement therapy patterns in pregnant women and perinatal outcomes in the offspring. Pharmacoepidemiol Drug Saf 2020;29(1):111 -21. Fredheim OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagn osis. Pain 2019;160(4):852 R. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5 -year prospective study. Breast 2019;44:52 -8. Handal M, Nechansk\u00e1 B, Skurtveit S, Ingunn Ole a L, Gabrhel\u00edk R, Engeland A, et al. Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway. Pharmacology Research & Perspectives 2019;7(5). Heggelund L, Singh R, Aballi S, Ro sseland CM, Mikkelsen Y, Damas JK. Retrospective analysis of co -medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012 -2018 using the Norwegian population -based prescription database. HI V Med 2019;20:45. Helland T, Hagen KB, Haugst\u00f8yl ME, Kval\u00f8y JT, K, et al. Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Res Treat 2019;177(1):185 -95. Hjellvik J, Vries F Furu K. Adjusting for unmeasured confounding using validation data: Simplified two- stage calibration for survival and dichotomous o utcomes. Statistics in Medicine. 2019 https://onlinelibrary.wiley.com/doi/abs/10.1002/sim.8131 Hylin H, Thrane H, Pedersen K, Kristiansen IS, Burger EA. The healthcare costs of treating human papillomavirus - related cancers in Norway. BMC Cancer. 2019 May 7;19(1):426. H\u00f8jlund M, -J\u00f8rgensen Correll CU. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. Br J Clin Pharmacol. BO. Validity of the FINDRISC as a prediction tool for diabetes in a contemporary Norwegian population: a 10 -year follow -up of the HUNT study. BMJ Open Diabetes Res Care. 2019 M, Hagquist C. Leisure -time physical activity among adolescents and subsequent use of antidepressant and hypnotic drugs: a prospective register linkage study. Eur Chil d Adolesc Psychiatry 2019;28(2):177 -88. Kravdal \u00d8, Grundy E. Children's age at parental divorce and depression in early and mid -adulthood. Population Studies 2019;73(1):37 al. Nonaspirin Nonsteroidal Antiinflammatory Drug Use in the Nordic Countries from a Cardiovascu lar Risk Perspective, 2000 -2016: A Drug Utilization Study. Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy 2019;39(2):150 -60. Langaas HC, Hurley E, Dyrkorn R, Spigset O. Effectiveness of an academic detailing intervention in primary care on the prescribing of non -steroidal anti -inflammatory drugs. Eur J M, Johannessen SI, Johannessen Landmark C. Therapeutic drug gabapentin in various indications. Acta Neurologica Scandinavica 2019;139(5):446 -54. Lund IO, Skurtveit S, Handal M, et al. Association of Constellations of Parental Risk With Children's Subsequent Anxiety and Depression: Findi ngs From a HUNT Survey and Magnus P, et al. Maternal history of miscarriages and measures of fertility in rel ation to childhood W, et al. Airway symptoms and atopy in young children prescribed asthma medications: A large -scale cohort study. I, Skurtveit S. Prescribed opioid analgesic use developments in three Nordic countries, 2006 -2017. Scand J Pain 2019;19(2):345 -53. Pedersen AB, Andersen IT, Overgaard S, Fenstad AM, Lie SA, Gjertsen JE, et al. Optimal duration of anticoagulant thromboprophylaxis in total hip arthroplasty: new evidence in 55,540 patients with osteoarthritis from the Nordic Arthroplasty Register Group. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segment ed regression analysis, Euro pean Union/European Economic Area, 2001 to 2018. doi: 10.2807/1560 -7917.ES.2019.24.46.1900656. Raknes G, in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone : A nation -wide register -based controlled before -after study. Sci 2019;9(1):15085. Raknes G, Sm\u00e5brekke L. Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register -based controll ed quasi -experimental before -after Hauge LJ, Kalseth J. Use of prescription medication prior to suicide in Norway. BMC Health Serv Res 2019;19(1):215. Sander SD, Nybo Andersen A- M, Murray JA, Karlstad \u00d8, Husby S, St\u00f8rda l K. Association Between Antibiotics in the First Year of Life and Celiac Disease. Gastroenterology. 2019 Schou MB, et al. Systematic assessment of prescribed medications and short -term risk of myocardial infarction - a pharmacopeia- wide association study from Norway and Sweden. Sci Rep 2019;9(1):8257 Solberg BS, Zenyats T, Posserud MB, J, Klungs\u00f8yr K. Psychiatric comorbidity and genetic correlations provide new insights into differences between attention -deficit/hyperactivity disorder and autism spectrum dis order. Biological Psychiatry 2019; 86: 587 -98. Steens A, Brants\u00e6ter AB, Vestrheim DF. Indirect Effects of Pneumococcal Childhood Vaccination in Individuals Treated With Immunosuppressive Drugs in Ambulatory Care: A Case - cohort Study. Kjennerud T, Stoltenberg C, et al. Tourette syndrome in children in Norway. Tidsskrift for Den Norske Legeforening Krokstad S, Helvik AS. Factors associated with alcohol consumption and prescribed drugs with addiction potential among older women and men - the Nord -Tr\u00f8ndelag health study (HUNT2 and HUNT3), Norway, Krokstad S, Helvik AS. Mortality in older adults with frequent alcohol consumption and use of drugs with addiction potential - The Nord Trondelag Health Study 2006 -2008 (HUNT3), Norway, a population study. PLoS ONE Handal LL, Dyb K. eHealth initiatives; the relationship between project work and institutional practice. BMC Health Serv Res Bliddal, Mette. (2019). Trend s in antidepressant use among children and adolescents: A Scandinavian drug utilization study. Acta Psychiatrica Scandinavica. 141. 10.1111/acps.13116. W\u00e6rholm AC, Meland E, Kjome RLS. Can subjective well - being and body concern in adolescence predict presc ribed medication in adulthood? Findings from the Nord - Trondelag Health Study and the Norwegian Prescription Database. Scand J P ublic Health 2019: Aug 13 [Epub ahead print] J, Hofsli M, Gade UL, Heegaard S, Pottegard A. Use of topical ocul ar antibiotics in young children: a Scandinavian drug utilization study. Acta Ophthalmol (Oxf) 2018;96(8):789 142 M, Berge LI, Engeland A, Fasmer OB, et al. Diabetes is associated with decreased migraine risk: A nationwide c ohort study. Cephalalgia 2018;38(11):1759 -64. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisatio n and polypharmacy aspects of antiepileptic drugs in elderly ve rsus younger patients with epilepsy: A pharmacoepidemiological stud y of CNS -active drugs in Norway, 2004 -2015. Epilepsy Res 2018;139:35 - 42. Bateman BT, Heide -J\u00f8rgensen U, Einarsdottir K, A, Selmer R , Zoega H. Beta -blocker use in pregnancy and the risk of congenital malformations: An international cohort study. Ann Intern M ed 2018; 169: 665 -73. Benko R, Matuz M, MC, Furtado C, Fungie G, -national co mparison of paediatric use in Norway, Portugal Registe r- based study showed that the age when children were prescribed ant ibiotic tablets and capsules instead of liquids increased from 2004 to 2016. Acta Paediatr 2018;22:22. Bergene EH, Nordeng H, for new oral antibiotic prescrip tions in children within 2 days: a Norwegian population study . Fam Pract 2018;35(6):690 Charlton Engeland A, Garne E, Gini R, Hansen AV, de Jong -van den Berg LT W, Jordan S, Klungs\u00f8yr K, Neville AJ, Pierini A, Puccini A, Sin clair M, Thayer D, Dolk H.The limitations of some European healthca re databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. Eur J Pharmaco l 2018; 74:513 -20 Cohen JM, Wood ME, Hernandez -Diaz S, Nordeng H. Agreement between paternal self -reported medication use and reco rds from a national prescription database. Pharmacoepidemiol Drug Saf 2018;27(4):413 -21. Cortese M, Riise T, Engeland A, Asch erio A, Bjornevik K. Urate and the risk of and Parkinsonism Relat Disord 2018;52:76 -82. Dalen D M, Locatelli M, Strom S. An Equilibrium Model Estimated on Pharmaceutical Data. Atl Econ J 2018;46(3):281 ations in women with epilepsy and antiepileptic drugs: a population -based cohort study of first pregnancies in Norway. BMJ Open 2018;8(4):e020998. Diaz E, Omland G, Hannestad Y, Ruths S. Use o f hormonal contraceptives among immigrant women and their daugh ters in Norway: Data from the Norwegian Prescription Obstetricia et Gynecologica Scandinavica 2018. Egeland AC, Eide GE, Daltveit AK, Klungsoyr K, et al. Pregnancy -Related Risk Factors Are Associated With a Significan t Burden of Treated Hypertension Within 10 Years of Delivery: Findi ngs From a Population -Based Norwegian Cohort. J Am Heart Assoc 2018;7(10):13. Engeland A, Bjorge T, Klungsoyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pre gnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol antibiotics when the stakes are highe r - do GPs prescribe less when patients are pregnant? A retrosp ective observational study. Gjelstad S, Kvaerner KJ. Relationship between Maternal and First Year of Life Dispensations of Antibio tics and Antiasthmatics. Antibiotics (Basel) 2018;7(3):17. Frank AS, Lupattelli A, Matteson DS, Nordeng H. Maternal use of thyroid hormone replacement therapy before, during, and after pregnancy: agreement between self - report and prescription records and group -based trajectory modeling of prescription patterns. Clin Epidemiol 2018;10:1801 -16. Fredheim OM, Skurtveit S, Handal M, Hjellvik V. A complete national cohort study of prescriptions of analgesics and benzodiazepines to cancer survivors in Norway 10 years after diagnosis. Pain 2018;07:07. Gulati S, et al. intracranial hemorrhage (RICH) in users of oral A. Associations between attention -deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population -based cross -sectional study. Eur Child Adolesc Bramness JG. Use of drugs for alcohol use disorder in Norway 2004 -16. Tidsskrift for Den Norske Laegeforening 2018;138(18):13. Hoff M, Skurtveit S, Meyer HE, Langhammer A, AJ, Syversen U, et al. Anti -osteoporosis drug use: too little, too much, or just right? The HUNT Amphetamine use in Pregnancy and Risk of Congenital Malformations: A cohort study from the Internatio nal Pregnancy Lindberg M, et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long -term Medical Complicati ons and rates of anxiolytics and hypnotics to survivors of cancer in childhood, adolescence, and young adulthood -A population -based study. Pediatr Blood Cancer 2018;65(2). Kasciuskeviciute S, Gumbrevicius G, Vendzelyte A, Sciupokas A, Petrikonis K, Kadusevicius E. Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti -Inflammatory Drug Use in Lithuania: An Observational Study. (Kaunas) Kjerpeseth Selmer R, Ariansen I, Furu K, Skovlund E. Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. Eur C. Leisure -time physical activity among adolescents and subsequent use of 143 antidepressant and hypnotic drugs: a prospective register linkage study. Eur Child Adolesc al. Antiepileptic and psychiatric medication in a nationw ide cohort of patients with glioma WHO grade II- IV. J Neurooncol 2 Aasarod KM. Cohort Study of Breastfeeding and the Risk of SJ, Wilcox AJ, Nyst ad W, H\u00e5berg SE. Maternal history of miscarriages and measures of fertility in relation to childhood asthma. Thorax. 2019;74(2 ):106 SJ, Nystad W. Association of Maternal Psychosocial Stress With Increased Risk of Asthma Development in Offspring. Am J Epidemiol.2018;187(6):1199 -209. Mau seth SA, Skurtveit S, Langhammer A, Spigset O. Incidence of and factors associated with anticholinergic drug use among Norwegian w omen with urinary Medication use and association with urinary incontinence in women: Data from the Norwegian Prescription Database and the HUNT study. Neurourol Urodyn 2018;37(4):14 E, Bolin K, Stavem K, Ersb\u00f8ll AK. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic child ren 2004 -2015 [Forskrivning av legemidler mot astma P. Incidence Trends of Atopic Dermatitis in Infancy and Early Childhoo d in a Nationwide Prescription Registry Study in Norway. JAMA netw 2018;1(7):e184145. Nakken Assessing amyotrophic lateral sclerosis prevalence in Norw ay from 2009 to 2015 from compulsory nationwide health registers. Amyotroph Lateral Scler Gabrhelik R, En geland A, Handal M. Neonatal Outcomes after Fetal Exposure t o Methadone and Buprenorphine: National Registry Studies from the Czech Republic and Norway. Addiction 2018. Nesvag R, Bramness JG, Handal M, Hartz I, Hjellvik V, S. The incidence, psych iatric co -morbidity and pharmacological treatment of severe mental disorders in children and adolescents. Eur Psychiatry 2018; 49:16 -22. -Blix NA, Haugen M, et al. Vitamin A and D intake in pregnancy, infant su pplementation, and asthma development: the Norwegian Mother and Child Cohort. Am J Clin 2018;107(5):789 M, Stephansson O. Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death . JAMA 2018. Raknes G, Simonsen P, Smabrekke L. The Effect o f Low - Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before -and-After Prescription Database Study. J Crohns Colitis 2018;12(6):677 -86. Raman SR, Man Bilder S, Boukhris T,Bushnell GA, Huei Karlstad \u00d8; Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Potteg\u00e5rd A, Pratt NL, Roughead EE, -Gerons DM, St\u00fcrmer Su CC, Zoega H, Sturkenbroom M, Chan EW, Coghill D, Ip P, Wong I. Regional and national trends in attention -deficit /hyperactivity disorder (ADHD) medication use: a multinational study in North America, Europe, Asia and Australia. Lancet Psychiat ry 2018; 5(10):824 -835. Reset A, Skurtveit S, Furu Skovlund E. Effect of the market withdrawal of dextropropoxyphene on us e of other prescribed analgesics. Scand J Pain 2018;18(4):667 -74. Roksvaag I, Skjeldestad FE. Decreasing trends in number of depo t medroxyprogesterone acetate starters in No rway Gulseth HL, et al. Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort S. New sc ore for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart 2018;5(2):e000931. , Hauge LJ, et al. Increase in diagnosis of depressive disorders contributes to th e increase in antidepressant use in adolescents. Acta Psychiatr Scand 2018;137(5):413 -21. M. Psoriasis and cardiovascular diseas e risk factors: the J, Klungs\u00f8yr K. Gender differences in Psychiatric Comorbidity in Diagnostikk barn Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consu mption information add to analyses spontaneous f alkoholbrukslidelser -rated health in adoles cence a predictor of prescribed medication in adulthood? Findings from the Nord Trondelag Health Study and the Norwegian Prescript ion Popul Health 2018;4:144 -52. Walle -Hansen MM, Hoye S. Geographic Variation in Antibiotic Consumption It D ue to \u00d8, Potteg\u00e5rd A. Trends in Use of Paracetamol in Countries. Basic Clin AT, et al. Stratification by interferon -gamma release assa y level predicts incident TB. 2018;05:05. Antonazzo Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migrain e risk: A nationwide cohort study. Cephalalgia 2017:333102417748573. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisa - tion and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A phar macoepidemiological study of CNS - active drugs in Norway, 2004 -2015. Epilepsy Res 2017;139:35 - 42. Bakken IJ, Furu K, Gr\u00f6neng GM, Stoltenberg C, \u00d6verland S, et al. General practice c onsultations and use of prescription drugs after changes to sc hool absence TB, Klepp O, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population - based study. OncoTargets S, et al. Does progestin -only contraceptive use after pregnancy affect recovery from pelvic girdle pain? A prospective populatio n study. M, Tysland T, Blix HS, Hoye S. Antibiotic switch during treatment with antibiotics against respiratory tract infections in ambulatory care in Norway. Infect Dis (Lond) 2017;49(11 -12):854 -8. Brakedal B, O, Dolle C, Assmus J, et al. Glitazone Use Associated With Reduc ed Risk of Parkinson's Disease. Mov Disord 2017;32(11):1594 -9. But A, De Bruin ML, Bazelier MT, V, Andersen M, Auvine n A, Starup - Linde J, Schmidt MK, Furu de V ries F, Karlstad \u00d8, Ekstr\u00f8m, N, Haukka J. Cancer Risk among insulin users: comparing analogues with human insulin in the CARING five HS. Comedication and Treatment Length in Users of Acetylcholinesterase Inhibit ors. Dement Geriatr Cogn Dis S, Daltveit AK, Vikse BE, Haugen M. Low Calcium Intake in Midpregnancy Is Associated w ith Hypertension Develop - ment within 10 Years after Pregnancy: The Norwegian Mother and Child Cohort Study. Journal of Nutrition 2017;147(9):1757 -63. Engeland A, Bjorge T, Klungsoyr K, Skurtveit S, Furu K. Preterm births and use of medication in early adu lthood: a population -based registry study. Pharma - coepidemiology and Drug Safety 20 17;26(7):742 P, Schwarze PE, et al. Road traffic noise and registry bas ed use of sleep medication. Environ Health 201 7;16:12. Ezat B, Pihlstrom L, Aasly OB, Egge Dietrichs E. Use of advanc ed therapies for disease in Norway. Tidsskr Nor Laegeforen 2017;137(9):619 -23. Fadnes LT, Diaz E. Primary healthca re usage and use of medications among immigran t children according to age of arrival to Norway: a population -based study. BMJ of analgesics du ring complete disease trajectories in patients who are diagnosed with and die from c ancer within the five- year period 2005 -2009. European Journal of Pain 2017;21(3):530 -40. Fredheim OMS, Skurtveit S, Borchgrevi nk PC. Provision of analgesics to children bef ore and after the new Utilization of Stimulants and Atom oxetine for Attention -Deficit/Hyperac - tivity Disorder among 5.4 million Children Using Population- based Longitu - dinal agent quetiapine i s increasingly not used as such: dispensed prescriptions in Norway 2004 -2015. Kieler H. Neurami nidase inhibitors during pregnancy, and the risk of adverse neonatal outcomes and congenital malformations -A population based Euro Mar 1;356:j629. http://www.bmj.com/content/356/bmj.j629.l ong Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. Immu n JB. Association of Warfarin U se With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Intern Med 2017;177(12):1774 -80. Halvorsen S, Ghanima W, Tvete IF, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with at rial fibrillation being prescribed ora l anticoagulants. Eur Heart J -Cardiovasc Pharmacother 2017;3(1):28 -36. Hoff M, Meyer HE, Skurtveit Sogaard AJ, Syversen U, et al. Validation of FRAX and the impact of self - reported falls among elderly in a general population: the HUNT stud y, Norway. Osteoporos easy access to contraception and Torgersen - Kjennerud T, Ystrom E, et al. Hypnotics use in children 0 - 18 months : moderate agreement between mother - reported survey data and prescription registry data. J 2017;10:28. 145 Johannsdottir IM, Karlstad O, Loge JH, serud C, Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Young Adulthood: A Population -Based TM, Jenum PA. Fecal carriage of extended spectrum beta - lactamase producing Escherichia coli and Klebs iella pneumoniae after urinary tract infection - A three prospective cohort study. PLoS One 2017;12(3):16. and in Relation to Children's Birth Month: Nationwide Study fr om Norway. Jun;45:343 drug purch ases before and after organizational downsizing: a natural experiment on the Norwegian working population (2004 -2012). Scand J Work Environ Health 2017;43(4):307 -15. Kjerpeseth H, Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anti coagulants in atrial fibrillation in and use of antidepres - sant medication in late mid -life: a register - based analysis of Norwegian women and men. Aging Ment Health. 2017 May;21(5):477 -486. doi: 10.1080/13607863.2015.1118010. Epub 2015 Gemzell -Danielsson Hognert H, Milsom I, et al . Contraceptive use in O. Incidence of and factors associated with anticholinerg ic drug use among Norwegian women with urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2017;04:04. Milenkovic M, Haavik S. Recording of pharmaceutical interventions of potential clinical importance in Norwegian pharmacies. Norsk Farmaceutisk Tidsskrift 2017;125(6):26 Hoff M, Forsmo S, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway. Br J Dermatol Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depres - sive symptoms: the 2017;31(12):2062 - 8. M\u00e5rild K, Blix HS, St\u00f6rdal K. Use of antibiotics in children during the period 2005 - 16. T idsskr Nor Laegeforen 2017;137(18):1414 -9. Assessing amyo trophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral sclerosis & Frontotempor al Degeneration 2017:1 -8. Odsbu I, Selmer R, Lundborg CS, Blix HS. Increased prescribing of systemic t etracyclines and isotretinoin H, Ueland PM, et al. Maternal Folate Intake during Pregnancy and Childhood Asthma in a Population -based Cohort. Am J Respir Crit Care - prescribing habits among Norwegian dentists: a survey over 25 years (1990 - 2015). Eur J Oral Sci 2017;125(4):280 -7. Raknes G, Smabrekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi -experimental study. PLoS One 2017;12(11):13. naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database. Pharmacoepidemiology and Drug Safety 2017;26(6):685 - 93. Raknes G, Smabrekke L. A sudden and unprecedented increase in lo w dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteris - tics, and dispense patterns. A drug utilization cohort study. Pharmacoepide - miology and Drug Safety 2017;26(2):136 - 42. Rebnord, Midttun, \u00d8. et al. The kyn urenine: tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. Diabetologia AK, Robsahm TE, et al. Cancer Ris k in Women Treated with Fertility Drugs According to Parity Status -A Registry -based Cohort Study. Cancer Epidemiology Biomarke rs & Prevention 2017;26(6):953 - 62. Saks haug S, Handal M, Hjellvik V, Berg C, Ripel A, Gustavsen I, et al. Long - term Use of Z -Hypn otics and Co - medication with Benzodiazepines and Bramness JG. Assessi ng prescription drug abuse using functional principal component analysis (FPCA) of waste- water data. Pharmacoepidemiology and Drug Safety 2017;26(3):320 - 6. Samuelsen PJ, Nielsen CS, Wilsgaard T, Stubhaug Svendsen K, Jason LA, Kirkevold M. From good health to illness with post - infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajecto ry. BMC family practice 2017;18(1):49. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non -refu - gees from War -Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Da tabase. Journal of Immigrant and Minori ty K, Halvorsen KH, Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J Clin Pharmacol 2017;18:18. Svendsen T, Brodtkorb aftiu A, Burns ML, Johannessen SI, Landmark CJ. Therapeutic Drug Monitoring of Lacosamide i n Norway: Focus S\u00e6tre Johannessen SI, Landmark CJ. Pharmacokinetic variability, efficacy and toler ability of eslicarbazepine acetate -A national approach to the evalu - ation of therapeutic drug monitoring data and clinical ou tcome. Epilepsy Research 2017;129:125 -31. 146 Svendsen efficacy and tolerability of eslicarbazepine acetate- A national approach to the evaluation of therapeutic drug moni - toring data and clinical out come. Epilepsy Res 2017;129:125 -31. Sverdrup Efjestad . Comedication and Length in of Inhibitors. Geriatr Cogn Dis K, Seim A, Krokstad S, Helvik AS. Use of alcohol and drugs with addiction potential among older wome n and men in a population- based study. The Nord -Trondelag Health benzodiazepine and Z-hypnotic users and disability pension: an eight -year nationwide observational follow -up study. Scand J Prim Health Care 2017;35(3):240 -6. Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription Patterns of Non -Vitamin K Oral Anticoagulants Ac ross Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012 -2015: A Study from the Norwegian Prescription Database. Drugs Aging 2017;34(8):635 -45. Vie TL, Hufthammer KO Breidablik HJ. Is self -rated health in adolescence a predictor of prescribed medication in adulthood? Findi ngs from the Nord Tr\u00f8ndelag Health Study and Norwegian Prescrip HS, Tong A, Trifir\u00f2 G, Ziv -Baran T, Kim SK. Anti - biotic Us e in Children - A Cross -National Analysis of 6 Countries. J Pediatr L. Psychosocial factors are strongly associated with insomnia in users an d nonusers of prescribed sleep medication: Evidence from the HUNT3 essen SI, Larsson PG. Changes utilisation of antiepileptic drugs in epi lepsy and non- epilepsy disorders - a pharmacoepidemiological study Dorum LM, et al. Aspirin as secondary prevention in patients with colorectal cancer: An unselected population - based study. Ruths S. Antipsychotic Drugs and Risk of H ip Fracture in People Aged 60 and Older in Norway. J Am Geriatr Soc AH, al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hy pnotics, antidepressants, and anxiolytics: Results from a hip N, et al. Opioids for outpatients with cancer in their last year of life: A nation - wide pharmacoepidemiological study. Journal of Op ioid Management 2016;12(1):25 -36. Charlton RA, Klungs\u00f8yr K, Neville AJ, Jordan S, Pierini A, de Jong -van den Berg LTW, et al. Pres cribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European Regions. PLoS One 2016; May 18 ;11(5): e0155737. doi: 10.1371/journal.pone.0155737. Charlton RA, Pierini A, Klungs\u00f8yr K, Neville AJ, Jordan S, de Jong -van den Be rg LT, et al. Asthma medication prescribing before, during and after pregnancy: a study in seven European regions. BMJ Open 20 16 Jan 19;6(1):e009237. leiner HF, Bjoro T, Midthjell K, Grill V, Asvold BO. Prevalence of thyroid dysfunction in autoimmune and t ype 2 diabetes: The population -based hunt study in Norway. J S, Lund IO, Handal M. A Unique Opportunity to Study Short and Long Term Consequences in Children Prenatall y Exposed to Illicit Drugs and Opioid Maintenance Treat - ment Using Czech and Scandinavian Registers. Cent Eur J Public Health 2016;24(3 ):248 -51. Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungs\u00f8yr K, Engeland A, et al. Risk of congenital anomalies aft er exposure to asthma medica - tion in the first trimester of pregnancy - a cohort linkage study. BJOG Revilla -Lopez C, Diaz E. Patterns of pharmaceutical use for immigrants to Sp ain and Norway: a comparative study of prescription databases in two European countries. International Journal for Equity in H ealth 2016 ;15. Halvorsen S, Jortveit J, Hasvold P, Thuresson M, \u00d8ie E. Initiation of and long -term adherence to secondary preventi ve drugs after Nesv\u00e5 g R, Handa l M. Antidepressant drug use among adolescents during 2004 - 2013: a population -based register linkage M. Psychotropic drug use among 0 -17 year ol ds during 2004 - 2014: a nationwide prescription database study. BMC Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Youn g Adulthoo d: A Population -Based Study. J Adolesc Young Adult Oncol 2016;14:14. Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS , Luteijn Linked Databases in Wales, S, Martikainen JE, Kieler H, et al. Use of drugs for ADHD among adults -a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol 2016;72(12):1507 - 14. Kaspersen D, Bjorngaard JH. Unemployme nt and initiation of psychotropi c medication: a case -crossover study of 2 A, Emneus M, Pukkala E, Bolin K, et al. Patterns of finasteride use in the male populations of four Nordic countrie s: A cross- national drug utilization study. Scand -7. Knudsen -Baas A, Gilhus NE, Storstein AM, Owe JF. Does the choice of antiepileptic drug effects parental deaths among adults in Norway: Purchases of prescript ion medicine before and after Karlstad \u00d8, et al. Pre- eclampsia and G, Nystad W. Prenatal and infant paracetamol exposure and development of asthma: The Norwegian Mother an d Child Cohort Study. Int J Epid emiol a l. Maternal plasma total neopterin and kynurenine/tryptophan levels during pregnancy in relation to asthma development in the offs pring. J Allergy Clin Immunol AK, Handal M, Haugen M, H\u00f8iseth G, Knudsen GP, Paltiel L, Schreuder P, Tambs K, Vold L, Stoltenberg C. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa ). Int J Epidemiol. 2016;45(2):382 Fredhei m OMS. The duration and course of opioid therapy in patients with chronic non -malig - Haukeland JW, Dalgard O. Hepatitis C Treatment Uptake among Patients Who Have Recei ved Opioid Substitution Treatment: A Population -Based Study. I, Bramness JG, Hjellvik V, Handal M, Skurtveit S. Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. Eur Neuropsychopharmacol 2016;26:1412 -8. Olah KS, Kim HH, Kim JM. Re: Use of hormonal contracepti ves among immigrant and n ative women in Norway: data from the Norwe - gian Prescription Database The contraceptive situation in S, Hofvind S, et al. Postmenopausal hormo ne therapy and breast can cer prognostic char - acteristics: A linkage between nationwide registries. Cancer Epidemiology Biomarkers Weiderpass E, Ursin G, et al. Postmenopau sal hormone therapy and t he risk of breast cancer in Norway. Int J Cancer 2016;138(3):584 -93. Samuelsen PJ, Svendsen K, Wilsgaard T, Stubhaug A, Nielsen CS, Eggen AE. Persistent analgesic use and the association with chronic pain and other risk factors in the population -a longitud inal study from the Tromso Study and the Norwegian Prescription Database. Eur J Clin Pharmacol 2016;72:97 7-85. Selmer R, Haglund B, Furu K, Andersen M, Norgaard M, Zoega H, et al. Individual -based versus aggregate meta- analysis in multi -database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and in 2016;25(10):1160 -9. Skipenes VP, Skjeldestad FE. Prevalence of combined S\u00f8rensen M, Arneberg F, TM, Berg TJ. Cost of diabetes in No rway 2011. Diabetes Res Clin Pract 2016;122:124 -32. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non -refugee s from War -Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. J Immigr Minor Healt h 2016;21:21. Tjagvad Gjersing L, Gossop M, Clausen T. Misuse of prescription drugs and overdose deaths. Journal of Substance Use 2016;21(5):515 -20. Tvete IF, Bj\u00f8rner T, Skomedal T. A 5 -year follow -up study of users of benzodia zepine: Starting with diazepam versus 5):e241 -e7. \u00d8vre -Eide V, Skjeldestad Norway. Acta Obstet Gynecol Scand 2016;95(11):1244 lvik V, Handal M. Reduced and cycles of Mycoplasma pneu moniae infections in Norway: can a nationwide prescription register be us ed for surveil - lance? Epidemiology and Infection. 20 15;143(9):1884 Skurtveit S, Clausen T, Kun\u00f8e N. The Norwegian Offender Mental Health and Addiction Study - Desig n and Implementation of a National Survey and Prospec Garne E, Wang H, Klungs\u00f8yr K, Jordan S, Neville A, Pierini A, Hansen A, Engeland A et al. Antiepileptic drug prescribing before, during and aft er pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1144 -54. doi: P, Skurtveit S. Prev alence of use of non - prescription analgesics in the N orwegian HUNT3 population: Impact of gender, age, exercise and prescription Public Jordan SE, Klungsoyr K, Loane M, et al. Improving Information on Maternal Me dication Use by Linking Prescription Data to Congenital Anomaly Skurtveit S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Epidemiology. 2015;30(6):501 fentanyl Risk factors for excessive benzodiazepine use in a working age populatio n: a nationwide 5 -year survey in Norway. Scand J Prim Health Care. 2015;33(4):252 M. Serotoni n-Reuptake Inhibitors and Venlafaxine in early pregnancy and risk of birth defect s - a population based cohort study and sibling design. BMJ 2015. Apr 17;350:h1798. TA. Socio -economic inequality in the u se of procedures and mortality among AMI patients: Quantifying the effects along different paths. -702. doi: PC, Dale O, Romundstad PR, Mahic M, et al. Consumption of and satisfaction with health care among opioid users with chronic Off - Label Use of Mela - tonin - A Register Linkage Study between the Norwegian Prescription Data - base and Patient Register. Basic Clinl Ph armacol Monitoring of Selec - tive Serotonin Reuptake Inhibitors in A, S\u00f8gaard AJ, Syversen U, e t al. Use of anti -osteoporotic drugs in central Norway after a forearm fracture. Archives of Osteoporosis. 2015;10:30. doi: 10.100 H. Has Previous Abuse of Fluni - trazepam Been Replaced by Clon azepam? European Addiction Midthjell K , Graue M, et al. Anxiety, depression and tim ing of insulin treatment among people with type 2 diabetes: Nine -year follow -up o f the Nord -Tr\u00f8ndelag Health Study, Norway. Journal of Psychosomatic Research. 2015;79(4):309 -15. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Vejrup K, et al. H ormonal contraceptive use before and after conception in relation to preterm birt h and small for gestational age: BJOG Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88 -91. doi:10.1016/j.seizure.2015.02.017 Kann IC, Lundqvist C, Lu r\u00e5s H. Polypharmacy Among the Elderly in a Li st-Patient System. Drugs - Real World Outcomes. 2015;2(3):193 -8. doi: 10.1007/s40 801 -015 - 0036 -3 Kelly E, Lu CY, Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. Journal of Pharmacy Furu K, Gissler M, et al. Use of antidepressants and association with elective termination of pre gnancy: population based case- control study. BJOG -an International Skirbekk V. Fertility history and use of anti - depressant medication in late mid -life: a register - based analysis of Norwegian women and men. Aging & mental health. 2015:1 -10. doi: 10.1080/13607863.2015.1 118010 Lund IO, Skurtveit S, Handal M. Commentary on Raitasalo et al: the great potential in nation -wide registers to study prescr iption drug use and abuse. (Abingdon, DOI: 10.1111/add.12856 Lund IO, S, Handal M, Nordfjaern T, Brunborg GS, Rossow I. A Cohort Study on Long -Term Adverse Effects of Parental Drinking: Background and Study Design. Subst Abuse. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. Sep;19(8):1095 Nystad W. Grandmother's smoking when pregnant with the mother and asthma in the grandchild: the Norwegian Mother and Child Cohort Stu dy. Thorax. 2015;70(3):237 - and increased mortality: causation JG. The total sale of prescription drugs with an abuse potential predicts the number of exc essive users: a national LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a n ationwide IF, Tanum L, Steen VM, Bramnes s JG. Incident Users of Antipsychotic Agents and Future Use of Cholesterol -Lowering Drugs: An Observational, Pharmacoepidemiol ogic -E6. doi: 10.4088/JCP.14m08996. Suhrke P, Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: A register -based cohort study. Cancer Medicine. 2015;4(8):1303 -8. doi: 10.1002/cam4.474 Tvete IF, Bj\u00f8rner T, Skomedal T. Risk factors for excessive benzodiaz - epine use in a working age popula tion: a nationwide 5 -year survey in Norway. Scand J Primary Health Care. \u00d8. Prescription patterns of inhaled corticosteroids for preschool children - A No rwegian register study. Allergy Valdimarsdottir U, Brandt L, et al. Use of SSRI and SNRI Antidepressants during Pregnancy: A Population -Based Study from Denmark, Iceland, Norway and Sweden. Plos One. 2015;10(12). Total drug treatment and comorbidity in myasthenia gravis: a population -based cohort study. Eur J Neurol 2014;21:948 - 955 Bakken AH, Hunskaar S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur J Clin Pharmacol -880 Berg -Hansen P, Moen S, Harbo H, Celius E. High prevalence and no latitude gradient of multipl e sclerosis in Norway. Mult Scler 2014;20:1780 -1782 Ferrer Rafaniello C, Sabate M, Ballarin E, Coma A, Zara C, et al. Cross - national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007 ealth. 2014;11:e9405 Skurtveit S, Dale O, Romundstad P, Borchgrevink PC. Chronic pain and use of opio ids: a population based pharmacoepidemio - logical study from the Norwegian prescription database and the Nord -Tr\u00f8n - delag health s B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication foll owing an episode of deliberate self -poisoning: a PLoS Foss\u00e5 KA. Use of b- Blockers and Prostate Cancer -Specific Survival: A Cohort Study of 3561 Prostate Cancer P atients with High -Risk or European Urology Halvorsen T, geography of chro nic obstructive pulmonary disease: A population -based study of Norway. Soc Sci Med 2014;21:25 -34. Jensen ET, Daniels JL, Sturm er T, Robinson WR, Williams CJ, Moster D, et al. Maternal hormonal contraceptive use and offspring overweight or obesity. Int J Ob es. 2014;38:1275 -81. Kalseth J, Halsteinli V. Cross -country comparisons of health -care costs: The case of cancer treatment in the Nordic countries. Health Policy 2014:115;172 -179. Kann IC, Lundqvist C, Luras H. Prescription of addictive and non- addictive drugs to home- dwelling elderly. Drugs Aging. 2014 Jun;31(6):453 -9. Karlst ad \u00d8, Furu K, Skurtveit S, Selmer R. Prescribing of Drugs for Attention - Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. Eur Addict Res 2014;20:59 -65. Kieler H, Malm H, Artama M, Engeland K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case- control study. BJOG. 2014 Nov Amundsen EJ, Dalgard O. HCV treatment uptake in people who ha ve injected drugs - observations in a large cohort that received addiction treatment 1970 - 1984. Scand J Gas troenterol. 2014 De c;49(12):1465 -72. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short - and Long -Term Mortality Risk Associ ated with the Use of Antipsy - chotics Among 26,940 Dementia Outpatients: A Population -Based Study. Am J Ger iatr Psychiatry 201 4;22:321 -331. Mahic M, Fredheim OM, Borchgrevink PC, Skurtveit of prescribed opioids by children and adolescents: Differenc es between Denmark, Norway and Sweden. Eur J Pain. 2014 Nov 20;[Epub ahead of print]: doi 10.1002/ ejp.632. Fredheim OM. Co-morbidity in persistent opioid users with chronic non -malignant pain in Norway. Eur J Pain. 2014;18:1083 -1093 Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41 -80 year old Norwegians, 2005 -2010. Eur J Pain. 2014 Mar;18(3):438 - 46. Nordfj\u00e6rn T, Bjerkeset O, Berk M, R Socio - demographic, lifestyle and psychological predictors of benzodiazepine and z -hypnotic use patterns. Nord J 2014;68:107 Norum J, Olsen AI, Nohr FI, Heyd A, Totth A. Medical treatment of children and youths with attention - deficit/hype ractivity disorder (ADHD): a Norwegian Prescription Registry Based Study. Glob J Health Sci. 2014 Jul;6(4): 155-62. 150 Omland G, R uths S, Diaz E. Use of hormonal contraceptives among immi - grants and native women in Norway: data from the Norwegian Prescription Database. BJOG 2014;121:1221 BS, Skurtveit Dispensing of benzo di- azepines and be nzodiazepine - related drugs to pregnant women: a popula - tion -based cohort study. Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0- 14 years be tween 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Child - hood Diabetes Registry. Diabetologia 2014 ;57:57 -62. Skurtveit S, Selmer R, Odsbu I, Handal M. Self -reported data on medicine use in the Norwegian mo ther and child coho rt study compared to data from the Norwegian prescription database. Norsk Epidemiologi. 2014;24(1 -2). Str\u00f8m H, Selmer R, Birkeland KI, Schirmer H, Berg TJ, Jenum AK, et al. No increase in new users of blood glucose - lowering drugs in Norw ay 2006 -2011: a nat ionwide prescription database study. BMC Public Health. use and socio PA. High rate per mecillinam treatment failure in communi ty-acquired Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 20 13;42:514 -20. Berge LI, Riise T, Iversen KJ, Midthjell K, et al. Does diabetes have a protective effect on migrain e? Epidemiology 201 3;24:129 Skomedal T. [Dispensing of benzodiazepines and Z drugs en S, et al. Antidepressants to cancer patients during the last year of life-- a population - based study. Psychooncology 2013;22:506 -14. Devold HM, So gaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti -osteoporosis drug use in Norway. Os teoporos 2013;24:1225 S, Vollset SE, et al. Effects of preconceptio nal paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population -based databases. British Journal of Clinical Pharmacology 2013;75:1134 Are children car rying the burden of broad -spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respi ratory M, Skurtveit S. A pharmacoepi - demiological cohort study of subjects starting strong opioids for nonma - lignant pain: a study from the Norwegian Prescription Database. Pain 201;154:2487 -93. Hold\u00f8 I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013;98:732 -6. Hoye S, Gjelstad S, Lindbaek M. Effects on antibiotic dispensing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care. Br J GenPract. 2013;63:e777 -86. Jonasson C, Tvete IF, proton pump inhibitor utilization in gastroesophageal reflux disease and the e ffect of restrictions on reimbursement: a nationwide prescription database Systematic screening with infor - mation and home sampling for genital Chlamydia trachomati s infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Dise ases 2013;13:30. Kravdal O. The p oorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? Social Science and Medicine 2013;81:4 2- 52. Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial ag ents in dogs in Norway - geograph ical patterns and trends during the period Pharmacol Ther MC, Fossa SD. A national study of adverse effects and global quality of life among candidat es for curative treatment for pro state cancer. BJU Int 2013;111:221 -32. Lillefjell M, Haugan T, Martinussen P, Halvorsen T. Treatment outcomes among individual s in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the di spensing of prescribed medication s. Journal of Musculoskeletal Pain 2013;21:311 - 319. Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record -linkage study. Eur J Clin Pharmacol Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. A ddic - tion 2013;108:367 -76. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from Multiple prescribers in older frequent opioid users --does safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759 Nordeng H, Lupattelli A, Rom\u00f8ren Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics and Gynecology 2013;121:306 -13. Nordfjaern S, Grawe RW. Clusters of person - ality traits and psychological symptoms associated with later ben zodiazepine prescriptions in the general population: The HUNT Cohort Study. Addict Behav 2013;38:2575 -80. 151 Nordfjaern T. Prospective associations between benzod iazepine use and later life satisfaction, somatic pain and psychological health among the elderly . Hum 2013;28:248 Tidsskrift for den M, Fetveit A, Dalen I, Straand J. Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. Br J GenPract. 2013;63:e55 62. Skogar Nilsson M, Tornha ge CJ, Lokk J. National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patte rns and patient experiences of symptom control and their impact on disease. J Multidiscip Healthc 2013;6:239 -47. Borchgrevink Laxa - tive prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67 -73. Skurtveit S, S elmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug expo - sure: inclusion of dispensed drugs before pregnancy may lead to underesti - mation of risk associatio ns. Dyb A, Schei B. Intimate partner violence and cardiovascula r risk in women: A population -based cohort study. Journal of Women's Health 2013;22:250 -8. Stephansson O, Kieler H, Haglund B, Artama A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy an d risk of stillbirth and infant mortality. JAMA 2013;309:48 -54. Thelle Jugessur A, Graff -Iversen S, et al. Resting heart r ate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 30 9,540 men and women. Heart 2013;9 9:1755 -60. Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3 -year survey quantifying the risk of dose escalation of benzodiazep ines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open 2013;3:e003296. Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slordal L. [Pregabalin should be moved to the Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti -diabetic agents. Diabet Med 2012;29:509 ant 19 -\u00e5ringer i mai. [Increased use of antibiotics among nineteen -year - olds in May]. Tidsskr Nor Laegeforen 2012;132:1084 -8. Blix av legemidler 1975 -2010. [Patterns in of antihypertensive in Norway, 1975 - 2010] Tidsskr Nor -8. Bramness JG, Furu S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Pharmacol A. An increased risk of motor ve hicle accidents after prescription of methado ne. Addiction 2012;107:967 -72. Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, S\u00f8g\u00e5rd AJ. Influence of socioeconomic facto rs on the adherence of alendronate treatment in inci - dent users in Norway. Pharmacoe Drug A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti -osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225 -33. Fasmer switching metha A study a prescrip - database. Palliative Medicine 2012;26:804 -12. Skurtveit S. Opoid switching to methadone: a pharmacoepidemiological study from Statin in patients treated with antiepileptic drugs in Norway. Pharmacoepidemiol Drug Saf 2012;21:881 -5. Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication avail ability and deliberate self -poisoning: a longitudinal study. J Clin Psychiatry. Handal M, Skurtveit S. Hypnotic drug use among 0-17 year old s during 2004 -2011: A nationwide prescription database study. Scandinavian Journal of Public Health 2012;40:704 -11. Hjellvik V, Mahic M, Tverdal A. Utdanning in an asthma population 8 -29 years old: A study from the Norwegian Prescription Database. Pharmacoep idemiol Drug Saf 2012;21:1045 -52. Kieler H, Artama A, Ericsson O, Furu K, Gissler M, N\u00f8rgaard M, Nielsen RB, Stephanss on Haglund B. Selec - tive serotonin -reuptake inhibitors during pregnancy and risks of persisten t pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries BMJ 2012;344:d8012. Kjome RL , Roraas T, sales of glucometer and S. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68:311 Holmen J. The HUNT st udy: Participation is associated with survival and depends on socioeco - nomic status, diseases and symptoms. BMC Medical Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication am ong persistent opioid users with chronic non - malignant pain. Acta Anaesthesiologica Scandinavica 2012;56:1267 -76. Neutel CI, Skurtveit is the point of guidelines? Benzo - diazepine and z -hypnotic use by an elderly population. Sleep Medicine 2012;13:893 -7. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medica - tion in the older persons - quant ifying Pharmacoepidemiol Drug S af 2012;21:199 -206 Neutel CI, Skurtveit S, Berg C. Benzodiazepine and z - hypnotic use in Norw e- gian elderly, aged 65 OM. transdermal buprenorphine - long -term use and co -medication with other potentially addictive drugs. Acta Anaesthesiol Scan d. 2012;56:88 -94. Nordfj\u00e6rn T. A population -based cohort study of anxiety, depression, sleep and alcohol outcomes among benzod iazepine and z -hypnotic J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journal of Clinical P harmacology 2012;68:1085 -94. Pedersen L, Hansen AB, Svendsen Fredheim H. Pregnancy outcome after gestational exposure to erythromycin - a population - based regi ster study from Norway. British Journal of Clinical R\u00f8nning PA, Helseth E, Meling TR, Johannesen A population -based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use-- a 4- year fo llow -up of 78,453 G, Hartz I. Mental d istress and subsequent use of psychotropic drugs among adolesce nts - a prospective register linkage study. J Adolescent Health 2012;50:578 -87 Steffenak AKM, Wilde -Larsson B, Nordstrom G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. Clinical Epidemiology 2012;4:225 -31. Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective co hort study of women in the Oslo Health Study. BMJ Open. 2012 Ap r 5;2(2):e000614. Svendal G, Fasmer OB, Engeland A, Berk M, Lun d A. Co - prescription of medi - cation for bipolar disorder and diabetes mellitus: A nationwide population - based study with focus o n gender differences. BMC Medicine 2012;10:148. Svendsen K, Sku rtveit S, Romundstad Different ial patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359 -69. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196 -201. Von Soest T, Bramness W, Wichstr\u00f8m L. The relationship between socio -economic status and antidepressant prescription: A longi tudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87 -95. the refer - ence range as a p redictor of future hypothyroidism and hyperthyroidism: 11 -year follow -up of the HUNT Study in Norway. J Clin Endocrinol Metab. Tverdal A. Cigarette smoking and risk of s ubsequent use of antibacterials: a follow -up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159 -67. Bramness JG, J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A populat ion based longitudinal observation study. BMC Public Health. 2011;11:144. Dalen DM, Furu K, Locatelli M, Str\u00f8m S. Generic subs titution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49 -59. Engeland A, Vangen S, Vollset SE, Furu K. R isk of diabetes after gestational diabetes and preeclampsia. A registry - based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157 - 63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepid emiol Drug Saf 2011;20:243 -8. Fasmer OB, S. - of lgesics patients in opioid maintenance therapy: A pharmaco - SJ, W. High validity of mother- reported use of antiasthmatics am ong children: a comparison with a population -based prescription database. J Epidemiol 2011;64:878 -84. Nor Laegeforen C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to 153 engineer low pric es to reduce reim - burs ement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121 -9. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba future Str\u00f8m H, Lindb\u00e6k M. Do general practitioners' consultation rates influence their prescribing patterns of antibiot ics for acute respiratory tract infections? J Antimicrob Chemother 2011;66:2425 -33. Hancock D, H\u00e5berg uru Whitworth KV, Na fstad P, Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. Pediat r Allergy Immunol 2011;22:528 -36. Handal M, Engeland A, R\u00f8nning M, Furu K. Use of prescribed o pioid analgesics and co -medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Phar macol 2011;67:953 -60 Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selec ted illicit drugs and t heir metabolites in wastewater, and subsequent year -long assessment of community drug usage. Environ Sci Technol. 2011;45:5676 Hartz I, Bramness antidepressants to patients on opioid maintenance Tverd al A, Str\u00f8m H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. Epidemiology 2011;22:418 -21. Hofvind S, Sakshaug S, Ursin G, Graff -Iversen S. Breast cancer incidence trends in Norway -explained by hormone therapy or mamm ographic K. A prospective study of asthm a and subsequent use of hypnotics in young adults. Pharmacoepide - miol Drug Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of anti - psychotics and antidepressants in general practice and specialist av antibakterielle midler til hund og kat t i SI. Prescription patterns of antiepileptic drugs in patients wi th epilepsy in a nation -wide population. Epilepsy Res. 201 1;95:51 -9. Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti - dementia drugs with psychotropic drugs in N orway --a population -based study. Pharmacoepidemiol Drug Saf. 2011;20:131 Hartz I, Handal M, Tverdal A, Furu K, Skurtvei t S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population -based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90 -8. Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign - or Norwegian -born parents. Scand J Pain 2011;2:36 -44. Mah ic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence an d persistence of etanercept and adalimimab in Norway 2005 -2009. Phar - macoepidemiol Drug Saf. 2011;20:457 -63. Neubert A, Hsia Y, de Jong -van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, N\u00f8rgaard M, Clavenna A, Wong IC. Comparison of anti -diabetic d rug prescribing in children and adolescents in seven Europ ean countries. Br J Clin P, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probabl e problematic JE.Use of ADHD drugs in the Nordic countries: A . Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the migraine and antidepressant medica- tions: Complete one year data from the Norwegian p opulation. J Affective Disorders 2011;129:198 -204. 2010: Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co -medication among users of antiobesity drugs: a population -based study. Pharm World Sci. 2010;32:752 -8. Amundsen MO, Engdahl B, Berg C, No rdeng H. Use of psychotropic drugs and analgesics among us ers of antiobesity drugs --a population based Pharmacoepidemiol Dr gravis requiring pyridostigmine treatment in a na tional population cohort. Eur J Neurol 2010;17:1445 -50. Berg [Use of glucosamine the need -relie I. Can the total consumption of a medicinal drug be u sed as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and Policy -80 Bramness P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gaba - pentin using the K, Meyer HE, Falch JA, S\u00f8gaard AJ. Prescription of anti -osteoporosis drugs during 2004- 2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299 -306. Fredheim OM, Skurtveit P. Increasing use of o poids from 2004 to 2007 - Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 20 10;14:289 - 294. Fredheim OM, Log T, Olsen W, Skurtveit S, S agen \u00d8, Borchgrevink P. opioids to and adoles cents; a study from a national prescrip - tion database in Norway. Pediatric Anesthesia 2010;20:537 - 544. Furu K, Skurtveit S, S R\u00f8nning M. JE, Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as a cohort Basic persistence and safety of antipsychotic medication: a national registry - based 3 -year follow -up. Eur J Clin Pharmacol 2010;66:911 - 7. Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predicto r of later use of benzodiazepines among benzodiazepines users. Soc Sci M ed 2010;70:921 -5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prosp ective population -based cohort study of 16 000 individuals . Scand J Public Health 2010;38:465 -73. Hjellvik V, Tverdal A, Furu K. B ody mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235 -42. Hunskaar S, Bi\u00f8rn E, Lur\u00e5s H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751 -64 Karlstad \u00d8, Nafstad P, Tverdal A, Skurtveit Furu K. Prevalence, incidence and persistence of anti -asthma medi cation use in 2 - to 29 -year -olds: a nationwide prescription study. Eur J Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population -based Eur Clin Kjome RL, Granas AG, Nerhus TH, Sandberg S. The prevalence of self -monitoring of blood glucose and costs of glucometer strips in a nation - wide cohort. Diabetes Technol Ther 2010;12:701 -5. Korn\u00f8r H, A. Benzodiazep ines predict use of opioids - a follow -up study of 17 074 men and women. Pain Med 2010;11:805 -14. Skurtveit S, Furu K, Selmer R , Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population -based cohort study. Ann Epidemiol 2010;20:890 -7. K, anti -inflammatory drugs: use and co -treatme nt with potentially interacting medications in the elderly. Clin Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine i Sogn og Fjordane [Use of lithium in the Norwegian counties Fjordane]. The use of lithium, va lproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004 -2007 - a prescriptio n database study. J Affect Disord 117:208 JG, Skurtveit S, Neutel I, J, Engeland A. An increased risk of road traffi c accidents after prescriptions of lithium or valproate? Pharma - coepidemiol Drug Saf 2009;18:492 -6. Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:224 -8. Devold H, Molden E, Co -medication of statins and CYP3A4 inhibitors before and after introduction of new K. Validation of disease registratio n in pregnant women in the Medical Birth Registry of Norway. Acta Prescription pattern of codeine for non - malig nant pain in Norway - a pharmacoepidemio - logic al study from The Norwegian Prescription Database. Anaesthesiol Scand 2009;53:627 -33. Gjerden P, Bramness and potential abuse of anticholin - ergic antiparkinson drugs in Norway: a -33. Gjerden P, Sl\u00f8rdal L, between the use of anticho - linergic antiparkinson drugs and safety and receptor drug -binding profiles agents. antipsychotic and anticholin- ergic antiparkinson drugs in Norway after Clin Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320 -6. Hartz I, Tverdal A, Skurtveit S. A comparison of self - reported data on disability pension status with data from a nationwide administrative register. Nor J Epidemi ol 2009;19:169 -172. 155 Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addic - tive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209 -218. SG, Aavitsland P. S ales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007 -08. Virol Furu Engeland A, Bramness Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Clin 2009;65:295 Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescripti on Database Pharmacoepidemiol Drug Saf 2009;18 :572 Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population -based study of prescriptions. Epilepsy Res 2009; 87: 31 -9. Selmer R, Furu K, Tverdal A. Statin treatment i n a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Phar Introduction of low dose trans - dermal buprenorphine - did it influence use of potentially addictive drugs in chronic non -malignant pain patients? Eur J Pain 2009;13:949 -53. Skrivarhaug T, M\u00f8rland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose -lowering drugs. Prospective follow -up study. Med 2009; 26:404 -08. Viktil K, Engeland A, Furu K. Use of a ntirheumatic drugs in mothers and fathers before and during pregnancy - a population -based cohort study Pharmacoepidemiol Drug Saf 2009;18:737 -42. Norge Repeate d dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185 JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril\u00ae) in Europe. Nor J Epidem iol 2008;18:167 -72. Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074 -5. Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of anti depressants. J Clin T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Pee r Academic Detailing (Rx -PAD) study. Scand J Prim Health S, Furu K. Prescription druguse among fathers and mothers be fore and during preg - nancy . A population - based cohort study of 106,000 pregnancies in Norway 2004 -06. Br J kohortstudie. [Traf fic accident risks associated with the prescription of medicinal drugs: a registry -based cohort study] Nor J Epidemiol 2008;18: 159 -66. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportu nities for research in phar 2008; eland A, Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, fluni trazepam use of antipsychotic medication: linking population -based prescription data - base to the HUNT study. Pharmacoepidemiol Drug Saf 2008 ;17:372 -7. Litleskare I, Bl ix norske kreftpasi - enter [Variable prescription of opioid s to cancer in Tverdal A. Benzodiazepi ne use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow -up study of 13 390 men and women aged 40 -42 years. Pharmaco epidemiol Drug Saf 2008;17:926 -933. Skurtveit S, A, Furu K. The validity of self-repo rted prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714 -17. Str\u00f8m H, Saks haug S, Skurtveit S. Use of statins in patients receiving oral blood glucose- lowering drugs. Nor J Epidemiol 2008;18:191 -94. 2007: Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national cons umption. J Antimicrob Chemo and gender -specific anti il f\u00e6rre forskrivninger? [The use of antidepressants amongst children and adolescents - did the warning s lead to fewer prescriptions?] Tidsskr Nor use and abuse in y. A pharmacoepidemiological study. Br J Clin Pharmacol 2007;64: 210 -8. Bramness JG, Korn\u00f8r H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203 -9. 156 Bramness JG, Sk urtveit S, M\u00f8rland J, Engel and A. The risk of road traffic acci - dents after J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry -based cohort study. Ann Epidemiol 2007;17:597 -602. Furu K, Skurtveit S, Langhammer A, Nafstad Use of anti - asthma tic medica - tions as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription databas e analysis. Eur J S. Aspect s of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual -level prescription database Langeland N, Hausken T, P. A large community outbreak of waterborne giardiasis -delayed detection in a non- endemic urban area. 200 R\u00f8nning M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a na tionwide prescription study. Br J Clin S akshaug S, R\u00f8nning M. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. Lindback M. antibi otic prescriptions in respiratory tract infe ctions be improved? A cluster - randomized educational intervention in general practice --the Prescription Peer Academic Detailing (Rx -PAD) M, Dalen I. A cluster - randomized educational intervention to reduce inappropriate prescription patterns for elde rly patients in general practice--The Prescription Peer Academic Detailing -PAD) Sakshaug S, R\u00f8nning M. [How many and who are receiving medication for mellitus? Tidsskr Prescription An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53 -56. 2001: public health perspe ctive: Establishing a national prescription register in Norway. Nor J Epidemiol 2001;11:55 -60. Utgitt av Folkehelseinstituttet Published by Norwegian Institute of Public Health Juni 2021 Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned as PDF from "}